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Background: Planned neck dissection (ND) after radical chemoradiotherapy (CRT) for locally advanced
nodal metastases in patients with head and neck squamous cell carcinoma (HNSCC) remains controversial.
Thirty per cent of ND specimens show histological evidence of tumour. Consequently, a significant
proportion of clinicians still practise planned ND. Fludeoxyglucose positron emission tomography
(PET)–computerised tomography (CT) scanning demonstrated high negative predictive values for persistent
nodal disease, providing a possible alternative paradigm to ND. Evidence is sparse and drawn mainly from
retrospective single-institution studies, illustrating the need for a prospective randomised controlled trial.
Objectives: To determine the efficacy and cost-effectiveness of PET–CT-guided surveillance, compared
with planned ND, in a multicentre, prospective, randomised setting.
Design: A pragmatic randomised non-inferiority trial comparing PET–CT-guided watch-and-wait policy
with the current planned ND policy in HNSCC patients with locally advanced nodal metastases and treated
with radical CRT. Patients were randomised in a 1 : 1 ratio. Primary outcomes were overall survival (OS) and
cost-effectiveness [incremental cost per incremental quality-adjusted life-year (QALY)]. Cost-effectiveness
was assessed over the trial period using individual patient data, and over a lifetime horizon using a
decision-analytic model. Secondary outcomes were recurrence in the neck, complication rates and quality
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of life. The recruitment of 560 patients was planned to detect non-inferior OS in the intervention arm with
a 90% power and a type I error of 5%, with non-inferiority defined as having a hazard ratio (HR) of no
higher than 1.50. An intention-to-treat analysis was performed by Cox’s proportional hazards model.
Settings: Thirty-seven head and neck cancer-treating centres (43 NHS hospitals) throughout the UK.
Participants: Patients with locally advanced nodal metastases of oropharynx, hypopharynx, larynx, oral or
occult HNSCC receiving CRT and fit for ND were recruited.
Intervention: Patients randomised to planned ND before or after CRT (control), or CRT followed by
fludeoxyglucose PET–CT 10–12 weeks post CRT with ND only if PET–CT showed incomplete or equivocal
response of nodal disease (intervention). Balanced by centre, planned ND timing, CRT schedule, disease
site and the tumour, node, metastasis stage.
Results: In total, 564 patients were recruited (ND arm, n = 282; and surveillance arm, n = 282; 17% N2a,
61% N2b, 18% N2c and 3% N3). Eighty-four per cent had oropharyngeal cancer. Seventy-five per cent of
tested cases were p16 positive. The median time to follow-up was 36 months. The HR for OS was 0.92
[95% confidence interval (CI) 0.65 to 1.32], indicating non-inferiority. The upper limit of the non-inferiority
HR margin of 1.50, which was informed by patient advisors to the project, lies at the 99.6 percentile of this
estimate (p = 0.004). There were no differences in this result by p16 status. There were 54 NDs performed
in the surveillance arm, with 22 surgical complications, and 221 NDs in the ND arm, with 85 complications.
Quality-of-life scores were slightly better in the surveillance arm. Compared with planned ND, PET–CT
surveillance produced an incremental net health benefit of 0.16 QALYs (95% CI 0.03 to 0.28 QALYs) over
the trial period and 0.21 QALYs (95% CI –0.41 to 0.85 QALYs) over the modelled lifetime horizon.
Limitations: Pragmatic randomised controlled trial with a 36-month median follow-up.
Conclusions: PET–CT-guided active surveillance showed similar survival outcomes to ND but resulted in
considerably fewer NDs, fewer complications and lower costs, supporting its use in routine practice.
Future work: PET–CT surveillance is cost-effective in the short term, and long-term cost-effectiveness
could be addressed in future work.
Trial registration: Current Controlled Trials ISRCTN13735240.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 17.
See the NIHR Journals Library website for further project information.
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Plain English summary
What was the problem?
Head and neck cancer has devastating effects on patients’ self-image, speech and swallowing.
Chemoradiotherapy (CRT) has become an important way to treat this cancer. In patients whose cancer has
spread to the neck lymph glands, current treatment includes removal of the neck lymph glands using an
operation called neck dissection (ND). This can have significant complications and after-effects, such as
shoulder disability, disfigurement of the mouth and neck, and long-term pain.
With the improvement in CRT, some now believe that ND may no longer be required if the neck disease
is treated adequately by CRT. Furthermore, owing to an improved scanning technology called positron
emission tomography (PET)-computerised tomography (CT), there is now better ability to identify patients
whose neck disease has responded completely to CRT and who do not require a ND.
What did we do?
We compared routine ND with a PET–CT-guided watch-and-wait policy in patients with advanced neck
disease to ascertain if PET–CT would result in a survival rate similar to ND, while reducing the number of
NDs being performed. We also looked at the costs of both treatment strategies and their impacts on
patients’ quality of life.
What did we find?
Patients who received PET–CT-guided surveillance showed similar survival outcomes to those who received
planned ND. PET–CT surveillance also resulted in fewer complications and lower costs, supporting its use in
routine practice.
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Scientific summary
Background
Chemoradiotherapy (CRT) has become the preferred method of treatment for patients with advanced head
and neck squamous cell carcinoma (HNSCC). The traditional standard care in the UK for these patients
included undertaking a neck dissection (ND) (surgery to remove the lymph nodes in the neck) before
or after CRT. However, there is considerable debate about whether or not ND is actually needed or
whether or not CRT alone is sufficient to treat the disease without the need for surgery and its added
complications. The standard imaging technology for assessing response to CRT has been computerised
tomography (CT) and/or magnetic resonance imaging (MRI). However, more advanced functional
modalities [especially positron emission tomography (PET) scans] have in recent decades been shown to
have a high negative predictive value for assessing response. Using a combination of PET with CT, for
example, has been shown in retrospective studies to have a higher predictive value than CT or MRI
combined, making it possible to perform a ND only if the nodal response to treatment is incomplete.
There is, however, a lack of multicentre high-quality evidence.
Objectives
l To compare the efficacy of a PET–CT-guided active surveillance (watch-and-wait) policy with the
current practice of planned ND on overall survival (OS), disease-specific survival, recurrence, quality of
life and cost-effectiveness in the management of advanced (N2 or N3) nodal metastasis in patients
treated with CRT for their HNSCC primary.
l To assess the predictive value of PET–CT scanning in detecting persistent/residual disease in the primary
site of patients with HNSCC treated with primary CRT.
End points
Primary end point
l Overall survival at 2 years.
l Cost-effectiveness [incremental cost per incremental quality-adjusted life-year (QALY)].
Secondary end points
l Disease-specific survival.
l Recurrence in the neck.
l Quality of life.
l Complication rates.
l Accuracy of PET–CT scanning for assessing the primary tumour.
Study design and methodology
A two-arm pragmatic multicentre randomised non-inferiority trial was performed to compare a PET–CT-guided
watch-and-wait policy (experimental arm) with the current planned ND policy (control arm) in HNSCC
patients with advanced neck metastasis treated by radical CRT. A total of 564 patients were randomised
in a 1 : 1 ratio.
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Stratification was performed according to centre, timing of ND (before vs. after CRT), chemotherapy
schedule [concomitant platinum, concomitant cetuximab Erbitax® (Merck Biopharma, Darmstadt,
Germany), neoadjuvant platinum, neoadjuvant docetaxel Taxotere® (Sanoti-Aventis, Gentilly, France),
platinum and 5-fluorouracil (TPF)], disease site (oropharyngeal, laryngeal, oral, hypopharyngeal or occult),
tumour (T) stage (T1–T2 vs. T3–T4 vs. occult) and nodal (N) stage (N2a–N2b vs. N2c–N3).
Treatment and investigations, radiotherapy and chemotherapy protocols
For each patient, the participating centre decided on the CRT schedule, which was chosen from an
approved list of schedules. All approved schedules were standard normal schedules used in the UK.
All were supported by a strong evidence base, and all were considered biologically equivalent.
Post-chemoradiotherapy assessment
This was performed at 12 (9–13) weeks after completion of CRT.
Patients were assessed for response to the CRT by:
l control arm – a single CT/MRI scan and examination (clinical or under anaesthetic)
l experimental arm – a single PET–CT scan followed by examination (clinical or under anaesthetic).
Diagnostic criteria and reporting protocols for PET–CT scanning
Standardised criteria for reporting of PET–CT scans were disseminated to all participating centres. A core
laboratory facility was set up in the Paul Strickland Scanner Centre, Mount Vernon Hospital, to read scans for
units that had the equipment and ability to perform PET–CT but did not have the expertise to read them. The
laboratory also performed second-stage quality assurance on all PET–CT scans performed for study patients.
Type of neck dissection
Modified radical ND involving nodal levels I to V or selective NDs were acceptable provided that involved
nodal groups were included.
Timing of neck dissection
Neck dissection before CRT had to be performed within 4 weeks of randomisation. ND after CRT had to
be performed 4–8 weeks after completion of CRT.
Sample size determination
The study was planned to randomise 560 patients (280 to PET–CT surveillance and 280 to planned ND),
which would allow for the demonstration of non-inferiority of the PET–CT arm, with a 5% one-sided
significance and 90% power, defining non-inferiority as no worse than 10% below the estimated 75%
2-year OS of the control arm, that is, having a hazard ratio (HR) no higher than 1.50. This allowed for a
3% loss to follow-up.
Follow-up
Follow-up was at 6, 12 and 24 months post randomisation and continued until at least 24 months after
randomisation. Long-term health status data on death and recurrence were collected for patients until the
end of the study. Patients were flagged with the Office for National Statistics and copies of their death
certificates were requested for long-term follow-up. This will be reported in a long-term follow-up paper.
Key inclusion/exclusion criteria
Inclusion criteria
Patients with all of the criteria listed below were eligible:
l histological diagnosis of oropharyngeal, laryngeal, oral, hypopharyngeal or occult HNSCC
l clinical and CT/MRI imaging evidence of nodal metastases staged N2 (a, b or c) or N3
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l indication to receive curative radical concurrent CRT for primary
l fitness for ND surgery
l ND was technically feasible to perform and to remove nodal disease (e.g. no carotid encasement,
no direct extension between tumour and nodal disease)
l aged 18 years old or more
l able to give informed consent
l receiving one of the CRT regimens approved by the study.
Exclusion criteria
Patients with any of the criteria listed below were ineligible:
l undergoing resection for their primary tumour, for example resection of the tonsil or base of tongue
with flap reconstruction (diagnostic tonsillectomy was not considered an exclusion criteria)
l distant metastases to chest, liver, bones or other sites
l previous treatment for HNSCC
l pregnant
l had had another cancer diagnosis in the past 5 years (except basal cell carcinoma or carcinoma of the
cervix in situ).
Patients with N2 or N3 histologically and/or cytologically proven squamous cell carcinoma and an occult
primary (after examination under anaesthetic and PET–CT scan) were eligible for the PET-NECK trial if they
were going to be treated with CRT.
Patients undergoing neoadjuvant chemotherapy followed by concomitant CRT were eligible for the
PET-NECK trial. If these patients were randomised to the ND (control) arm, it was recommended that
they have a ND after, not before, CRT. Patients with recurrence remained in the trial for the purposes of
follow-up and data collection.
Results
In total, 564 patients were recruited (ND arm, n = 282 and surveillance arm, n = 282; 17% N2a, 61%
N2b, 18% N2c and 3% N3). Eighty-four per cent had oropharyngeal cancer. Seventy-five per cent of
tested cases were p16 positive. The median length of follow-up was 36 months.
The HR for OS was 0.92 [95% confidence interval (CI) 0.65 to 1.32] indicating non-inferiority. The upper
limit of the non-inferiority HR margin of 1.50, which was informed by patient advisors to the project, lies
at the 99.6 percentile of this estimate (p = 0.004). There were no differences in this result by p16 status.
There were 54 NDs performed in the surveillance arm, with 22 surgical complications, and 221 NDs in
the ND arm, with 85 complications. Quality-of-life scores were slightly better in the surveillance arm.
Compared with planned ND, PET–CT surveillance produced an incremental net health benefit of 0.16
QALYs (95% CI 0.03 to 0.28 QALYs) over the trial period, and 0.21 QALYs (95% CI to 0.41 to 0.85
QALYs) over the modelled lifetime horizon.
Conclusions
Positron emission tomography–computerised tomography-guided active surveillance showed similar survival
outcomes to the ND arm, but resulted in considerably fewer NDs, fewer complications and, probably,
lower costs. Further exploration of the significance of persistent nodal enlargement but no PET uptake
is required.
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Trial registration
This trial is registered as ISRCTN13735240.
Funding
Funding for this study was provided by the Health Technology programme of the National Institute for
Health Research.
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Chapter 1 Introduction
Background
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with
approximately 500,000 new cases per year.1 It poses a significant therapeutic problem and has a
high mortality and morbidity. Survival rates [apart from those for oropharyngeal cancer (OPC)] have
not considerably improved over the past three decades despite newer aggressive surgical and
chemoradiotherapy (CRT) regimens. Furthermore, both the disease and its treatments have considerable
effects on vital functions (such as speech, eating, swallowing and appearance) and can result in significant
functional deficits and quality-of-life effects.
Organ preservation treatment protocols, using radical concomitant CRT, have evolved in the past three
decades, resulting in improved control rates (6.5% absolute improvement) at the primary site compared
with radiotherapy alone.2–4 Therefore, in many centres, CRT has become the preferred first line of
treatment for several types of HNSCC, especially of the base of the tongue, tonsil, larynx and hypopharynx.
For patients who have advanced nodal metastasis in the neck [tumour, node, metastases (TNM) stages
N2 or N3 nodes > 3 cm in size], the evidence for management is controversial.1 Previously, the standard
care in these patients was to perform a neck dissection (ND) (an operation to remove all lymph glands in
the neck), either before or after CRT. A ND can result in morbidity, which can be lifelong, and (even a
small risk of) mortality.4 Since 2000, it appears that there has been a shift towards active surveillance
guided by imaging, but there remains a significant proportion of patients being treated by planned routine
ND.5 Therefore, there continues to be lack of consensus regarding the best management for advanced
nodal disease in patients receiving CRT.
This controversy continues mainly because of the poor quality and contradictory evidence (level 3/4) from
prospective and retrospective case series for both management strategies. Furthermore, the advent of
newer and more accurate functional modalities for the detection of persistent disease [such as positron
emission tomography (PET)–computerised tomography (CT) scanning6,7] has further strengthened this
debate. Several studies and systematic reviews have reported a high negative predictive value for PET
scanning for the detection of persistent nodal disease. However, studies are small, mainly retrospective,
single-centre studies. Many authorities on head and neck (H&N) cancer and literature reviews7,8 have
stressed the need for a multicentre randomised trial to obtain an answer to this important question.
Existing research
Evidence in support of planned (routine) neck dissection
Until recently the standard care in the UK was to perform a ND with CRT. In other countries, a significant
proportion of patients are still treated with planned ND.5 Proponents of this management policy maintain
that CRT does not eradicate large-volume nodal disease in a large proportion of patients (up to 50%),
putting them at risk of recurrence. Some believe that for most of these patients, salvage by surgery will not
be possible,9 resulting in devastating consequences.
The only randomised controlled trial available in the literature on the subject compared conservative follow-up
with planned ND before radical CRT.10 It found that there was significantly improved disease-specific survival
following ND. However, it was small (50 patients) and had several major limitations, casting strong doubts on
the validity of its results and findings. Other single-arm and retrospective studies have reported that planned
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ND demonstrated excellent locoregional control, although some did not detect improvement in overall or
disease-specific survival in their series.11–14
In addition, it has been found that in up to 40% of patients who show a complete clinical response to CRT
but who undergo ND 8–10 weeks later tumour deposits can still be detected histologically in the ND
specimen.11,14,15 It has therefore been suggested that CRT does not completely eradicate the tumour in up
to 40% of patients. Furthermore, proponents of ND maintain that selecting patients at a high risk of
persistent disease is not possible using CT and/or magnetic resonance imaging (MRI), as studies have found
that clinical and imaging evidence of complete response (CR) of nodal disease to CRT does not predict a
complete pathological response (i.e. it does not correlate with an absence of pathological evidence of the
disease in the ND specimen).12,14
Evidence supporting a watch-and-wait policy in patients with complete
response to chemoradiotherapy
Many clinicians now advocate a conservative surveillance policy, performing ND only if there is clinical
evidence of persistent nodal disease after CRT. The rationale is that, among patients who exhibit a clinical
CR in the neck following CRT, the recurrence rate in the neck is low (< 10%), and similar to that (8%) in
patients with pathologically negative neck following ND.8,16 Other level 2/3 studies9,17,18 have also found
that ND in patients who show a CR to CRT does not confer any benefit in terms of improved survival or
reduction in nodal recurrence compared with a watch-and-wait policy. Importantly, a large retrospective
cohort study found that 43% of patients showed CR on CT, with a control rate of 92% at 5 years. Among
those who experienced less than a CR, the 5-year control rate among those who underwent ND was similar,
at 90%, but among those who did not undergo ND it was significantly lower (76%).19
There is also evidence to suggest that, in many cases, the cells in the residual nodal deposits found on
histology in ND specimens following CRT are not viable.7,18 An experimental study, examining a
proliferation marker, Ki-67, appears to confirm this hypothesis.20
Accuracy of PET–CT scanning in the assessment of response to
chemoradiotherapy and detection of residual nodal disease
Crucial to a watch-and-wait policy is the ability to detect residual disease in the neck post CRT, so that
these patients can be targeted to have a ND. Detection of residual disease in the neck is not accurately
assessed by examination in the clinic or by CT and/or MRI. Evidence suggests that PET is able to accurately
identify those patients who do not have residual tumour in their neck following CRT (i.e. PET has a high
negative predictive value).
Positron emission tomography has been reported in several small single-institution prospective and
retrospective series and two meta-analyses21,22 to have a negative predictive value of 90–100% for the
detection of persistent nodal metastasis following radiotherapy or CRT, with a variable positive predictive
value of approximately 30–60%.23–31 It has also been shown in several studies to have higher predictive values
than CT and/or MRI,21,27,32,33 and better than combined clinical examination and ultrasound.31 Finally, studies
have found that co-registering PET and CT (PET–CT) is even more accurate than PET alone33,34 (Table 1).
TABLE 1 aReported accuracy of PET–CT, PET and CT33
Modality Sensitivity (%) Specificity (%) Accuracy (%)
Positive predictive
value (%)
Negative predictive
value (%)
PET–CT 98 92 94 88 99
PET 87 91 90 85 92
CT 74 75 74 63 83
a n= 125 lesions in 64 patients.
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There is also evidence from same studies that PET–CT is highly sensitive to the detection of residual tumour
at the primary site following CRT and radiotherapy, with a high negative predictive value of 90–100%.35–37
Indeed, it has been suggested that PET–CT may have similar a predictive value in the exclusion of residual
disease at the primary site to examination under anaesthesia (EUA), the current gold standard, and may be
capable of replacing it as a result of it being less invasive.38,39 However, there is no existing level 1 evidence
to corroborate this theory.
The study had not intended to measure human papillomavirus (HPV) status at the time of inception.
However, over the past 5 years, there have been reports on the significant increasing incidence of
HPV-associated OPC, with the proportion of OPCs that are HPV associated increasing from 40.5% to
72% over a period of 20 years.40 HPV association appears to have a remarkable effect on the prognosis
and outcomes of treatment, with a 58% reduction in the risk of death [hazard ratio (HR) 0.42, 95%
confidence interval (CI) 0.27 to 0.66].41 This has necessitated examining outcomes by HPV status.42
Research objectives
l To test the hypotheses that a PET–CT-guided watch-and-wait policy (experimental arm) is non-inferior
to the current practice of planned ND (control arm) when comparing overall survival (OS) in the
management of advanced (N2 or N3) nodal metastasis in patients treated with CRT for primary HNSCC.
l To assess the cost-effectiveness of the PET–CT-guided watch-and-wait policy.
l To compare, as secondary outcomes, the efficacy of the PET–CT-guided watch-and-wait policy in terms
of disease-specific survival, recurrence and quality of life.
l To describe the accuracy of PET–CT in the detection of persistent disease at the primary site and the
neck following CRT.
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Chapter 2 Methods
Trial design
The trial was a two-arm, pragmatic, multicentre, randomised, non-inferiority trial comparing a PET–CT-guided
watch-and-wait policy (experimental arm) with the current planned ND policy (control arm) in HNSCC patients
with advanced neck metastases and treated with radical CRT.
Target recruitment was 560 patients. Patients were randomised in a 1 : 1 ratio. Primary outcomes were OS and
health economics. Secondary outcomes were recurrence in the neck, complication rates and quality of life.
Amendments to the protocol
Substantial amendments to the trial protocol were approved since conception, which were significant to
evaluate the economic costs, to help increase recruitment and to clarify eligibility and which included
the following:
l The introduction of health economics evaluation at local sites. A health economic cost analysis was
required because the avoidance of a ND with its costs and possible complications and morbidity is expected
to be one of the most significant benefits of the watch-and-wait policy. Furthermore, the economic effect
of replacing EUA and CT with a PET–CT scan would need to be evaluated to assess its potential for the
future. The aim of the economic evaluation was to identify the within-trial (WT) and long-term incremental
cost-effectiveness of PET–CT-guided watch-and-wait compared with planned ND in HNSCC patients.
l To extend the inclusion criteria to allow patients with occult primary tumours to enter the PET-NECK
trial. Patients occasionally have pathologically occult tumours but, if all other diagnostic procedures
point towards a H&N primary, and all other primary sites are excluded, they are routinely diagnosed
and treated as having H&N cancer. There was no reason why these patients should not also have been
given the opportunity to enter the PET-NECK trial if they wished and if they met all other criteria.
l To allow ND to be performed before or after CRT in patients randomised to receive standard ND
(control arm). There had been a change in practice in the previous 2–3 years regarding the timing of
planned ND. In the USA and Europe, planned ND is usually carried out after CRT, rather than before,
and there has been a gradual shift towards this practice in the UK over the previous 2–3 years.
Therefore, amending the control arm to allow this was intended to increase recruitment and
‘future-proof’ the study if this trend continues in the UK.
l To exclude patients with tumours that were not histologically squamous cell carcinoma and patients
with primary nasopharyngeal carcinoma. Both non-squamous cell carcinomas and nasopharyngeal
carcinomas have different biological behaviours and natural histories from squamous cell carcinoma of
the H&N, and they should not be treated in a similar manner. Nasopharyngeal carcinoma is highly
sensitive to radiotherapy and should not be treated by a ND. Non-squamous cell carcinoma is much
less radiosensitive and, therefore, a ND is indicated in these cases. The literature available pertains to
only squamous cell carcinoma in sites of the H&N other than nasopharyngeal.
l To clarify that patients with equivocal PET–CT scans should receive a ND. The management policy in
the UK for patients with equivocal PET–CT scans at the time of conducting the study was that they
should receive a ND.
Ethics and research and development approvals
A favourable opinion was given by the Oxfordshire Multi-Research Ethics Committee in May 2007
(reference number 07/Q1604/35). Research and development approval was obtained from University
Hospitals Coventry and Warwickshire (UHCW) in June 2007, and permissions to conduct the study at each
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site were obtained from the NHS trusts covering the Heart of England, Coventry and Warwickshire, Bath,
Velindre, London North West, London Central, London South East, Marsden, Poole, Barnet and Chase Farm,
Blackpool, Lancashire, Beatson West of Scotland, Abertawe Bro Morgannwg, Sunderland, Luton and
Dunstable, Hull and East Yorkshire, Basildon and Thurrock, Southend, Sheffield and Chesterfield, Bradford,
Nottingham, East Lancashire, Mid Essex, Aintree, Derby, Royal Devon, Bristol North, Bristol South, East Kent,
Portsmouth, Plymouth, Manchester Central, Christie, Pennine, Hertfordshire, Dumfries and Galloway,
Lothian, Royal Surrey, Newcastle Upon Tyne, Dudley, Grampian, Wolverhampton, Belfast, South Devon,
Gloucestershire, Walsall, Birmingham West Midlands and South Tees. Participating hospitals are listed in the
Acknowledgements of this report. All sites were activated between September 2007 and May 2012.
Sponsorship
The PET-NECK trial was co-ordinated by the Warwick Clinical Trials Unit and it has a co-sponsorship
agreement with UHCW. The Warwick Clinical Trials Unit stores the data within the University of Warwick
central information technology service host computers. All data are securely stored under the Data
Protection Act 200443 and adhere to the University of Warwick Clinical Trials Unit data sharing standard
operating procedure in which data sharing agreements have to be approved by both the Trial
Management Group and the sponsor.
Participants
The study sought to recruit patients diagnosed with HNSCC with advanced nodal metastases who had not
received previous treatment for their HNSCC and who had had no other cancer diagnoses within the past
5 years (exceptions given in Exclusion criteria), from H&N cancer-treating centres throughout UK NHS
hospital trusts.
Inclusion criteria
Patients who met all of the criteria listed below were eligible to participate in the study:
l had a histological diagnosis of oropharyngeal, laryngeal, oral, hypopharyngeal or occult HNSCC
l had a clinical and CT/MRI imaging evidence of nodal metastases, stage N2 (a, b or c) or N3
l had a multidisciplinary team (MDT) decision to receive curative radical concurrent CRT for primary
l had an indication to receive one of the CRT regimens approved by the study
l were fit for ND surgery
l ND was technically feasible to perform to remove nodal disease (e.g. no carotid encasement, no direct
extension between tumour and nodal disease)
l were aged ≥ 18 years
l were able to provide written informed consent.
Patients with N2 or N3 histologically and/or cytologically proven squamous cell carcinoma and an occult
primary (after EUA and PET–CT scan) were eligible for the trial if they were going to be treated with CRT.
Exclusion criteria
Patients who met any of the criteria listed below were ineligible:
l had tumours that were not squamous cell carcinomas histologically
l were undergoing resection for their primary tumour, for example resection of the tonsil or base of
tongue with flap reconstruction (diagnostic tonsillectomy was not considered an exclusion criteria)
l had N1 stage nodal metastasis
l were receiving neoadjuvant CRT with no concomitant chemotherapy
l were receiving adjuvant chemotherapy
l were undergoing chemotherapy with or without radiotherapy for palliative purposes
METHODS
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l were undergoing radiotherapy alone (this is not an optimal treatment for neck node disease)
l had distant metastases to the chest, liver, bones or other sites
l were unfit for surgery or CRT
l had received previous treatment for HNSCC
l had primary nasopharyngeal carcinoma
l were pregnant
l had had another cancer diagnosis in the past 5 years (with the exception of basal cell carcinoma or
carcinoma of the cervix in situ).
Patients undergoing neoadjuvant chemotherapy followed by concomitant CRT were eligible to enter the trial.
The patients in the study were similar to those in the studies that established the efficacy of CRT of the
larynx42 and oropharynx,44 and were similar to the patients included in a wide range of studies examining
PET–CT in the assessment of persistent nodal disease.21,22
Settings and locations
In total, 38 centres (57 NHS hospitals) throughout the UK took part in the study. Participating centres were
Department of Health-approved MDTs working in NHS clinics and undertaking the management of H&N
cancer. MDTs are assessed according to defined criteria set by the Department of Health, including
national standards for diagnosis, staging, therapy, radiology, pathology and patient support.45 All clinicians
have to be core members of the approved MDTs meeting minimum qualifications and throughput criteria.
All trusts undertaking the management of H&N cancer undergo regular peer review and quality assurance
(QA).46 To participate, centres had to have centrally satisfactorily conducted a peer review report in the last
2 years. A list of participating hospitals is given in the Acknowledgements of this report.
All centres were required to provide confirmation of trust research and development and Administration of
Radioactive Substances Advisory Committee (ARSAC) approval to conduct the study at each site. Centres
also needed access to a PET–CT scanner either locally or at a distant site.
Administration of Radioactive Substances Advisory Committee approval
Administration of Radioactive Substances Advisory Committee licences were study specific and related only
to the PET–CT centre, which was stated on the application.
Therefore, when a licence was held for the PET-NECK trial at a particular PET–CT centre, the site could
send their patients to be scanned there as long as the ARSAC licence holder agreed to oversee the safety
of the patients. The trials office had a list of ARSAC licence holders and arranged this for the centre.
However, when PET–CT centres were not close by or when the site had its own PET–CT centre but did not
hold a licence, its radiologist had to make an application under the Ionising Radiation (Medical Exposure)
2000 Regulations47 to the appropriate ARSAC. Approval of applications took around 1 month and patients
could not be scanned without the licence being in place. ARSAC licences were issued for 2 years and had
to be renewed after that time. The trials office kept a log of all expiry dates for ARSAC certificates and
reminded the radiologist to renew them and send a copy of the renewal. A list of ARSAC licence holders is
given in the Acknowledgements section of this report.
Quality assurance testing for PET–CT scanners
Before sites could scan patients in the surveillance arm of the trial, the PET–CT scanner to be used had to
receive a successful QA review by the study’s central physicist.
All scanners had to be quality assured by the physicist. Each site had to arrange with the PET–CT centre to
send a test case to the PET-NECK trial core laboratory for standardisation and quality control for each
scanner that would be used in the trial.
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7
The test case had to be an 18F or 68Ge Dicom phantom scan. All Dicom images had to be anonymised with
patient trial number and initials and the compact disc or digital versatile disc had to be correctly labelled
with ‘PET-NECK Trial’, scan date, site name and coded identifier and be sent along with an anonymised
copy of the local report and a completed study Dicom patient scan transfer form.
Providers of PET–CT scanning units used in the study were InHealth (InHealth Group, High Wycombe, UK),
Alliance (Alliance Healthcare, Hinckley, UK) and Cobalt Healthcare (Cobalt Healthcare, Cheltenham, UK).
Scanners used for the study were either ‘static’, that is, fixed at a specific hospital site, or ‘mobile’, that is,
able to travel various hospitals around the country.
Static scanners had to be quality assured every 2 years; however, mobile scanning units had to be tested
by the core laboratory half yearly. The trial team kept a log of the pass dates for scanning units and
organised with the PET–CT providers to renew the QA review.
A set-up visit to each centre by the trial co-ordinator also took place, during which information about the
trial protocol was presented and site staff were given the opportunity to clarify information. Each site was
provided with the TNM staging manual and written procedural requirements for PET–CT scanning and
reporting. Once all approvals were in place, an activation letter was sent to the principal investigator and
trust research and development department for each site to activate the start of recruitment.
Recruitment procedure
Participants were identified following pre-study assessments for diagnosis and tumour staging. Clinical,
radiological and pathological staging was performed in accordance with the Union for International Cancer
Control’s TNM Classification of Malignant Tumours staging manual.48
Assessments for diagnosis and tumour staging
Each of the following assessments had to be done within the 4 weeks prior to randomisation, or at least
CT/MRI or EUA had to have been carried out within the 4 weeks before randomisation:
1. CT/MRI of the primary site and neck (which had to be carried out before biopsy or not less than
2 weeks after biopsy).
2. Examination of the primary site with biopsy. In most cases, this necessitated examination under general
anaesthesia. However, it was not mandatory if adequate clinical examination and biopsy could be
performed without general anaesthetic.
3. CT of the chest.
4. Assessment for fitness for anaesthetic by treating clinician or anaesthetist.
Patient treatment was discussed by the MDT and each patient was considered for the PET-NECK trial.
Eligible patients were invited to the clinic to discuss treatment and were told about the PET-NECK study.
The study was discussed in detail with the patient and carer and all questions were answered. Once a
patient decided to enter the study, informed consent was taken.
Informed consent
Adequate time was allowed for patients to consider their participation in the trial. There was no pre-agreed
specified time by which to consent. Consent was required to be informed and voluntary, with time for
questions and reflection. However, the patient also had the right to make an immediate decision to consent.
Consent to participate in the PET-NECK study was sought by the clinician involved in the patient’s care,
with the involvement of the research nurse in the consent discussion. Patients were asked to confirm their
consent to participate in the PET-NECK trial by initialling the appropriate boxes on the consent form and
signing the form in the presence of the person taking consent. A copy was given to the patient, another
copy was kept in the patient notes and the original was kept in the local site file.
METHODS
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The PET-NECK trial intervention
Patient randomisation
In total, 564 patients were recruited from 37 centres (43 NHS hospitals). For all patients recruited to the
study, written informed consent was obtained.
Randomisation occurred centrally through the Warwick Clinical Trials Unit, where the study was being
managed. Treatment allocation was performed using a minimisation algorithm and was stratified by the
following: centre, timing of planned ND (before or after CRT), chemotherapy schedule {concomitant
platinum, concomitant cetuximab [Erbitux® (Merck Biopharma, Darmstadt, Germany)], neoadjuvant and
concomitant platinum, neoadjuvant docetaxel [Taxotere® (Sanofi-Aventis, Gentilly, France)] and platinum
and 5-fluorouracil (TPF) with concomitant platinum} disease site (oropharyngeal, laryngeal, oral,
hypopharyngeal or occult), tumour (T) stage (T1–T2 vs. T3–T4) and nodal (N) stage (N2a–N2b vs. N2c–N3)
(Figure 1).
At randomisation, the eligibility of the patient was checked and the trial number and treatment arm
allocated. Before being informed of the random allocation, each patient was asked to complete a
quality-of-life questionnaire. Following randomisation, the patient’s general practitioner (GP) was notified
of study participation by letter.
Randomise eligible and consenting patient 
with MDT decision for concurrent CRT
Standard concomitant
 CRT
Standard concomitant 
CRT and planned ND 
(before or after CRT)
PET–CT and assessmenta
9–13 weeks after 
CRT completion
If CR in primaryb
is neck positive or 
equivocal on PET–CT?
CT/MRI and assessment
after CRT completion
If CR in primary
ND within 4 weeks
Clinical follow-up:
Year 1 – monthly
Year 2 – 2-monthly
NoYes
FIGURE 1 Trial schema. a, EUA; b, if the patient’s primary tumour showed no response or an incomplete response
to CRT or the patient developed a recurrence in primary site or neck, the patient was immediately referred back to
the MDT for consideration for salvage surgery.
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Treatment
Chemoradiotherapy regimens
To be enrolled in the study, patients had to have been recommended for concomitant CRT by the MDT.
Patients randomised to the ND arm underwent ND either within 4 weeks before or within 4–8 weeks after
CRT. For each patient, the participating centre had to specify at randomisation the schedule to be used.
The CRT schedule was required to be one that the centre uses in its normal peer-reviewed practice and on
the list of approved trial schedules in Box 1.
The recommended CRT schedule and the approved variations to the schedule were selected after
consultation with several oncologists nationwide. The approved schedules were selected because they each
fulfilled the following criteria: the schedule was supported by a strong evidence base and the schedule
was well established and a standard schedule in UK centres. Variations from the approved trial schedules
as a result of emerging evidence or changes in the practice of a centre were individually appraised and
approved when appropriate by the PET-NECK trial management team. Patients receiving radiotherapy only
(even if receiving accelerated radiotherapy schedules) were not eligible to enter the trial.
Planned neck dissections
The randomising centre was required to decide before randomisation whether, in the case of a patient
being randomised to the ND (control) arm, the planned ND would be performed before or after CRT.
Timing of neck dissection
If the ND was to be performed before CRT, it had to be performed within 4 weeks of randomisation.
If the ND was to be performed after CRT, it had to be performed 4–8 weeks after completion of CRT.
It was recommended that patients undergo assessment by CT when possible to assess the primary site
(but this was not mandatory) and clinical examination with or without EUA before ND.
Type of neck dissection
The recommended surgical procedure was a modified radical ND. This involves the removal of lymphatic
structures in levels I–V, with preservation of one or more of the following: spinal accessory nerve, internal
jugular vein and sternocleidomastoid muscle.54
Selective NDs (including lymphatic tissues in fewer than the five levels I–V) were also acceptable provided
the following conditions were met:
1. All clinically evident involved nodal groups were included in the ND.
2. The lymphatic tissues of levels I–V that had not been removed in the ND were included in the
radiotherapy fields to a minimum of 50 Gy.
The type of access incision was left to the surgeon to decide.
Quality assurance of histological assessment of neck
dissection specimens
Histological assessment of ND specimens was performed in accordance with the requirements and
standards of the minimum pathology data set published by the Royal College of Pathologists.46
METHODS
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BOX 1 Approved CRT schedules
Recommended trial chemoradiotherapy regimen
The recommended standard schedule for the trial was:
l radiotherapy doses of 65–70 Gy in 30–35 daily fractions of 2 Gy or more with at least two doses of
concomitant 3-weekly i.v. cisplatin (100 mg/m2) or carboplatin (4.5–5 AUC).2,3
The following radiotherapy schedules are examples of approved schedules and are considered equivalent:
70 Gy in 35 fractions and 65 Gy in 30 fractions.
Approved variations to the recommended trial chemoradiotherapy schedule
The following variations to the recommended trial standard regimen were also permitted:
1. Radiotherapy schedule variations: doses of 55 Gy in 20 daily fractions or equivalent.
2. Concomitant chemotherapy schedule variations:
i. Weekly cisplatin doses (30–40mg/m2) to a minimum cumulative cisplatin dose of 200 mg/m2 or more or
weekly carboplatin (1.5 AUC).49,50
ii. The use of epidermal growth factor receptor modulation with cetuximab instead of cisplatin-based
chemotherapy was permitted: loading dose of 400 mg/m2 body surface area followed by weekly i.v.
infusions of 250 mg/m2.51,52
iii. Variations from the approved trial schedules above as a result of emerging evidence or changes in the
practice of a centre were at times permitted, after consultation with the PET-NECK trial management team.
Neoadjuvant with concomitant chemotherapy schedules
1. Patients undergoing neoadjuvant chemotherapy followed by concomitant CRT were eligible for the trial.
If these patients were randomised to the ND (control) arm, it was recommended that patients have their
ND within 2 weeks of randomisation if possible, followed by the neoadjuvant schedule.
2. Neoadjuvant with concomitant chemotherapy schedules could be used at the centre’s discretion, provided
that the following schedules were used:
i. Up to three cycles of neoadjuvant platinum-based chemotherapy were permissible, for example cisplatin
75–100 mg/m2 or carboplatin AUC 5–6 and 5-fluorouracil 1000 mg/m2 a day for 4–5 days or equivalent.
ii. Docetaxel 75 mg/m2 with platinum (75–100 mg/m2) and 5-fluorouracil (1000 mg/m2) schedules were
also permitted.53
3. Variations from the approved trial schedules above, as a result of emerging evidence or changes in the
practice of a centre may have been permitted, after consultation with the PET-NECK trial management team.
4. Adjuvant CRT and neoadjuvant-only chemotherapy followed by radiotherapy schedules were not permissible.
AUC, area under the curve; i.v., intravenous.
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
A central pathology review of 10% of pathology specimens was performed for the purposes of ensuring
quality control. The cases were selected at random by the PET-NECK trial office and requested from the
participating centres. There were no differences in the results of the local centre pathologist and the
central pathology reviewer.
Three-month post-chemoradiotherapy assessment
All patients were assessed for response after CRT. In the case of patients randomised to the PET–CT
(surveillance) arm, this assessment took place 9–13 weeks after completion of CRT. In patients who were
randomised to ND (control) arm and who received ND before CRT, assessment was performed 9–13 weeks
after CRT. In patients in the control arm who received ND after CRT, assessment for response to CRT was
done 4 weeks prior to the ND.
The timing of the assessment was chosen to reflect literature findings that PET–CT is most accurate when
done at least 8 weeks post CRT, and preferably > 12 weeks after CRT. However, this was balanced by the
need to perform the ND as soon as possible to avoid regrowth of the residual tumour post CRT, and the
increased technical difficulty in performing ND later than 12 weeks post CRT because of ensuing fibrosis
and scarring. As this was a pragmatic trial, some flexibility was afforded.
At any time, if a patient was found to have residual primary disease, he or she was immediately referred
back to the treating clinician and MDT for consideration for salvage treatment.
Neck dissections for persistent disease identified on PET–CT
post chemoradiotherapy
Persistent disease on PET–CT was defined as metastatic nodal disease in the neck identified by PET–CT at
the 3-month post-CRT assessment. Patients in whom PET–CT findings 3 months post CRT were equivocal
had to be treated as if they had persistent disease and had to undergo ND. The ND had to be performed
within 4 weeks of a decision at the multidisciplinary meeting (MDM) to perform surgery following
identification of residual disease on PET–CT. As for planned NDs, both modified radical ND and selective
NDs were acceptable, provided that the conditions were met. The type of access incision was left to the
surgeon to decide.
Recommended clinical guidelines for PET–CT scanning
1. Patient scheduling:
¢ PET–CT should have ideally been performed between 10 and 12 weeks after completion of the
last dose of CRT. However, it could be performed between 9 and 13 weeks after completion of
CRT and before any biopsies.
2. Preparation:
¢ Patients had to fast for 6 hours prior to the scan.
¢ Patients had to be weighed without shoes and coats (ensuring that the weighing device
was calibrated).
¢ Blood glucose had to be recorded using Boehringer Mannheim’s Glucometer (Boehringer
Mannheim, Mannheim, Germany) (ensuring that the device was calibrated).
¢ Patients had to drink 2–3 glasses of water prior to the test to ensure hydration.
¢ Metal denture fixtures had to be removed whenever possible (to reduce CT artefacts and improve
semiquantitative accuracy).
METHODS
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3. Injection:
¢ Fludeoxyglucose had to be injected via a butterfly cannula under quiet conditions.
¢ The patient had to be asked to remain silent.
¢ The injected dose had to be 4.5 MBq of fludeoxyglucose per kilogram of body weight up to a
maximum of 400 MBq.
4. Fludeoxyglucose uptake:
¢ The patient had to remain inactive in a comfortable and quiet environment during the uptake.
¢ The patient had to empty their bladder just prior to positioning on scanner bed.
¢ The emission scan had to start at 90 minutes post injection.
5. Positioning:
¢ The patient had to be scanned on a regular couch top.
¢ Scanning had to begin at the skull vertex and end at the groin.
¢ The scan had to be done with arms down if a single whole-body scan was performed. If the body
was scanned separately from the H&N, then the body had to be scanned with the arms up.
6. Acquisition parameters:
¢ Each PET–CT centre was advised to use routine local protocols.
7. Reconstruction parameters:
¢ The PET–CT centre was advised to use ordered subset expectation maximisation, with CT for
attenuation correction using local routine parameters.
8. Archive:
¢ The reconstructed CT, PET attenuation-corrected and non-attenuation-corrected data had to be
archived locally.
9. QA and quality control:
¢ This was done under an agreed QA and quality control protocol.
10. Reporting PET–CT findings:
¢ A standardised criterion was used for reporting PET–CT findings.
¢ The PET–CT findings had to be reported by the local hospital imaging team.
¢ The PET–CT findings had to be reviewed at the central laboratory by an expert in the PET core
laboratory, who was independent of the local report.
¢ Differences in reporting between the local hospital and the central laboratory were resolved by
consensus, otherwise a third expert at the core laboratory reported on the scan and the majority
view was taken.
11. PET–CT data transfer to the central laboratory:
This was under an agreed protocol transfer following reconstructed and anonymised files:
¢ CT
¢ PET attenuation corrected
¢ PET non-attenuation corrected
¢ PET–CT report from local imaging team.
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12. Adverse events and serious adverse events (SAEs) during PET CT:
¢ Adverse events and SAEs were required to be recorded and documented by the local
investigational team in accordance with agreed protocols. However, none of these was reported.
Quality assurance review of PET–CT scans
For patients in the PET–CT arm of the trial, the PET–CT scan was reviewed by both the local reporter and
the trial core laboratory radiologist. When there were significant differences between the reports of the
local PET–CT clinician and the central PET–CT reviewer that might have affected patient management, the
central PET–CT reviewer (from the core laboratory) and the participating centre radiologist conferred and a
final report was agreed. If agreement could not be reached, a second independent reviewer from the core
laboratory was asked to review the scans and issue a second opinion report. If there was still a significant
difference between the local PET–CT report and the core laboratory reports, the final decision on which
report to use rested with the local PET–CT clinician, local treating clinicians and MDT.
Any discordance between the reports of the local PET–CT clinician and central PET–CT reviewer was
documented in the patient’s assessment form including which report was used to make the final
clinical decision.
Quality assurance review of staging and response scans
Central QA review was performed on 10% of staging scans (and response scans for patients in the ND
arm) to check for concordance. The results of the review are not yet finalised and this will be reported in a
later paper.
Patient assessments
The schedule of assessments is shown in Table 2. All biobank samples collected at baseline and follow-up
will be retained for future work.
Patient follow-up
Patient follow-up was monthly for the first year up to the 12th month after randomisation, and 2-monthly
for the second year up to the 24th month after randomisation. It was recommended, but not mandatory,
that patients should have chest radiography annually.
At each follow-up visit, the patient received a full clinical examination with palpation of the neck and
visualisation of primary site when possible, with appropriate trial forms and questionnaires completed at
the completion of CRT, and at 6, 12 and 24 months after randomisation.
Patients with confirmed recurrence
Recurrent disease was defined as a confirmed tumour in the primary site after a clear 3-month post-CRT
assessment or metastatic nodal disease identified in the neck after negative PET–CT post CRT or after a
ND, during the follow-up period. A tumour was confirmed as recurrent if disease was confirmed by biopsy
or radiological cross-sectional imaging.
Patients with recurrence, confirmed by biopsy or needle aspiration and CT/MRI or by their PET–CT scan
were referred back to the treating clinician and MDM urgently for consideration for salvage treatment,
including ND for patients with isolated nodal recurrence.
Serious adverse events
Investigators were required to inform the trials unit immediately of any SAEs following CRT, PET–CT or ND.
METHODS
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Each time the patient was seen in clinic he or she was asked if any SAEs had occurred. The occurrence of
SAEs was based on information provided by either patients or their carers. The following adverse events
were considered serious:
l death
l life-threatening disease
l hospitalisation or prolongation of hospitalisation
l congenital abnormality
l persistent disability
l other medically significant event.
Trial-specific exclusions from reporting SAEs included any of the following:
l elective hospitalisations for the treatment of the primary cancer and its effects
l elective hospitalisation for social reasons
l elective hospitalisation for pre-existing conditions that were not exacerbated by the treatment.
Adverse effects of PET–CT scanning
If, after administration of the radiopharmaceutical required for PET–CT, the biodistribution within
the patient was not as would be expected, the ARSAC certificate holder had to be informed and a
check made to determine that the correct radiopharmaceutical was administered. If the correct
radiopharmaceutical was administered, the supplier of the radiopharmaceutical had to be informed.
In the case of an incorrect radiopharmaceutical being administered to a patient, the ARSAC licence
certificate holder and a senior member of staff had to be informed immediately who was then required to
follow the guidance in Health and Safety Guidance Number 95.55
(a) The ARSAC certificate holder was required to inform the patient of the error.
(b) The referring clinician had to be informed.
(c) The GP of the patient had to be informed.
(d) A risk assessment was required to be requested from the radiation protection advisor.
(e) The staff member was required to inform the chief investigator and the sponsor.
A report of any incident, including action taken in order to prevent a recurrence, was required to be
compiled by the radiation protection supervisor and forwarded to the radiation protection advisor. Any
such incident was required to be recorded as an unexpected SAE and also reported through the individual
trust critical incident policies.
Patient withdrawal
Patients were informed about the right to withdraw from the study at any time without giving a reason.
However, site staff were asked to make every effort to identify the reason for withdrawal. Withdrawn
patients were asked if any data collected prior to their withdrawal could be used in the analyses.
The reason for withdrawal (when known) was recorded on the patient notes and the trial office was
informed of the withdrawal.
Patients who elected to withdraw from the trial interventions remained in the trial for follow-up per
protocol unless they withdrew their consent.
Patients who changed their mind about withdrawal and wished to rejoin the study could chose to do so at any
time, but they needed to be reconsented and follow-up data were to be collected only from that point onwards.
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Patients moving out of the area
When patients moved away from the area to another participating centre, every effort had to be made,
with the patients’ consent, to transfer the follow-up of patients so that the new centre could take over the
responsibility for follow-up. Close co-ordination with the PET-NECK trial office was essential for this.
Outcomes
Overall survival (primary outcome)
Information on death and survival was obtained from centres via death and follow-up forms.
Cost-effectiveness (primary outcome)
Data for the health economic analysis were collected from the trial EuroQoL-5 Dimensions (EQ-5D) and
resource use questionnaires, as well as the case report forms. Full details of the health economic analysis
are given in Chapter 4.
Complication rates
Complications following ND surgery were reported.
Disease-specific survival
Causes of death were reported on the death form. Deaths were regarded as caused by H&N cancer if they
were reported as such, if there was persistent, recurrent or metastatic disease present at death or if the
patient died as a result of complications of treatment for H&N cancer.
Recurrence in neck nodes
Details of recurrences were reported at follow-up visits. Any notification of recurrence within 3 months
of radiotherapy was regarded as persistent disease and notifications after that date were regarded as
recurrences. Recurrences in the neck nodes were reported as ipsilateral or contralateral in the notification
of recurrence.
Quality of life
The questionnaires included the following instruments:
l EQ-5D: five 3-point scales and one summary 100-point scale. This was used for the health
economics evaluation
l European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for
Cancer (with 30 questions) (QLQ-C30): five functional, three symptom and a global scale and six single
items for assessment of general quality of life
l EORTC Quality of Life Questionnaire for Cancer head and neck module with 35 questions (QLQ-H&N35):
seven scales and 11 single items for H&N cancer-related quality of life
l MD Anderson Dysphagia Inventory (MDADI): an overall function scale and four subscales.
Patients were requested to complete these questionnaires at five time points. The first was completed in
clinic prior to randomisation. Later questionnaires were received either in clinic or through the post before
the assessment dates were due at these time points: within 2 weeks of CRT completion, 6 months after
randomisation, and 12 and 24 months after randomisation.
Accuracy of PET–CT scanning
Positron emission tomography–computerised tomography scans were assessed both by the local radiologist
and by the trial core radiologist.
METHODS
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Sample size
The trial was designed to allow demonstration of non-inferiority of the PET–CT surveillance arm compared
with the control arm (planned ND), which was assumed to have a 2-year OS of 75%. The margin for
non-inferiority was set at 10%, implying that the 2-year OS of the experimental arm should not be below
65%, a difference equivalent to a HR of 1.50.
The trial was expected to recruit for 3 years, with an additional follow-up period of 2 years. The sample
size was set at 560 patients in total (280 in each treatment arm), giving a 90% power with a type I error
of 5%, allowing for a 3% loss to follow-up. The sample size was calculated by simulation assuming
unadjusted analysis by a Cox’s proportional hazards model and assuming follow-up to the end of the trial
5-year period (using data from the Office for National Statistics). If no follow-up existed beyond the 2-year
requested data, then the power would be 76%. It was expected that the true power would lie between
these figures (i.e. 76% and 90%). The assumptions underlying the sample size calculation were monitored
by the Independent Data and Safety Monitoring Committee (IDSMC) throughout the study.
Randomisation
Treatments were centrally allocated through the PET-NECK trial office at the Warwick Clinical Trials Unit.
Allocation was performed using a minimisation algorithm balancing by the following: centre, timing of
planned ND (before or after CRT), chemotherapy schedule (concomitant platinum, concomitant cetuximab,
neoadjuvant and concomitant platinum, neoadjuvant TPF with concomitant platinum, other approved),
disease site (oropharyngeal, laryngeal, oral, hypopharyngeal or occult), T stage (T1–T2 vs. T3–T4) and
N stage (N2a–N2b vs. N2c–N3). At randomisation, the eligibility of the patient was checked and the trial
number and treatment arm were allocated. Each patient was asked to complete a quality-of-life
questionnaire (before being informed of the randomisation allocation).
Allocation concealment
When the randomisation service was telephoned, participant details were taken and registration into the
trial followed. The allocation was then generated, ensuring concealment.
Blinding
It was not possible to blind either the doctor or the patient to the allocated treatment.
Statistical methods
Participants were analysed according to the treatment group to which they were randomised. Analyses
were guided by an analysis plan prepared before data were available.
A preplanned early stopping guideline was applied, assuming that at least 2 years’ follow-up would be
available for each patient, and that 140 deaths (25%) would be expected. Three analyses of the primary
outcome were prespecified, equally spaced at 47, 94 and 140 deaths, to be viewed only by the IDSMC
and trial statistician. At each of these points, it could be concluded that the experimental treatment is
equivalent (non-inferior). The 5% one-sided type I error rate for testing non-inferiority was controlled by an
O’Brien–Fleming-like alpha spending rule set at p-values of 0.004, 0.007 and 0.047. It could alternatively
be concluded that the experimental arm is inferior. A similar 10% type I rate for testing non-equivalence
was used, with p-values set at 0.02, 0.032 and 0.084. At the first interim analysis (48 deaths), when
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84% of patients had been randomised, the p-value for non-inferiority was 0.0025, which was below the
(0.004) threshold for consideration of stopping. The IDSMC considered that data were immature and that
the trial should continue. At the second interim analysis (102 deaths) the p-value for non-inferiority was
0.008, that is, above the threshold for the second analysis, and the trial continued to the final analysis.
Demographic and clinical characteristics and baseline measurements are presented to evaluate the
comparability of intervention groups and generalisability to clinical settings. A Consolidated Standards of
Reporting Trials (CONSORT) flow diagram was produced.56
The primary end point, OS, was measured for every patient from the date of randomisation to the date
of death. Survival times for patients on follow-up and patients lost to follow-up were censored at the
latest date at which they were known to be alive. Kaplan–Meier survival curves were plotted. To test
non-inferiority of the surveillance arm the HR was estimated using a Cox’s proportional hazards model
stratified by intended timing of planned ND (before or after CRT), with the trial treatment arm as the only
covariate. Non-inferiority is demonstrated by the 95% quantile of the estimated HR of the surveillance arm
being less than the inferiority limit (HR 1.50). Proportionality of hazards was checked using a time-dependent
treatment effect. A secondary analysis adjusting for N stage, T stage, tumour site, chemotherapy schedule
and timing, sex and centre was performed. Kaplan–Meier OS was also calculated for the planned timing of
ND (before or after CRT) subgroups and also for p16-positive and -negative tumours. The treatment effect
on OS was also presented for subgroups of site of tumour, T stage, planned chemotherapy schedule and
p16 status, using HR plots with interaction statistics using methods described by the Early Breast Cancer
Trialists’ Collaborative Group.57
Causes of death were classified as H&N cancer or other causes. Cumulative incidence rates by treatment
arm were plotted for these competing risk groups and the difference between treatments was tested using
Gray’s test.58
Patients were deemed at risk of recurrence when they completed their CRT and time to recurrence was
measured from that date. This meant that patients in the planned ND group who underwent surgery
before CRT were not at risk until they had finished all their treatment. Counts of neck node recurrences by
treatment were reported.
Quality-of-life scales at five time points were available for the EORTC QLQ-C30 version 3, EORTC QLQ-H&N35
H&N-specific quality-of-life questionnaire and the MDADI. The recommended scoring methods were applied59
(see also Fayers60 and Chen et al.61). The differences between treatments in mean changes from baseline
scores were calculated and compared for each of the assessment points separately using the Wilcoxon
signed-rank test. The proportion of patients whose scores changed by at least 10% was also reported.
Complications of ND surgery were reported as counts and as proportion of NDs with Agresti–Coull
binomial CIs.
Positron emission tomography–computerised tomography accuracy was difficult to assess, as it is difficult
to define a false positive. Therefore, it was not possible to measure PET–CT accuracy in a meaningful way.
Concordance of local PET–CT scan assessments with that of the trial review radiologist were reported.
Statistical analyses were performed using SAS version 9.3 software (SAS Institute Inc., Cary, NC, USA).
METHODS
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Database and data processing
The database was held on the Warwick Clinical Trials Unit’s Microsoft Structured Query Language server
system (Microsoft Corporation, Redmond, WA, USA) and imposed rules for data entry that included valid
range for responses, linked dates and patient identification numbers.
Data were single entered into the database by study personnel. The trial statistician carried out checks of
plausibility of values, missing data and form return rates to enable further queries to be resolved prior to
freezing data for scheduled IDSMC reports and analysis. A 100% check on the details in death reports
was applied.
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Chapter 3 Results
Screening and recruitment
Recruitment
A total of 564 patients were recruited between 2 October 2007 and 23 August 2012: 282 to each trial
arm (Figure 2).
Two patients in the surveillance arm were subsequently found to be ineligible: one patient’s disease was
found to be T1N1 and another patient had metastatic disease at the time of randomisation. Follow-up
data were collected and the patients are included in analyses.
The participant flow diagram outlines the passage of patients through the study; more detail is given in
later sections (Figure 3).
Screening
All patients newly diagnosed with HNSCC were considered potentially eligible and had to be screened by
the MDT prior to their clinic appointment.
Both screened patients and those approached for study participation had to be recorded anonymously on
the screening log. The log was updated monthly and passed to the co-ordinating centre.
If a screened patient was not eligible for the trial, an anonymous record of the case was recorded on the
screening log. Recorded details included the name of the centre, the patient’s initials and the reason for
non-randomisation, if not randomised. Patients randomised to the trial were also recorded.
In total, 1792 patients were screened. The number of patients screened by centre is given in Table 3.
Of the 1792 patients screened, 564 were randomised, 1032 did not fulfil the eligibility criteria, and 196
patients refused consent. Table 4 shows reasons for patients not meeting the standard eligibility criteria
and Table 5 shows reasons for unwillingness of eligible patients to enter the study.
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FIGURE 2 Recruitment.
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Did not receive a ND
(n = 42)
• Clinical decisions, n = 17
• Died, n = 1
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   surgery, n = 23
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Received ND after CRT, 
no PET–CT scan
(n = 149)
Planned to receive 
ND before CRT
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(n = 8)
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Randomised to ND arm
(n = 282)
(a)
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(n = 77)
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(n = 6)
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(n = 2)
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(n = 69)
Died
(n = 7)
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(n = 3)
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(n = 6)
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(n = 3)
Follow-up of all patients
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after ND
(n = 6)
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   claustrophobic, n = 1
• Did not receive 
   CT, n = 1
• Reason neither CT 
   nor RT, n = 3
Received ND
(n = 69)
Received CRT after ND
(n = 63)
FIGURE 3 Participant flow diagram. (a) ND arm; and (b) surveillance arm. Adapted from the New England Journal of
Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT Surveillance versus
Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016) Massachusetts Medical Society.
Reprinted with permission.62 (continued )
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Randomised to 
surveillance arm
(n = 282)
(b)
Did not receive CRT
(n = 6)
• Died, n = 1
• Progression/metastases, n = 2
• Withdrew, n = 1
• Reason unknown, n = 2
Follow-up of all patients
(n = 282)
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• No ND, n = 181
• ND, n = 4
FIGURE 3 Participant flow diagram. (a) ND arm; and (b) surveillance arm. Adapted from the New England Journal of
Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT Surveillance versus
Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016) Massachusetts Medical Society.
Reprinted with permission.62
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TABLE 3 Number of patients screened by centre
Site Number of patients screened
Aberdeen Royal Infirmary 7
Barnet and Chase Farm Hospitals 2
Beatson West of Scotland Cancer Centre 31
Belfast City Hospital 33
Blackpool Victoria Hospital 29
Birmingham Heartlands Hospital 70
Bradford Royal Infirmary 23
Bristol Haematology and Oncology Centre 40
Castle Hill Hospital 22
Cheltenham General Hospital 5
Christie Hospital 25
Derriford Hospital 12
Guy’s and St Thomas’ Hospitals 41
James Cook University Hospital 10
Kent and Canterbury Hospital 77
Mount Vernon Hospital 17
New Cross Hospital 11
North Manchester General Hospital 12
Nottingham University Hospital 17
Poole Hospital 10
Queen Alexandra Hospital 5
Queen Elizabeth Hospital Birmingham 77
Royal Blackburn Hospital 126
Royal Derby Hospital 59
Royal Devon and Exeter Hospital 35
Royal Marsden Hospital 5
Royal Preston Hospital 21
Royal Surrey County Hospital 42
Royal United Hospital 44
Russells Hall Hospital 11
Singleton Hospital 101
Sir Bobby Robson Cancer Trials Research Centre (Freeman Hospital) 32
Southend University Hospital 4
Sunderland Royal Hospital 153
Torbay Hospital 11
UHCW 143
University College London Hospital 32
University Hospital Aintree 131
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TABLE 3 Number of patients screened by centre (continued )
Site Number of patients screened
Velindre Cancer Centre 26
Walsall Manor Hospital 12
Western General Hospital 39
Weston Park Hospital 188
William Harvey Hospital 1
TABLE 4 Known reasons for ineligibility of screened patients
Ineligibility criteria Number of patients in category
Patient did not have the required histological diagnosis 187
Patient did not have N2 or N3 disease 223
Patient had distant metastases 57
Patient had previous treatment for HNSCC 59
Previous cancer in past 5 years 4
Patient would not receive protocol-driven CRT regimen 26
Patient was unfit for surgery and/or CRT 115
Patient required resection of tumour 151
Inoperable nodes 5
Patient required palliative treatment 69
For radiotherapy only 3
Clinical decision not to enter patient in the trial 15
Other treatment planned 41
Other reasons not specified above 47
Reason for ineligibility not specified 30
Total 1032
TABLE 5 Reasons for unwillingness of eligible patients to participate
Reason Number of patients in category
Patient wanted ND or standard treatment 47
Patient did not want surgery 36
Patient wanted more control over the type or place of treatment 16
Patient had anxieties about the large amount of information and making decisions on
randomisation and treatment
12
Patient did not want to take part in clinical study 11
Total 122
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The majority of patients who were ineligible either had the wrong type or severity of disease or a different
type of treatment was indicated. There were 47 patients who were not approached about the study for
reasons such as cognitive impairment, psychiatric issues or short-term memory problems that were likely to
affect compliance. Other examples include language barriers, too much information to give to a patient as a
result of having to tell them about their disease at the same time as giving study information, lack of clinicians
available to discuss trial/consent patients, patient travelling elsewhere for treatment, a patient refusing to be
treated or a patient being entered into another incompatible study. For 30 patients, the reason for ineligibility
was not known.
Of the 196 patients who refused to participate, 74 did not give a reason for non-participation. The reasons
for non-participation of the other 122 patients are given below.
One patient was anxious about being randomised in the trial, 11 patients were not interested in participating
in a clinical trial, two patients did not want to travel for PET–CT if randomised to the surveillance arm of the
trial, one patient felt that more imaging would be too much, four patients were overwhelmed with the
amount of information given (trial information as well as diagnosis and treatment information), seven patients
were too distressed after receiving diagnosis information to make a decision about the trial, one patient
requested treatment at another clinic, one patient wanted to remain private, one patient wanted to retain
control over his/her treatment and 93 patients had specific treatment preferences. Of these, 42 patients
preferred ND and 36 patients did not want ND. There were two patients whose treatment preference was
not specified. One patient wanted radiotherapy only, one wanted photodynamic therapy, four wanted
CRT only, one wanted CRT followed by PET and one patient wanted to proceed immediately to adjuvant
chemotherapy. Finally, five patients wanted standard CRT with ND, before or after CRT.
Baseline characteristics
Baseline characteristics of participants by trial arm
Treatment allocation by minimisation was balanced by the six characteristics in Table 6. A total of
38 centres took part, randomising mainly oropharyngeal patients (84.4%). Neoadjuvant chemotherapy
was intended in 35.8% of patients.
TABLE 6 Baseline characteristics balanced at treatment allocation
Baseline characteristic
Trial arm, n (%)
Surveillance ND
Centre
Arden 30 (10.6) 30 (10.6)
Sheffield and Chesterfield 25 (8.9) 25 (8.9)
Birmingham 23 (8.2) 24 (8.5)
Bristol 19 (6.7) 19 (6.7)
Edinburgh 17 (6.0) 19 (6.7)
Lancashire 14 (5.0) 14 (5.0)
Glasgow 13 (4.6) 12 (4.3)
Royal Surrey 12 (4.3) 13 (4.6)
East Peninsula 11 (3.9) 11 (3.9)
Guy’s and St Thomas’ 11 (3.9) 11 (3.9)
Newcastle 11 (3.9) 11 (3.9)
Black Country 10 (3.5) 9 (3.2)
Manchester 11 (3.9) 8 (2.8)
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TABLE 6 Baseline characteristics balanced at treatment allocation (continued )
Baseline characteristic
Trial arm, n (%)
Surveillance ND
Cardiff 9 (3.2) 9 (3.2)
Swansea 8 (2.8) 9 (3.2)
East and North Herts 6 (2.1) 7 (2.5)
Bath 5 (1.8) 7 (2.5)
West Peninsula 6 (2.1) 5 (1.8)
Nottingham 5 (1.8) 5 (1.8)
Sunderland 4 (1.4) 6 (2.1)
Derby 5 (1.8) 3 (1.1)
East Kent 5 (1.8) 3 (1.1)
Liverpool 3 (1.1) 4 (1.4)
East Lancashire 3 (1.1) 2 (0.7)
Gloucestershire 3 (1.1) 2 (0.7)
South Tees 3 (1.1) 2 (0.7)
Hull & East Yorkshire 1 (0.4) 3 (1.1)
Portsmouth 2 (0.7) 2 (0.7)
Dorset 1 (0.4) 2 (0.7)
Essex 3 (1.1) –
Barnet 1 (0.4) 1 (0.4)
Aberdeen 2 (0.7) –
Bradford – 1 (0.4)
Belfast – 1 (0.4)
Royal Marsden – 1 (0.4)
University College London Hospital – 1 (0.4)
ND policy before or after CRT
ND before CRT 76 (27.0) 77 (27.3)
ND after CRT 206 (73.1) 205 (72.7)
Approved chemotherapy schedules
Concomitant platinum 163 (57.8) 169 (59.9)
Concomitant cetuximab 14 (5.0) 14 (5.0)
Neoadjuvant and concomitant platinum 10 (3.6) 9 (3.2)
Neoadjuvant TPF with concomitant platinum 89 (31.6) 85 (30.1)
Other agreed schedules 6 (2.1) 5 (1.8)
Tumour site
Oral 4 (1.4) 7 (2.5)
Oropharyngeal 240 (85.1) 236 (83.7)
Laryngeal 18 (6.4) 19 (6.7)
Hypopharyngeal 15 (5.3) 14 (5.0)
Occult H&N 5 (1.8) 6 (2.1)
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Other baseline characteristics of participants by trial arm
The patient characteristics in Table 7 were collected either at randomisation or via baseline information
forms. The mean age was 57.9 years and 83.3% were male. Three-quarters of participants were either
current or past smokers and, of those tested for p16 status, 335 out of 446 (75%) were positive.
Further details of the tumour and nodal stages of randomised patients are given in Tables 8 and 9.
TABLE 6 Baseline characteristics balanced at treatment allocation (continued )
Baseline characteristic
Trial arm, n (%)
Surveillance ND
T stage
T1/T2 162 (57.4) 160 (56.7)
T3/T4 116 (41.1) 116 (41.1)
Occult H&N 4 (1.4) 6 (2.1)
N stage
N2a/N2b 221 (78.4) 222 (78.7)
N2c/N3 61 (21.6) 60 (21.3)
Adapted from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
TABLE 7 Further baseline characteristics by trial arm
Baseline characteristic
Trial arm
Surveillance ND
Age (years)
n 282 282
Mean (SD) 57.6 (7.5) 58.2 (8.1)
Median (IQR) 57 (53–63) 58 (53–63)
Minimum, maximum 37, 79 38, 83
Sex, n (%)
n 282 282
Male 223 (79.1) 237 (84.0)
Female 59 (20.9) 45 (16.0)
Primary site, n (%)
n 277 277
Tonsil 138 (49.1) 134 (48.4)
Base of tongue 82 (29.6) 83 (30.0)
Floor of mouth 1 (0.4) –
Palate 4 (1.4) 3 (1.1)
Tongue 1 (1.1) 2 (0.4)
Supraglottis 15 (5.4) 17 (6.1)
Glottis/subglottis/transglottis 2 (0.7) 1 (0.7)
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TABLE 7 Further baseline characteristics by trial arm (continued )
Baseline characteristic
Trial arm
Surveillance ND
Pyriform fossa 14 (5.1) 12 (4.3)
Posterior pharyngeal wall 3 (1.1) 6 (2.2)
More than one site 17 (6.1) 19 (6.9)
Tonsil, base of tongue 9 9
Tonsil, base of tongue, pyriform fossa 1 –
Tonsil, base of tongue, palate 1 –
Tonsil, base of tongue, post-pharyngeal wall – 1
Tonsil, palate, tongue – 1
Tonsil, palate 1 2
Tonsil, tongue – 1
Tonsil, pyriform fossa – 1
Tonsil, supraglottis, pyriform fossa – 1
Tonsil, posterior pharyngeal wall 1 –
Tonsil, supraglottis 1 –
Base of tongue, supraglottis – 2
Base of tongue, floor of mouth 1 1
Base of tongue, posterior pharyngeal wall 1 –
Supraglottis, posterior pharyngeal wall 1 –
T stage, n (%)
n 282 282
T1 48 (17.0) 52 (18.4)
T2 114 (40.4) 108 (38.3)
T3 61 (21.6) 52 (18.4)
T4 55 (19.5) 64 (22.7)
Occult 4 (1.4) 6 (2.1)
N stage, n (%)
n 282 282
N2a 54 (19.1) 44 (15.6)
N2b 167 (59.2) 178 (63.1)
N2c 52 (18.4) 52 (18.4)
N3 9 (3.2) 8 (2.8)
Side of primary, n (%)
n 280 278
Left 120 (42.9) 102 (36.7)
Right 129 (46.1) 142 (51.1)
Midline and/or left and right 31 (11.1) 34 (12.2)
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TABLE 7 Further baseline characteristics by trial arm (continued )
Baseline characteristic
Trial arm
Surveillance ND
Differentiation, n (%)
n 237 235
Well differentiated 15 (6.3) 10 (4.3)
Moderately differentiated 101 (42.6) 90 (38.3)
Poorly differentiated 119 (50.2) 134 (57.0)
Undifferentiated 2 (0.8) 1 (0.4)
Type of staging scan, n (%)
n 282 281
PET–CT 27 (9.6) 27 (9.6)
CT 169 (59.9) 173 (61.6)
MRI 86 (30.5) 81 (28.8)
ECOG performance status, n (%)
n 281 281
0 220 (78.3) 218 (77.6)
1 60 (21.4) 60 (21.4)
2 1 (0.4) 3 (1.1)
Smoking, n (%)
n 281 281
Current 88 (31.3) 76 (27.0)
Past 119 (42.3) 134 (47.7)
Never 74 (26.3) 71 (25.3)
Alcohol, n (%)
n 280 279
Current 222 (79.3) 234 (83.9)
Past 34 (12.1) 18 (6.5)
Never 24 (8.6) 27 (9.7)
Ethnic group, n (%)
n 281 280
White 280 (99.6) 278 (99.3)
Black or black British 1 (0.4) 2 (0.7)
p16 status, n (%)
n 226 220
p16 positive 164 (72.6) 171 (77.7)
p16 negative 62 (27.4) 49 (22.3)
p16 test not done or result not available 56 62
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; SD, standard deviation.
Adapted from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
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TABLE 8 The TNM stages by trial arm (1)
Stage
ND intended (n)
Before CRT After CRT
Surveillance ND Surveillance ND
T1N2a 3 4 12 11
T1N2b 5 12 24 21
T1N2c 1 2 3 –
T1N3 – 1 – 1
T2N2a 14 4 12 11
T2N2b 21 24 48 50
T2N2c 2 4 12 12
T2N3 1 1 4 2
T3N2a 2 1 7 5
T3N2b 11 5 24 25
T3N2c 3 5 11 9
T3N3 1 1 2 1
T4N2a – 4 2 4
T4N2b 8 4 25 32
T4N2c 3 2 17 17
T4N3 – – – 1
Occult N2a – – 2 –
Occult N2b 1 3 – 2
Occult N2c – – – 1
Occult N3 – – 1 –
TABLE 9 The TNM stages by trial arm (2)
Stage
ND intended, n (%)
Before CRT After CRT
Surveillance ND Surveillance ND
T stage
T1 9 (11.8) 19 (24.7) 39 (18.9) 33 (16.1)
T2 38 (50.0) 33 (42.9) 76 (36.9) 75 (36.6)
T3 17 (22.4) 12 (15.6) 44 (21.4) 40 (19.5)
T4 11 (14.5) 10 (13.0) 44 (21.4) 54 (26.3)
Occult 1 (1.3) 3 (3.9) 3 (1.5) 3 (1.5)
N stage
N2a 19 (25.0) 13 (16.9) 35 (17.0) 31 (15.1)
N2b 46 (60.5) 48 (62.3) 121 (58.7) 130 (63.4)
N2c 9 (11.8) 13 (16.9) 43 (20.9) 39 (19.0)
N3 2 (2.6) 3 (3.9) 7 (3.4) 5 (2.4)
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Withdrawals
There were 13 withdrawals in the ND group and three in the surveillance group (Table 10).
Protocol deviations
Categories and frequencies of protocol deviations are given in Table 11. A number of patients were found to
have been randomised on the basis of incorrect information. The tumour site category (oral, oropharyngeal,
laryngeal, hypopharyngeal or occult) was inconsistent with the more detailed subsites. These errors were
later corrected. Chemotherapy schedules were incorrectly recorded because of confusion over the three
schedules containing cisplatin. Correction of these errors did not adversely affect the balance of the
treatment allocation (see Baseline characteristics). The reasons why some patients in the ND arm did not
undergo a ND are better described in Neck dissections. Twenty patients were randomised after they had
already started CRT because the centre misunderstood the correct trial procedure.
Chemotherapy
Chemotherapy schedules planned at randomisation
Planned chemotherapy schedules are counted separately for patients in whom ND was planned to take
place before CRT (Table 12) and for those in whom ND was planned to take place after CRT (Tables 13 and 14).
Neoadjuvant schedules were more frequent when the planned timing was ND after CRT. A slightly higher
proportion of patients in the ND arm whose ND was planned to be before CRT had a planned concomitant
platin schedule.
Type of chemotherapy delivered
Chemotherapy details were received for 272 patients in the ND arm and 277 patients in the surveillance
arm. Overall, 10 ND patients and five surveillance patients did not have chemotherapy for the reasons
given in Table 15.
One patient in the ND arm, who was planned (at randomisation) to receive neoadjuvant and concomitant
chemotherapy, received only concomitant chemotherapy. At the same time, two patients randomised to
concomitant platinum received only neoadjuvant and concomitant therapy.
TABLE 10 Reasons for withdrawal from the trial
Reason
Trial arm (n)
Surveillance ND
Ineligible – 1
Patient did not want ND/wanted surveillance arm – 4
Wished to consent to another clinical trial – 1
Migrated to the USA for IMRT – 1
Patient decision 1 2
Patient and clinician decision 1 –
Clinician decision 1 –
No reason given – 4
IMRT, intensity-modulated radiotherapy.
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TABLE 11 Protocol deviations
Description
Trial arm (n)
Total numberSurveillance ND
Related to randomisation
Randomised on the basis of incorrect ND timing – 4 4
Randomised on the basis of incorrect T stage 1 – 1
Randomised on the basis of incorrect chemotherapy schedule 27 30 57
Randomised on the basis of incorrect tumour site 39 33 72
Subtotal 67 67 134
Others related to either trial arm
Started CRT prior to randomisation (mostly one centre) 11 9 20
Timeline of response – 1 1
Chest radiography not CT of chest 1 1 2
MRI standardised uptake value details – 1 1
Different chemotherapy schedule to planned 2 – 2
Ineligible 2 2 4
Subtotal 16 14 30
Others related to surveillance arm only
No PET–CT scan done 1 – 1
Watch and wait on partial response 1 – 1
Timeline of PET–CT 2 – 2
Partial response in nodes led to biopsy taken after PET–CT 2 – 2
Subtotal 6 – 6
Others related to ND arm only
Randomised to ND arm but patient elected not to undergo ND – 25 25
No surgery, clinician decision – 9 9
ND surgery later than protocol timeline – 2 2
Timing of surgery changed (before/after CRT) – 1 1
Underwent PET–CT – 1 1
Subtotal – 38 38
TABLE 12 Planned chemotherapy schedules: randomised as planned ND before CRT
Schedule
Trial arm, n (%)
Surveillance ND
Concomitant cisplatin or carboplatin 55 (72.4) 63 (81.8)
Concomitant cetuximab 5 (6.6) 5 (6.5)
Neoadjuvant and concomitant platinum 3 (3.9) –
Neoadjuvant docetaxel, cisplatin and 5-fluorouracil and concomitant cisplatin 12 (15.8) 9 (11.7)
Other agreed (neoadjuvant carboplatin) 1 (1.3) –
Total 76 77
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TABLE 13 Planned chemotherapy schedules: randomised as planned ND after CRT
Schedule
Trial arm, n (%)
Surveillance ND
Concomitant cisplatin or carboplatin 108 (52.4) 106 (51.7)
Concomitant cetuximab 9 (4.4) 9 (4.4)
Neoadjuvant and concomitant platinum 7 (3.4) 9 (4.4)
Neoadjuvant docetaxel, cisplatin and 5-fluorouracil and concomitant cisplatin 77 (37.4) 76 (37.1)
Other agreed (see Table 14) 5 (2.4) 5 (2.4)
Total 206 205
TABLE 14 Descriptions of other agreed chemotherapy
Chemotherapy received Number of patients
Surveillance arm
Neoadjuvant cisplatin and 5-fluorouracil, concomitant cisplatin 2
Cisplatin and 5-fluorouracil 1
TPF 2
ND arm
Neoadjuvant docetaxel, cisplatin and 5-fluorouracil, concomitant cetuximab 1
Neoadjuvant cisplatin and 5-fluorouracil, concomitant cisplatin (2) 2
Induction cisplatin and 5-fluorouracil followed by concomitant cisplatin neoadjuvant and
concomitant platinum
1
Neoadjuvant docetaxel and cisplatin and 5-fluorouracil, concomitant carboplatin 1
TABLE 15 Reasons why no chemotherapy was received
Reason for no chemotherapy
Trial arm (n)
Surveillance ND
Refused 1 –
Patient unwell – 2
Death 1 3
Did not want ND – 2
Wanted surgery 1 –
Progression/metastases 1 1
Went to the USA for treatment – 1
Withdrew 1 –
Not known – 1
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Individual drug details were available for 269 patients in the ND arm and 274 patients in the surveillance
arm (Table 16). The type of chemotherapy delivered was very similar in the trial arms.
Chemotherapy dose information
Table 17 gives median doses received as reported on the CRT chemotherapy forms.
TABLE 16 Chemotherapy received
Chemotherapy received
Trial arm (n)
Surveillance ND
Concomitant cisplatin or carboplatin schedule planned
Concomitant (cisplatin or carboplatin) 154 153
Concomitant (cisplatin or carboplatin) and 5-fluorouracil – 1
Concomitant (cisplatin or carboplatin) then changed to cetuximab – 3
Concomitant cetuximab 1 2
TPF 2 –
Concomitant cetuximab schedule planned
Concomitant cetuximab 12 13
Neoadjuvant and concomitant platin schedule planned
Neoadjuvant (cisplatin or carboplatin) and 5-fluorouracil, concomitant (cisplatin or carboplatin) 8 7
Neoadjuvant (cisplatin or carboplatin) and 5-fluorouracil 1 2
Neoadjuvant (cisplatin or carboplatin) 1 –
TPF schedule planned
TPF 71 61
Neoadjuvant (cisplatin or carboplatin), 5-fluorouracil and docetaxel 6 8
Neoadjuvant (cisplatin or carboplatin), 5-fluorouracil and docetaxel, concomitant cetuximab 8 6
Neoadjuvant (cisplatin or carboplatin) – 1
Neoadjuvant docetaxel and concomitant cisplatin or carboplatin – 1
Neoadjuvant (cisplatin or carboplatin), 5-fluorouracil and cetuximab, concomitant cetuximab 1 –
Neoadjuvant (cisplatin or carboplatin), cetuximab, 5-fluorouracil, docetaxel – 1
Neoadjuvant (cisplatin or carboplatin) and 5-fluorouracil, concomitant (cisplatin or carboplatin) 3 4
Concomitant (cisplatin or carboplatin) – 1
Other approved schedules planned
Neoadjuvant (cisplatin or carboplatin) and 5-fluorouracil, concomitant (cisplatin or carboplatin) 4 3
TPF – 2
Neoadjuvant (cisplatin or carboplatin), 5-fluorouracil and docetaxel, concomitant cetuximab 1 –
Neoadjuvant (cisplatin or carboplatin), 5-fluorouracil and docetaxel 1 –
Total 274 269
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Radiotherapy
There were 270 completed case report forms for patients randomised to ND and 278 for patients
randomised to PET–CT surveillance. Intensity-modulated radiotherapy (IMRT) was administered in 159 out
of 263 (60%) ND patients and 173 out of 269 (64%) surveillance patients. Reasons why patients did not
receive radiotherapy are given in Table 18.
There were few modifications to radiotherapy duration (Table 19). The duration of treatment in six ND
patients and three surveillance patients was 5 or more days longer than planned.
The planned doses to primary in the two treatment arms were similar (Table 20).
Median and interquartile range (IQR) planned doses to involved neck nodes were also the same (54.0 Gy,
IQR 50.0–54.0 Gy).
Neck dissections
Neck dissection was performed in 221 patients in the ND arm and in 54 patients in the surveillance arm.
TABLE 17 Median chemotherapy doses
Schedule and drug
Trial arm
Surveillance ND
n Dose (mg), median (Q1, Q3) n Dose (mg), median (Q1, Q3)
Concomitant platin
Cisplatin 136 340 (240, 420) 140 337 (240, 400)
Carboplatin (excluding AUC)a 19 780 (550, 1050) 22 645 (440, 960)
Schedule 2: concomitant cetuximab
Concomitant cetuximab 11 3500 (2580, 4210) 13 3260 (1400, 3870)
Neoadjuvant and concomitant platin
Concomitant cisplatin 7 300 (282, 320) 6 335 (120, 360)
Neoadjuvant cisplatin 8 236 (180, 266) 8 284 (210, 400)
Neoadjuvant 5-fluorouracil 8 7625 (4450, 12,450) 8 10500 (7260, 14,820)
Schedule 4: neoadjuvant TPF and concomitant platin
Concomitant cisplatin 46 332 (183, 400) 47 312 (200, 400)
Concomitant carboplatin (when not AUC) 27 920 (740, 1310) 18 972 (650, 1270)
Cetuximab 9 2120 (1650, 2300) 6 2250 (2000, 2650)
Neoadjuvant cisplatin 84 373 (264, 450) 74 400 (300, 450)
Neoadjuvant docetaxel 81 390 (240, 440) 71 420 (300, 450)
Neoadjuvant 5-fluorouracil 86 14500 (6000, 18,000) 75 14600 (5700, 18,000)
AUC, area under the curve.
a Carboplatin doses recorded as AUC are omitted.
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TABLE 19 Reasons for modification of radiotherapy duration
Reason
Trial arm (n)
Surveillance ND
Skin toxicity and mucositis 1 –
Myelosuppression – 1
Pneumonia – 1
Perforated duodenal ulcer 1 –
Did not attend 1 –
Weight loss: required replan – 1
Neutropenia and infection – 1
Admitted to hospital – 1
Constipation/poor nutritional intake – 1
TABLE 20 Planned radiotherapy schedules
Radiotherapy dose fractionation
Trial arm, n (%)
Surveillance ND
68–70 Gy in 34 or 35 fractions 95 (34.7) 86 (32.2)
60–66 Gy in 30 fractions 144 (52.6) 144 (53.9)
55 Gy in 20 fractions 28 (10.2) 28 (10.5)
Other 7 (2.6) 9 (3.4)
Not known 4 3
Reproduced from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
TABLE 18 Reason for no radiotherapy
Reason
Trial arm (n)
Surveillance ND
Refused (claustrophobic) – 1
Patient unwell – 1
Death 1 4
Did not want ND – 2
Progression/metastases 2 2
Went to the USA for IMRT – 1
Withdrew 1 –
Not known – 1
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Patients in neck dissection arm who did not undergo a neck dissection
Of the 282 patients in the ND arm, 221 underwent a planned ND. In total, 25 refused to have surgery.
A summary of reasons for the 61 who did not receive a planned ND is given in Table 21.
Summary of surveillance arm patients who had a neck dissection
According to the trial protocol, patients in the surveillance arm should undergo a ND if the PET–CT
findings are positive or equivocal. Fifty-four patients underwent ND, with 48 (36 incomplete responders
in nodes and 12 incomplete responders in primary and nodes) of them conforming to protocol in
that PET–CT was positive or equivocal. Of the remaining six, two patients did not undergo PET–CT, in
two patients PET–CT findings were equivocal or node positive in the central reviewer’s PET–CT read and
in two cases the reason is unknown.
Summary of surveillance arm patients who did not have a neck dissection
There were 228 patients in the surveillance arm who had no ND (Table 22).
Surgical details
Surgery forms were received for 275 patients who received ND surgery (Table 23).
From the above, it is important to note that, overall, the number of participants who experienced nerve
sacrifice (which is morbid) was considerably lower in the surveillance arm (4 out of 220) than in the
ND arm (22 out of 220); similar findings were obtained for sacrifice of the internal jugular vein and
sternocleidomastoid muscle.
If the numbers of structures removed are summed (counting potentially one for left and one for right),
the mean number of structures removed per ND is 0.59 in the ND arm and 0.56 in the surveillance arm.
The mean number of structures removed in the ND before group is 0.78, whereas in the ND after group
it is 0.49. Combining the five structures given, fewer patients whose planned ND was after CRT had one
or more of the structures removed (see Table 23, p = 0.02). On examination of these data, this does
not correlate with more advanced disease.
TABLE 21 Reasons for patients in ND arm not undergoing ND
Reason
ND planned (n)
Before CRT After CRT
Clinical decision – 3
Inoperable or unsuitable for surgery 1 1
Progression/metastases/residual disease 1 8
Patient unwell 1 6
Early death - 4
Patient elected not to have ND 2 23
Went to the USA for IMRT 1
Patient elected not to have ND after delay in finding operation list date 1
Had PET–CT scan and CR – 2
Patient wanted PET–CT arm – 3
No information 1 3
Reproduced from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
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Follow-up
Patients were due to be followed up by examination at the clinic at 6, 12 and 24 months after
randomisation. Late requests for survival and recurrence information were made in the last year of the trial
to obtain follow-up data for up to 5 years after randomisation.
Median follow-up for survival in the ND arm is 36.1 months (IQR 25.6–43.7 months) and for the
surveillance arm is 35.6 months (IQR 29.2–42.5 months). The survival status at 24 months is unknown for
28 patients in the ND arm and 16 in the surveillance arm. Eleven patients in the ND arm and one in the
surveillance arm have no follow-up, having, with one exception, withdrawn early. Table 24 gives
information on the timing of follow-up visits.
Serious adverse events
Summary
In the study, 282 SAEs were reported and are summarised in Table 25. There were 169 in the ND arm and
113 in the PET–CT arm; none was deemed unexpected by the chief investigator.
TABLE 22 Reasons for patients in surveillance arm who had no ND
Reason n
PET–CT, CRT, CR in primary and nodes 181
PET–CT, CRT, CR in nodes but not in primary 15
PET–CT, CRT, incomplete response in primary and nodes 7
Did not receive CRT 6
CR in primary, not in nodes 11
Retroperitoneal nodes 1
Nodes reported as CR, but after PET–CT reviewed reassigned as involved 1
New lung primary 1
Distant metastases 1
Neck node judged by MDT to be reactive 1
Recurred 5 weeks after post-CRT assessment 1
Metastases of liver and bone found at assessment 1
Biopsy confirmed no malignancy 1
Faint activity in lymph node on PET–CT but deemed to be a CR 1
MDT deemed nodal response as clear, CR 1
Biopsy, found only residuum of previously involved node 1
No information about response in primary 4
Had imaging other than PET–CT 2
Missed appointment and died 1
Had progressive disease 1
No response information having died early 2
Adapted from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
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TABLE 23 Neck dissection details
ND details
ND, n (%) Trial arm, n (%)
Before CRT
(N= 69) After CRT (N= 152) ND (N= 221) Surveillance (N= 54)
Laterality
Unilateral left 26 (37.7) 62 (41.3) 88 (40.2) 23 (42.6)
Unilateral right 36 (52.2) 68 (45.3) 104 (47.5) 28 (51.9)
Bilateral 7 (10.1) 20 (13.3) 27 (12.3) 3 (5.6)
Not available – 2 2 –
Type of ND
Modified radical 39 (56.5) 57 (37.5) 96 (43.4) 19 (35.2)
Selective 29 (42.0) 87 (57.2) 116 (52.5) 30 (55.6)
Super selective 1 (1.4) 8 (5.3) 9 (4.1) 5 (9.3)
Type of incision
J-shaped 15 (22.7) 39 (27.1) 54 (25.7) 14 (26.4)
Y-shaped (triradiate) 13 (19.7) 9 (6.3) 22 (10.5) 1 (1.9)
U-shaped (utility) 11 (16.7) 26 (18.1) 37 (17.6) 10 (18.9)
McFee 3 (4.5) 8 (5.6) 11 (5.2) 9 (17.0)
Other 24 (36.4) 62 (43.1) 86 (41.0) 19 (35.8)
Not available 3 8 11 1
Neck structures removed
Internal jugular vein 20 (29.0) 24 (15.8) 44 (19.9) 14 (25.9)
Spinal accessory nerve 12 (17.4) 10 (6.6) 22 (10.0) 4 (7.4)
Sternocleidomastoid muscle 20 (29.0) 30 (19.7) 50 (22.6) 11 (20.4)
Common and internal carotid artery 2 (2.9) 2 (1.3) 4 (1.8) –
Skin 3 (4.3) 1 (0.7) 4 (1.8) 1 (1.9)
Number of patients with any of the
above structures removed
30 (43.5) 42 (27.6) 72 (32.6) 17 (31.5)
Adapted from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
TABLE 24 Timing of follow-up visits by trial arm
Trial follow-up time point
Trial arm
Surveillance ND
Number of
patients
Time (months)
from randomisation
to examination
median (IQR)
Number of
patients
Time (months)
from randomisation
to examination
median (IQR)
6 months 270 6.3 (5.9–7.1) 258 6.3 (5.8–7.3)
12 months 257 12.2 (11.7–12.9) 234 12.3 (11.8–13.1)
24 months 227 24.3 (23.7–25.3) 210 24.3 (23.8–25.3)
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Tables 26 and 27 show that the most common SAE was hospitalisation or prolongation of hospitalisation
due to CRT, which was very high for ND post CRT. The rates of other SAEs are similar in the ND before
and after CRT trial arms and in the surveillance ND arm.
TABLE 25 Serious adverse events summary
SAE summary
Trial arm, n
ND Surveillance
Planned
Total
(N= 282)
Total
(N= 282)
Before CRT
(N= 77)
After CRT
(N= 205)
Number of SAEs 35 134 169a 113a
Number of patients with at least one SAE 25 87 112 89
Percentage of patients experiencing SAEs 32.5 42.4 39.7 31.6
a p= 0.001 for difference in number of SAEs between arms.
TABLE 26 Primary reasons for reporting SAEs
Primary reasons for reporting
(> 1 allowed per patient)
Trial arm, n
ND Surveillance
Planned
Total
(N= 282)
Total
(N= 282)
Before CRT
(N= 77)
After CRT
(N= 205)
Death 2 1 3 3
Life-threatening event 2 13 15 11
Inpatient hospitalisation or prolongation of
existing hospitalisation
29 129 158 104
Persistent or significant disability/incapacity 3 6 9 10
Other medically significant reason for reporting 2 4 6 5
TABLE 27 Causality of serious events
Causality
Trial arm, n
ND Surveillance
Planned
Total TotalBefore CRT After CRT
Surgery 4 6 10 5
CRT 22 88 110 75
CRT and surgery – 2 2 –
CRT and other – 4 4 1
Other 9 34 43 32
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Of the SAEs with hospitalisation as a result of to CRT in the ND after CRT group, 67 out of 71 patients
(94.4%) had their SAE before surgery (Table 28).
The highest symptom grades of the events are given comparing trial arms in Table 29 and comparing ND
before CRT with ND after CRT in Table 30. No difference is seen between groups in either case (p = 0.99
and p = 0.42 for trend).
TABLE 28 Outcome of SAEs
Outcomes
Trial arm, n
ND Surveillance
Planned
Total TotalBefore CRT (N= 35 events) After CRT (N= 134 events)
Resolved 27 107 134 94
Not yet resolved 6 23 29 15
Deaths 2 4 6 4
TABLE 29 Symptom grades of SAEs by trial arm
Highest symptom grade of event
Trial arm, number of SAEs (%)
Surveillance (N= 89) ND (N= 112)
5 1 (0.4) 1 (0.4)
4 8 (2.8) 15 (5.3)
3 64 (22.7) 71 (25.2)
2 10 (3.5) 18 (6.4)
1 6 (2.1) 7 (2.5)
No difference is seen in the grades of the events (p = 0.99 for trend).
TABLE 30 Symptom grades of SAEs: ND before and after CRT
Highest symptom grade of event
ND, number of SAEs (%)
Before CRT (N= 77) After CRT (N= 205)
5 – (–) 1 (0.5)
4 4 (5.2) 11 (5.4)
3 13 (16.9) 58 (28.3)
2 6 (7.8) 12 (5.9)
1 2 (2.6) 5 (2.4)
0, that is, no SAE 52 (67.5) 118 (57.6)
p= 0.09 for trend; p= 0.42 excluding last line.
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Overall survival
Median follow-up for survival was 35.6 months (IQR 29.2–42.5 months) in the surveillance arm and
36.1 months (IQR 25.6–43.7 months) in the ND arm.
There have been 123 deaths reported in the trial: 62 in the ND arm and 61 in the surveillance arm. Of
these, 92 occurred within 2 years of randomisation. One death in the surveillance arm occurred > 5 years
after randomisation and is not included in the time-to-event analysis.
Overall survival is plotted by treatment arm (Figure 4). The 2-year OS rate for the trial was 83.2% (95% CI
80.1% to 86.4%). This was higher than that expected at the start of the trial (75%). Consequently, the
retrospective power of the study with 122 deaths was 72%.
The 2-year OS in the ND arm was 81.5% (95% CI 76.9% to 86.2%) and in the PET–CT surveillance arm
was 84.9% (95% CI 80.7% to 89.1%).
Primary outcome overall survival
The prespecified analysis takes account of timing of planned ND by stratification (planned ND before CRT
and planned ND after CRT). These are plotted separately in Figures 5 and 6, respectively.
Analysing by proportional hazards model (Table 31) stratified by intended timing of ND before or after
CRT, the HR is 0.924 (95% CI 0.648 to 1.318) in favour of the surveillance arm. The limit for non-
inferiority in the trial design was set at a HR of 1.50, which lies at the 99.63th percentile of the estimated
CI for the HR, which can be interpreted as a one-sided p-value of 0.0037, that is, indicating non-inferiority
(HR < 1.5). The conventional two-sided p-value for difference between treatments is 0.6621.
Further analyses of overall survival
The early drop in the Kaplan–Meier curve of the group that had a planned ND before CRT suggests some
non-proportionality of hazards between treatment groups. This is confirmed by testing an interaction between
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FIGURE 4 Overall survival by treatment arm. Reproduced from the New England Journal of Medicine, Mehanna H,
Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT Surveillance versus Neck Dissection in
Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016) Massachusetts Medical Society. Reprinted
with permission.62
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treatment and log-(time) (p-value for the time interaction is 0.03). No evidence of non-proportionality is
seen in the planned ND after CRT stratum (p = 0.38). An alternative analysis to the Cox’s model is stratifying
analysis into two risk periods, namely the first year and rest of the period at risk. The result of this additional
unplanned analysis gives a very similar HR of 0.922 (instead of 0.924 in Table 31).
Adjusting for centre, T stage, N stage, site of primary, chemotherapy schedule, sex and age gives a very
similar result, as does further adjustment for p16 status on a reduced sample (Table 32).
p16 status was highly prognostic, but there was no difference between p16-positive and p16-negative
status in terms of the trial result, as shown in Table 32 and Figures 7 and 8.
The HRs in Figure 9 are stratified by planned ND timing (before or after CRT). Some of the groups are
small and differences between them should be interpreted cautiously. There is some evidence that the ND
arm did better in the T stage 1/2 group than in the T3–T4 group. The small group of females in the trial
did particularly well in the surveillance arm (treatment interaction p = 0.01), although with a total of only
18 deaths this is not a reliable result. There was no difference in the trial result by p16 status, which was
highly prognostic. In unplanned analyses, the ND arm did worse in the first year at risk, and no difference
was seen in the trial result by radiotherapy dose, IMRT versus conformal radiotherapy or high- versus
low-recruiting centres.
Mortality by cause
Deaths attributable to head and neck cancer
The causes of death are summarised in Table 33. These include complications attributable to surgery or
CRT and persistent, recurrent or metastatic H&N cancer at death. There were 92 deaths due to H&N
cancer and 29 deaths from other causes (detailed in Table 34).
TABLE 32 Overall survival: Cox’s models adjusted and subgroups
OS proportional hazards model
Number
of events
Treatment HR estimate
(95% CI) HR 1.50 (%)
Stratified by ND pre/post adjusted for centre, T stage,
N stage, tumour site, chemotherapy schedule, sex
and age
122 0.835 (0.571 to 1.222) 99.87
Stratified by ND pre/post, adjusted as above plus p16
status (categorised as positive/negative/not known)
122 0.759 (0.513 to 1.124) 99.97
ND before CRT subgroup 31 0.664 (0.325 to 1.356) 98.7
ND after CRT subgroup 91 1.033 (0.685 to 1.558) 96.2
p16-positive subgroup stratified by ND pre/post 40 0.736 (0.393 to 1.378) 98.7
p16-negative subgroup stratified by ND pre/post 58 0.982 (0.583 to 1.654) 94.4
Adapted from the New England Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M,
Hartley AGJ, PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright ©
(2016) Massachusetts Medical Society. Reprinted with permission.62
TABLE 31 Primary outcome: OS
OS proportional hazards model Number of events Treatment HR estimate (95% CI) HR 1.50 (%)
Stratified by ND pre/post (prespecified
analysis of primary outcome)
122 0.924 (0.648 to 1.318) 99.63
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Head and neck cancer mortality: cumulative incidence
There is little difference between the trial arms in the incidence of H&N cancer-related deaths (Figure 10).
The 2-year cumulative incidence rates for H&N mortality are 13.66% (95% CI 9.88% to 18.04%) in the
ND arm and 12.25% (95% CI 8.72% to 16.42%) in the surveillance arm. A Gray’s test for difference
between cumulative incidence functions gives a p-value of 0.7992.
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100
90
80
70
60
50
Pe
rc
en
ta
g
e
40
30
20
10
0
0 24
Months
12 36 48 60
171
164
Number at risk
ND
PET–CT surveillance
140
145
157
157
81
78
23
24
5
4
p16 positive, ND (23 deaths) 
(n = 171)
p16 positive, PET–CT 
surveillance (17 deaths)
(n = 164)
FIGURE 7 Overall survival: p16 positive.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Events/patients
PET–CT ND
13/76
(17.1%)
47/206
(22.8%)
18/77
(23.4%)
44/205
(21.5%)
0.67 (0.33 to 1.35)
1.03 (0.68 to 1.56)
Timing
     ND before CRT
     ND after CRT
(a) aHR and CI
PET–CT : ND
aHR and CI
PET–CT : ND
Interaction between two groups   1 = 1.1; p = 0.29χ2
28/162
(17.3%)
32/116
(27.6%)
0/4
(0.0%)
18/160
(11.3%)
42/116
(36.2%)
2/6
(33.3%)
1.50 (0.84 to 2.68)
0.70 (0.44 to 1.11)
T stage
     T stage 1/2
     T stage 3/4
     Occult
Heterogeneity between three groups   2 = 6.4; p = 0.04χ2
54/223
(24.2%)
6/59
(10.2%)
50/237
(21.1%)
12/45
(26.7%)
1.15 (0.78 to 1.69)
0.29 (0.11 to 0.77)
Sex
     Male
     Female
Interaction between two groups   1 = 6.7; p = 0.01χ
2
6/37
(16.2%)
28/135
(20.7%)
22/90
24.4%
4/20
(20.0%)
9/43
(20.9%)
23/113
(20.4%)
24/107
(22.4%)
6/19
(31.6%)
0.77 (0.27 to 2.15)
0.96 (0.55 to 1.68)
1.09 (0.61 to 1.95)
0.58 (0.16 to 2.14)
Age (years)
     < 50
     50–59
     < 60–69
     > 70
60/282
(21.3%)
62/282
(22.0%)
0.92 (0.65 to 1.32)
10.05.04.03.02.00.5
PET–CT better ND better
0.40.30.20.1
All patients
Heterogeneity between four groups   3 = 0.9; p = 0.82χ2
Test for trend over four groups   1 = 0.0; p = 0.97χ2
1/4
(25.0%)
46/240
(19.2%)
7/18
(38.9%)
6/15
(40.0%)
0/5
(0.0%)
1/7
(14.3%)
42/236
(17.8%)
8/19
(42.1%)
8/14
(57.1%)
3/6
(50.0%)
1.05 (0.69 to 1.59)
0.76 (0.27 to 2.16)
0.45 (0.15 to 1.32)
Site
     Oral
     Oropharyngeal
     Laryngeal
     Hypopharyngeal
     Occult
Heterogeneity between five groups   4 = 5.3; p = 0.26χ2
31/163
(19.0%)
5/14
(35.7%)
1/10
(10.0%)
22/89
(24.7%)
1/5
(20.0%)
35/169
(20.7%)
5/14
(35.7%)
4/9
(44.4%)
18/85
(21.2%)
0/5
(0.0%)
0.88 (0.54 to 1.43)
1.03 (0.30 to 3.60)
1.10 (0.59 to 2.04)
Chemotherapy schedule
     Concomitant platin
     Concomitant cetuximab
     Neoadjuvant and concomitant platin
     Neoadjuvant TPF with concomitant 
     platin
     Other
Heterogeneity between five groups   4 = 2.7; p = 0.61χ
2
95% CI
95% CI
a
FIGURE 9 Overall survival of subgroups. Method as described in Early Breast Cancer Trialists’ Collaborative Group.
Treatment of Early Breast Cancer. Volume 1. Worldwide Evidence 1985–1990. Oxford: Oxford University Press;
1990.57 (a) Overall survival of subgroups 1; and (b) overall survival of subgroups 2. Adapted from the New England
Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT
Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016)
Massachusetts Medical Society. Reprinted with permission.62 (continued )
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Other cause mortality: cumulative incidence
The difference in non-cancer deaths is also small (Figure 11).
The 2-year cumulative incidence rates for other causes of mortality are 4.80% (95% CI 2.68% to 7.82%)
in the ND arm and 2.88% (95% CI 1.36% to 5.37%) in the surveillance arm. A Gray’s test for difference
between cumulative incidence functions gives a p-value of 0.4124.
Events/patients
PET–CT ND
14/206
(6.8%)
42/259
(16.2%)
16/205
(7.8%)
33/243
(13.6%)
0.59 (0.33 to 1.05)
1.22 (0.78 to 1.92)
Risk period
     First year at risk
     After first year
(b) aHR and CI
PET–CT : ND
aHR and CI
PET–CT : ND
Interaction between two groups   1 =3.7; p = 0.05
χ2
17/164
(10.4%)
33/62
(53.2%)
10/56
(17.9%)
23/171
(13.5%)
25/49
(51.0%)
14/62
(22.6%)
0.74 (0.40 to 1.37)
0.98 (0.58 to 1.66)
0.76 (0.34 to 1.70)
p16 status
     p16 positive
     p16 negative
     p16 unknown
Heterogeneity between three groups   2 = 0.6; p = 0.75
χ2
33/148
(22.3%)
27/134
(20.1%)
34/155
(21.9%)
28/127
(22.0%)
0.97 (0.60 to 1.57)
0.89 (0.52 to 1.51)
Size of recruiting centre
     Centres recruiting > 20 patients
     Centres recruiting < 20 patients
Interaction between two groups   1 = 0.1; p = 0.80
χ2
60/282
(21.3%)
62/282
(22.0%)
0.92 (0.65 to 1.32)
10.05.04.03.02.00.5
PET–CT better ND better
0.40.30.20.1
All patients
24/95
(25.3%)
23/144
(16.0%)
9/28
(32.1%)
14/96
(14.6%)
29/144
(20.1%)
9/28
(32.1%)
1.65 (0.87 to 3.12)
0.75 (0.43 to 1.29)
0.90 (0.36 to 2.28)
Radiotherapy schedule
     RT dose 68–70 in 34–35 fractions
     RT dose 60–66 in 30 fractions
     RT does 55 in 20 fractions
Heterogeneity between three groups   2 = 3.5; p = 0.17
χ2
Test for trend over three groups   1 = 2.0; p = 0.16
χ2
18/96
(18.8%)
36/173
(20.8%)
21/104
(20.2%)
30/159
(18.9%)
0.91 (0.48 to 1.70)
1.05 (0.65 to 1.70)
IMRT
     Conformal radiotherapy
     IMRT
Interaction between two groups   1 = 0.1; p = 0.72
χ2
95% CI
95% CI
a
FIGURE 9 Overall survival of subgroups. Method as described in Early Breast Cancer Trialists’ Collaborative Group.
Treatment of Early Breast Cancer. Volume 1. Worldwide Evidence 1985–1990. Oxford: Oxford University Press;
1990.57 (a) Overall survival of subgroups 1; and (b) overall survival of subgroups 2. Adapted from the New England
Journal of Medicine, Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT
Surveillance versus Neck Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016)
Massachusetts Medical Society. Reprinted with permission.62
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TABLE 34 Description of non-H&N cancer causes
Arm Cause
PET–CT
Before CRT stratum Cardiac failure
Malignant plasma cell neoplasm: extramedullary plasmacytoma
Pneumonia
After CRT stratum Road traffic accident
New primary non-small cell lung cancer
Extensive bilateral consolidation secondary to severe infection
Second primary lung
Bronchopneumonia: squamous cell carcinoma oropharynx
Severe depression
Post-operative complications for second primary oesophagus
Chest sepsis
Unknown primary: probably lung, widespread metastases
Renal cancer, cardiovascular and respiratory failure. Low anterior resection plus ileostomy
ND
Before CRT Pneumonia
Aspiration pneumonia
Glioblastoma
Bilateral pneumonia
Infection
After CRT Unknown
Patient on dialysis, died of renal failure
Metastatic non-small cell lung cancer
Left ventricular failure, myocardial infarction
Second primary
Sudden death at home, no recurrence of H&N cancer
Neutropenic sepsis as a result of colitis
Bronchopneumonia
Cerebrovascular accident
Coronary artery atherosclerosis
Not known as patient moved away
Aspiration pneumonia
TABLE 33 Causes of death
Cause of death
Randomised as ND policy (n)
Total (n)Before CRT After CRT
Surveillance ND Surveillance ND Surveillance ND
H&N cancer 11 13 37 31 48 44
Other causes 3 5 10 11 13 16
Not known – – – 2 – 2
Total 14 18 47 44 61 62
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Recurrences
Information on recurrences and persistent disease is obtained mainly from recurrence forms, and also via
cause of death information. Recurrence is defined using the date of completion of radiotherapy. Disease
that is apparent < 3 months after radiotherapy is defined as persistent disease. Disease that is apparent
later than 3 months is defined as a recurrence. Frequencies of persistent disease and reported sites of
recurrence are shown in Table 35.
For Kaplan–Meier analysis of recurrence (Figure 12), the time of recurrence is taken as the time from
completion of radiotherapy to reported recurrence or to cancer death if there is no reported recurrence.
Consequently, the time at risk for some patients starts after the ND, while for others it is before ND and
others still have no ND. The 2-year recurrence rates are 16.0% (95% CI 11.4% to 20.6%) in the ND arm
and 14.4% (95% CI 10.1% to 18.7%) in the surveillance arm.
Four of the six surveillance patients with recurrence in neck nodes were complete responders on the
post-CRT PET–CT scan.
Two of the three surveillance patients with recurrence in the neck had a CR only on post-CRT PET–CT.
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FIGURE 10 Mortality attributable to H&N cancer.
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FIGURE 11 Mortality attributable to causes other than H&N cancer.
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Complications of neck dissection
Information on surgical complications was supplied for 220 of the 221 NDs in the ND arm and 53 of 54 in
the surveillance arm. Table 36 separates the results by ND pre/post CRT planned at the time of randomisation.
The overall complication rate per ND is 0.38 in the ND arm and 0.42 in the surveillance arm.
TABLE 35 Recurrences and persistent disease
Recurrence/persistent disease
Trial arm, n
Surveillance ND
Total reports of recurrence/persistent disease 59 52
Reports via recurrence forms 54 46
Reports via cause of death only 5 6
Persistent disease (< 3 months after radiotherapy completion) 14 10
Recurrence (> 3 months after radiotherapy completion) 45 42
Recurrence in primary 21 16
In primary only 15 12
Recurrence in neck nodes 6 2
In neck nodes only 3 1
Recurrence site distant 21 23
Distant only 17 18
Site unknown 4 6
100
90
80
70
60
50
Pe
rc
en
ta
g
e
40
30
20
10
0
0 24
Months
12 36 48 60
260
264
Number at risk
ND
PET–CT surveillance
158
159
212
234
72
62
17
21
ND (42 events) 
PET–CT surveillance (45 events)
FIGURE 12 Time to recurrence by treatment arm.
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TABLE 36 Complications of ND surgery by trial arm
Surgical complication
Trial arm, n (rate) [95% CI]
ND (N= 220) Surveillance (N= 53)
Pre CRT (n= 69) Post CRT (n= 151) Pre CRT (n= 16) Post CRT (n= 37)
No complications 50 (72.46%)
[60.89% to 81.67%]
118 (78.15%)
[70.86% to 84.03%]
10 (62.50%)
[38.53% to 81.63%]
24 (64.86%)
[48.70% to 78.23%]
General
Chest infection 1 (1.45%)
[0.00% to 8.52%]
3 (1.99%)
[0.42% to 5.94%]
– –
Urinary tract infection – – – 2 (5.41%)
[0.57% to 18.63%]
Septicaemia – 1 (0.66%)
[0.00% to 4.03%]
– –
Other general
(see Table 37)
– 2 (1.32%)
[0.06% to 5.01%]
– 1 (2.70%)
[0.00% to 15.05%]
Local
Breach of tumour 1 (1.45%)
[0.00% to 8.52%]
– – –
Intraoperative chyle leak 1 (1.45%)
[0.00% to 8.52%]
1 (0.66%)
[0.00% to 4.03%]
– 2 (5.41%)
[0.57% to 18.63%]
Wound infection 3 (4.35%)
[0.99% to 12.52%]
9 (5.96%)
[3.02% to 11.09%]
1 (6.25%)
[0.00% to 30.31%]
3 (8.11%)
[2.06% to 22.03%]
Postoperative chyle leak 1 (1.45%)
[0.00% to 8.52%]
3 (1.99%)
[0.42% to 5.94%]
1 (6.25%)
[0.00% to 30.31%]
–
Vagal palsy 1 (1.45%)
[0.00% to 8.52%]
– – –
Marginal mandibular
nerve palsy
5 (7.25%)
[2.77% to 16.23%]
3 (1.99%)
[0.42% to 5.94%]
1 (6.25%)
[0.00% to 30.31%]
–
Postoperative
haematoma
3 (4.35%)
[0.99% to 12.52%]
5 (3.31%)
[1.21% to 7.72%]
1 (6.25%)
[0.00% to 30.31%]
–
Breakdown of wound 2 (2.90%)
[0.20% to 10.57%]
6 (3.97%)
[1.65% to 8.59%]
– 1 (2.70%)
[0.00% to 15.05%]
Shoulder movement
disability
4 (5.80%)
[1.85% to 14.40%]
10 (5.96%)
[3.02% to 11.09%]
– 3 (8.11%)
[2.06% to 22.03%]
Hypoglossal nerve palsy – 2 (1.32%)
[0.06% to 5.01%]
1 (6.25%)
[0.00% to 30.31%]
2 (5.41%)
[0.57% to 18.63%]
Seroma 1 (1.45%)
[0.00% to 8.52%]
5 (3.31%)
[1.21% to 7.72%]
– 1 (2.70%)
[0.00% to 15.05%]
Other local
(see Table 37)
1 (1.45%)
[0.00% to 8.52%]
9 (5.96%)
[3.02% to 11.09%]
1 (6.25%)
[0.00% to 30.31%]
1 (2.70%)
[0.00% to 15.05%]
Total number of
complications
24 59 6 16
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
54
The complications given in the table as ‘other local’ and ‘other general’ are as in Table 37.
In Table 38, complication counts are given by whether or not the NDs were actually performed before or
after CRT.
Quality of life
Completion of quality-of-life questionnaires
The total return rate of quality-of-life questionnaires, based on the number that could have been received
if all surviving patients completed all of them, was 76.4% in the ND arm and 80.6% in the surveillance
arm. Generally, the return rates (Table 39) were at least 70% at each time point and they were returned at
the required times.
The patients who responded to the questionnaire at 24 months were broadly similar in terms of baseline
characteristics to those living patients from whom there was no response, but the non-responders had
slightly worse survival beyond 24 months.
Questionnaires in both trial arms were completed at the designated times (Table 40). The questions were
well answered, allowing most scales to be computable in the majority of cases (Table 41). The questionnaires
were well completed, with most scales computable in the majority of cases.
Baseline quality-of-life questionnaire scores
The quality-of-life, H&N function and dysphagia-related scores were well balanced between the treatment
arms (Table 42).
TABLE 37 Complications of ND surgery, other
Arm ND pre/post Other general complication
ND Pre Fistula
ND Post Throat pain
ND Post Tracheostomy
ND Post Other nerve damage
ND Post Reduced oral intake
ND Post Oedema
ND Post Other nerve damage
ND Post Reduced sensation over right ear
ND Post Oedema
ND Post Infection
ND Post Dysphagia
ND Post Oedema
PET–CT Pre Fistula
PET–CT Post Intraoperative possible air embolism unconfirmed
PET–CT Post Required continuous pressure airway support for 1 day
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TABLE 38 Complications of ND surgery as received that are not intention to treat
Surgical complication
Trial arm, n (rate) [95% CI]
ND arm Surveillance arm
ND performed
pre CRT (N= 64)
ND performed
post CRT (N= 152)
ND performed
(N= 54)
No complications 49 (76.56%)
[64.76% to 85.35%]
118 (77.63%)
[70.34% to 83.56%]
34 (62.96%)
[49.60% to 74.60%]
General
Chest infection 1 (1.56%)
[0.00% to 9.14%]
3 (1.97%)
[0.41% to 5.90%]
–
Urinary tract infection – – 2 (3.70%)
[0.30% to 13.26%]
Septicaemia – 1 (0.66%)
[0.00% to 4.00%]
–
Other general – 2 (1.32%)
[0.06% to 4.97%]
1 (1.85%)
[0.00% to 10.69%]
Local
Intraoperative chyle leak 1 (1.56%)
[0.00% to 9.14%]
1 (0.66%)
[0.00% to 4.00%]
2 (3.70%)
[0.30% to 13.26%]
Wound infection 1 (1.56%)
[0.00% to 9.14%]
9 (5.92%)
[3.00% to 11.02%]
4 (7.41%)
[2.42% to 18.05%]
Postoperative chyle leak 1 (1.56%)
[0.00% to 9.14%]
3 (1.97%)
[0.41% to 5.90%]
1 (1.85%)
[0.00% to 10.69%]
Vagal palsy 1 (1.56%)
[0.00% to 9.14%]
– –
Marginal mandibular nerve palsy 5 (7.81)
[3.00% to 17.4%]
3 (1.97%)
[0.41% to 5.90%]
1 (1.85%)
[0.00% to 10.69%]
Postoperative haematoma 2 (3.13%)
[0.23% to 11.33%]
5 (3.29%)
[1.21% to 7.68%]
1 (1.85%)
[0.00% to 10.69%]
Breakdown of wound 1 (1.56%)
[0.00% to 9.14%]
6 (3.95%)
[1.63% to 8.53%]
1 (1.85%)
[0.00% to 10.69%]
Shoulder movement disability 4 (6.25%)
[2.01% to 15.44%]
10 (6.58%)
[3.48% to 11.82%]
3 (5.56%)
[1.32% to 15.70%]
Hypoglossal nerve palsy – 2 (1.32%)
[0.06% to 4.97%]
3 (5.56%)
[1.32% to 15.70%]
Seroma 1 (1.56%)
[0.00% to 9.14%]
5 (3.29%)
[1.21% to 7.68%]
1 (1.85%)
[0.00% to 10.69%]
Other local 1 (1.56%)
[0.00% to 9.14%]
9 (5.92%)
[3.00% to 11.02%]
2 (3.70%)
[0.30% to 13.26%]
Total number of complications 19 59 22
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TABLE 39 Questionnaire received
Quality-of-life questionnaire status
Trial arm
Surveillance ND
Total randomised 282 282
Number of quality-of-life questionnaires received 1 5
Baseline questionnaire
Received (% of total alive) 262 (92.9) 261 (92.6)
Not received 19 16
2 weeks after CRT
Received (% of total alive) 211 (75.4) 196 (70.8)
Not received 67 71
Died 2 5
Withdrawn from trial 1 5
6 months after randomisation
Received (% of total alive) 208 (76.5) 183 (68.3)
Not received 61 71
Died 10 14
Withdrawn from trial 2 9
12 months after randomisation
Received (% of total alive) 197 (76.1) 181 (72.7)
Not received 58 53
Died 23 33
Withdrawn from trial 3 10
24 months after randomisation
Received (% of total alive) 195 (81.9) 179 (76.8)
Not received yet 38 39
Died 44 49
Withdrawn from trial 4 10
TABLE 40 Timing of questionnaires
Time point
Time from randomisation to completion, median (IQR)
Surveillance ND
2 weeks after CRT 87 days (69–117 days) 95 days (72–117 days)
6 months 6.2 months (5.8–7.1 months) 6.4 months (5.8–7.3 months)
12 months 12.2 months (11.9–13.1 months) 12.4 months (11.9–13.2 months)
24 months 24.5 months (23.9–25.8 months) 24.5 months (23.9–25.7 months)
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TABLE 41 Completeness of quality-of-life questionnaires
Completeness
Trial arm, n (%)
Total, N (%)Surveillance ND
EORTC QLQ-C30
All scales computable 1000 (93.2) 928 (92.8) 1928 (93.0)
One scale (out of 15) missing 54 (5.0) 52 (5.2) 106 (5.1)
More than one scale missing 19 (1.8) 20 (2.0) 39 (1.9)
EORTC QLQ-H&N35
All scales computable 865 (80.5) 818 (81.9) 1683 (81.2)
One scale (out of 18) missing 142 (13.2) 115 (11.5) 257 (12.4)
More than one scale missing 67 (6.2) 66 (6.6) 133 (6.4)
MDADI dysphagia questionnaire
All scales computable 1023 (95.3) 949 (94.9) 1972 (95.1)
One scale (out of five) missing 19 (1.8) 18 (1.8) 37 (1.8)
More than one scale missing 31 (2.9) 33 (3.3) 64 (3.1)
EQ-5D (3L)
All items present 1008 (93.9) 937 (93.7) 1945 (93.8)
At least one item missing 65 (6.1) 63 (6.3) 128 (6.2)
3L, three levels.
TABLE 42 Baseline quality-of-life scores
Quality-of-life scale
Trial arm, mean (SD)
Surveillance (n= 281) ND (n= 277)
QLQ-C30 scores (scale 0–100, high values are good)
Global health status 71.3 (20.5) 71.0 (21.4)
Physical functioning 91.2 (15.6) 90.6 (16.7)
Role functioning 84.3 (26.3) 84.0 (25.7)
Emotional functioning 74.5 (22.3) 74.8 (22.6)
Cognitive functioning 85.1 (20.7) 84.8 (20.9)
Social functioning 82.5 (25.1) 80.3 (24.4)
QLQ-C30 symptoms and side effects (scale 0–100, low values are good)
Fatigue 77.0 (24.1) 77.4 (23.6)
Nausea and vomiting 94.7 (13.4) 95.8 (11.6)
Pain 78.4 (26.2) 77.8 (26.1)
Dyspnoea 90.6 (18.6) 89.5 (22.3)
Insomnia 72.2 (30.7) 69.1 (31.3)
Appetite loss 81.5 (28.3) 83.5 (25.6)
Constipation 87.0 (23.4) 86.9 (23.2)
Diarrhoea 95.3 (13.7) 94.6 (14.9)
Financial difficulties 76.8 (33.9) 79.7 (30.7)
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The European Organisation for Research and Treatment of Cancer’s Quality
of Life Questionnaire for Cancer (with 30 questions) quality-of-life outcomes
In Tables 43–47, ‘mean treatment difference’ is the mean change from baseline in the surveillance arm
minus the mean change from baseline in the ND arm. For these preplanned analyses of quality-of-life
scores, no p-value was specified for determining a significant difference. In Table 43, global and
functioning scales are low = bad, high = good. So, a positive mean treatment difference is good for the
PET–CT arm. There are no clear differences as, for example, in global health status depicted in Figure 13,
but results are slightly more favourable for the surveillance arm. It suggests that the symptoms and
quality-of-life effects of ND are less impactful that those of the CRT.
TABLE 42 Baseline quality-of-life scores (continued )
Quality-of-life scale
Trial arm, mean (SD)
Surveillance (n= 281) ND (n= 277)
H&N35 scores (H&N quality of life) (scale 0–100, high values are good)
Pain 75.7 (23.7) 73.5 (25.2)
Swallowing 87.0 (19.9) 85.1 (22.5)
Senses problems 91.6 (17.4) 90.6 (17.8)
Speech problems 87.8 (18.5) 87.5 (18.2)
Trouble with social eating 86.7 (22.2) 87.5 (21.8)
Trouble with social contact 93.0 (15.7) 93.9 (14.0)
Less sexuality 75.9 (32.3) 78.0 (32.9)
Teeth 87.1 (26.6) 85.5 (26.6)
Opening mouth 87.5 (25.8) 85.3 (28.0)
Dry mouth 77.4 (28.6) 81.7 (24.4)
Sticky saliva 84.0 (25.4) 84.4 (27.2)
Coughing 74.2 (25.4) 74.8 (26.9)
Felt ill 84.2 (25.5) 86.5 (21.0)
Used painkillers 36.4 (48.2) 33.8 (47.4)
Taken nutritional supplements 84.3 (36.5) 84.5 (36.3)
Used a feeding tube 97.3 (16.2) 94.6 (22.7)
Weight loss 72.7 (44.7) 71.4 (45.3)
Weight gain 85.0 (35.8) 85.5 (35.3)
MDADI (dysphagia scales) (scale 0–100, high values are good)
Global 76.5 (29.0) 75.3 (29.7)
Emotional 77.8 (18.9) 76.8 (18.0)
Functional 81.2 (19.7) 80.8 (19.1)
Physical 76.2 (24.5) 75.4 (23.3)
Total 78.1 (20.3) 77.2 (19.4)
SD, standard deviation.
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TABLE 43 The EORTC’s QLQ-C30 quality-of-life treatment differences
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
QLQ-C30 global health status
Post CRT 196 186 0.12 0.97
6 months 192 169 4.94 0.03
12 months 182 171 3.03 0.09
24 months 180 166 –0.81 0.85
QLQ-C30 physical functioning
Post CRT 198 190 –0.45 0.93
6 months 190 173 3.51 0.08
12 months 183 173 4.29 0.01
24 months 179 170 –0.9 0.89
QLQ-C30 role functioning
Post CRT 196 187 0.81 0.93
6 months 188 172 3.71 0.14
12 months 182 169 12.09 0.001
24 months 177 169 –0.71 0.74
QLQ-C30 emotional functioning
Post CRT 197 185 0.97 0.82
6 months 192 168 3.83 0.26
12 months 183 170 4.05 0.34
24 months 180 166 0.86 0.48
QLQ-C30 cognitive functioning
Post CRT 194 181 –0.09 0.82
6 months 190 168 1.24 0.48
12 months 178 167 4.63 0.31
24 months 175 161 0.15 0.93
QLQ-C30 social functioning
Post CRT 191 180 –2.69 0.64
6 months 184 166 2.51 0.41
12 months 181 168 5.37 0.07
24 months 176 163 –5.57 0.04
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TABLE 44 The EORTC’s QLQ-C30 symptom scale treatment differences
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
QLQ-C30 fatigue
Post CRT 199 190 –2.35 0.52
6 months 191 173 5.25 0.08
12 months 184 173 4.75 0.07
24 months 180 170 4.52 0.20
QLQ-C30 nausea and vomiting
Post CRT 195 189 2.81 0.62
6 months 189 172 –1.48 0.29
12 months 184 171 3.09 0.06
24 months 180 167 –1.17 0.43
QLQ-C30 pain (i.e. general)
Post CRT 191 182 0.46 0.92
6 months 185 165 7.65 0.01
12 months 179 169 8.49 0.01
24 months 176 165 3.98 0.11
QLQ-C30 dyspnoea
Post CRT 197 188 0.91 0.69
6 months 188 173 0.3 0.60
12 months 183 171 3.79 0.08
24 months 179 170 1.34 0.69
QLQ-C30 insomnia
Post CRT 197 190 –2.45 0.28
6 months 191 173 5.07 0.21
12 months 184 172 –1.1 0.93
24 months 179 170 –4.14 0.19
QLQ-C30 appetite loss
Post CRT 195 189 6.42 0.10
6 months 189 172 7.22 0.11
12 months 184 172 7.49 0.09
24 months 179 167 4.35 0.35
QLQ-C30 constipation
Post CRT 198 189 –4.48 0.28
6 months 191 172 –0.43 0.50
12 months 183 171 0.99 0.57
24 months 180 169 –0.33 0.70
continued
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TABLE 44 The EORTC’s QLQ-C30 symptom scale treatment differences (continued )
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
QLQ-C30 diarrhoea
Post CRT 198 186 –0.21 0.99
6 months 192 169 –3.27 0.13
12 months 182 170 –2.88 0.05
24 months 180 167 –0.17 0.94
QLQ-C30 financial difficulties
Post CRT 195 183 –1.28 0.79
6 months 189 168 –0.15 0.87
12 months 181 170 4.24 0.28
24 months 178 165 –1.69 0.73
TABLE 45 The EORTC’s H&N35 H&N quality-of-life score treatment differences
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
H&N35 pain (mouth, jaw or throat)
Post CRT 197 189 –1.48 0.77
6 months 190 172 –1.83 0.53
12 months 182 172 –1.43 0.86
24 months 180 168 –3.67 0.42
H&N35 swallowing
Post CRT 188 185 –1.41 0.68
6 months 188 169 –0.68 0.69
12 months 182 173 –1.07 0.75
24 months 180 168 –3.08 0.43
H&N35 senses problems
Post CRT 193 182 –1.17 0.89
6 months 186 168 –1.76 0.70
12 months 178 169 0.6 0.89
24 months 176 167 –4.08 0.06
H&N35 speech problems
Post CRT 198 189 0.31 0.99
6 months 190 173 –0.33 0.84
12 months 182 172 1.23 0.75
24 months 179 167 –1.21 0.38
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TABLE 45 The EORTC’s H&N35 H&N quality-of-life score treatment differences (continued )
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
H&N35 trouble with social eating
Post CRT 173 178 –1.43 0.84
6 months 182 166 2.55 0.54
12 months 180 170 2.77 0.30
24 months 176 166 0.23 0.99
H&N35 trouble with social contact
Post CRT 198 189 1.96 0.55
6 months 190 173 1.47 0.38
12 months 182 172 6.96 0.01
24 months 179 167 0.12 0.87
H&N35 less sexuality
Post CRT 163 161 2.79 0.62
6 months 163 156 2.03 0.54
12 months 161 156 6.42 0.21
24 months 154 148 1.08 0.77
H&N35 problems with teeth
Post CRT 191 178 0.09 0.86
6 months 186 168 3.12 0.21
12 months 179 169 6.92 0.10
24 months 176 164 –2.9 0.44
H&N35 problems opening mouth wide
Post CRT 198 185 –6.13 0.23
6 months 191 172 0.92 0.59
12 months 181 172 2.93 0.29
24 months 179 167 5.75 0.08
H&N35 dry mouth
Post CRT 198 188 –0.12 0.95
6 months 191 172 –0.73 0.66
12 months 181 171 7.38 0.08
24 months 179 168 –2.39 0.44
H&N35 sticky saliva
Post CRT 196 189 0.49 0.95
6 months 188 172 –4.7 0.14
12 months 181 171 –4.69 0.23
24 months 177 168 –3.47 0.42
continued
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TABLE 45 The EORTC’s H&N35 H&N quality-of-life score treatment differences (continued )
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
H&N35 coughing
Post CRT 197 189 –4.35 0.20
6 months 192 171 3.08 0.73
12 months 182 172 2.77 0.65
24 months 180 167 –0.05 0.81
H&N35 felt ill
Post CRT 197 189 4.04 0.26
6 months 190 172 5.21 0.07
12 months 182 173 4.91 0.19
24 months 180 167 1.63 0.55
H&N35 used painkillers (yes/no)
Post CRT 198 188 –1.32 0.79
6 months 189 172 3.87 0.53
12 months 181 171 16.45 0.01
24 months 179 166 4.75 0.61
H&N35 taken nutritional supplements (yes/no)
Post CRT 195 186 2 0.53
6 months 189 171 6.18 0.26
12 months 182 167 0.97 0.89
24 months 177 165 1.79 0.74
H&N35 used a feeding tube (yes/no)
Post CRT 197 187 –0.04 0.93
6 months 189 171 1.34 0.82
12 months 180 169 –2.16 0.62
24 months 178 167 –2.17 0.40
H&N35 weight loss (yes/no)
Post CRT 186 183 –3.5 0.61
6 months 185 163 –5.93 0.38
12 months 175 169 1.53 0.83
24 months 175 163 1.49 0.78
H&N35 weight gain (yes/no)
Post CRT 180 173 0.56 0.91
6 months 181 156 7.27 0.21
12 months 167 166 1.32 0.88
24 months 172 159 10.48 0.10
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TABLE 46 The MDADI dysphagia score treatment differences
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
MDADI dysphagia global
Post CRT 187 182 0.95 0.65
6 months 180 167 8.46 0.05
12 months 173 161 4.31 0.17
24 months 168 161 –0.27 0.92
MDADI dysphagia emotional
Post CRT 185 179 –1.68 0.36
6 months 178 163 2.11 0.43
12 months 173 164 2.83 0.44
24 months 168 160 –1.05 0.91
MDADI dysphagia functional
Post CRT 189 181 –1.39 0.54
6 months 186 166 1.46 0.48
12 months 175 166 1.22 0.76
24 months 172 162 –0.87 0.77
MDADI dysphagia physical
Post CRT 185 177 0.53 0.87
6 months 178 161 0.27 0.97
12 months 173 164 1.38 0.70
24 months 168 159 –0.49 0.99
MDADI dysphagia total
Post CRT 189 183 –0.98 0.56
6 months 183 166 1.62 0.46
12 months 175 166 1.75 0.58
24 months 171 162 –0.64 0.99
TABLE 47 The EQ-5D health status treatment differences
Scales/measures
Trial arm, number of patients
Mean treatment difference p-value (Wilcoxon)PET–CT ND
EQ-5D overall health status
Post CRT 187 174 0.04 0.20
6 months 181 166 0.04 0.09
12 months 173 161 0.07 0.007
24 months 175 156 0.02 0.21
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FIGURE 13 The EORTC’s QLQ-C30 global health status. Reproduced from the New England Journal of Medicine,
Mehanna H, Wong W-L, McConkey CC, Rahman JK, Robinson M, Hartley AGJ, PET-CT Surveillance versus Neck
Dissection in Advanced Head and Neck Cancer, 374, 1444–54. Copyright © (2016) Massachusetts Medical Society.
Reprinted with permission.62
The European Organisation for Research and Treatment of Cancer’s Quality
of Life Questionnaire for Cancer (with 30 questions) symptom scales
For simplicity of interpretation the symptom scales in Table 44 have been transformed so that, here also, a
positive mean treatment difference is good for the PET–CT arm. There are no clear differences, but results
are slightly more favourable for the surveillance arm.
The European Organisation for Research and Treatment of Cancer’s Quality
of Life Questionnaire for Cancer head and neck module with 35 questions
quality-of-life outcomes
All scales in Table 45 have been set to low as bad and high as good, so a positive difference in mean
treatment difference is good for the PET–CT arm. There is little to suggest differences between trial
treatments. No difference is seen in pain in H&N cancer and in problems with swallowing (Figures 14 and
15). The difference in problems with teeth is small (Figure 16). Reported use of painkillers at 12 months
was higher in the ND arm (Figure 17).
The MD Anderson Dysphagia Inventory dysphagia scales
All scales in Table 46 have been set to low as bad and high as good, so a positive difference in mean
treatment difference is good for the PET–CT arm. There is little to suggest differences between trial
treatments (see, e.g., Figure 18).
European Quality of Life-5 Dimensions
The EQ-5D is used for the health resource study. In Table 47, positive values for mean treatment difference
indicate a better response in the PET–CT arm.
Differences of at least 10% in quality-of-life scales
Another way of presenting these data is to display differences from baseline of at least 10%. Figures 19–25
compare the randomised groups on that basis. Tables 48–54 give similar information, comparing patients
who underwent ND before CRT with those who did not. The swallowing measures in Figures 21, 24 and 25
show no difference between trial treatments, with both having a low proportion of improvers.
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FIGURE 14 The EORTC’s H&N35 pain in H&N cancer: mean scores unadjusted.
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FIGURE 15 The EORTC’s H&N35 problems with swallowing: mean scores unadjusted.
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FIGURE 16 The EORTC’s H&N35 problems with teeth: mean scores unadjusted.
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FIGURE 17 The EORTC’s H&N35 used painkillers: mean scores unadjusted (higher score = less pain).
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FIGURE 18 The MDADI dysphagia total: mean scores unadjusted.
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FIGURE 19 The EORTC’s QLQ-C30 global health status, percentages changed by ≥ 10%.
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FIGURE 20 The EORTC’s QLQ H&N35 pain scale, percentages changed by ≥ 10%.
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FIGURE 21 The EORTC’s QLQ H&N35 swallowing scale, percentages changed by ≥ 10%.
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FIGURE 22 The EORTC’s QLQ H&N35 problems with teeth, percentages changed by ≥ 10%.
> 10% worse
Similar
> 10% better
ND: post CRT
Surveillance: post CRT
ND: 6 months
Surveillance: 6 months
ND: 12 months
Surveillance: 12 months
ND: 24 months
Surveillance: 24 months
142
0% 20% 40% 60% 80% 100%
146
113
105
92
84
72
78
29
536
41
54
47
69
65
64
11
13
21
22
22
24
26
FIGURE 24 The MDADI dysphagia global scale, percentages changed by ≥ 10%.
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FIGURE 23 The EORTC’s QLQ H&N35 use of painkillers, percentages changed by ≥ 10%.
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FIGURE 25 The MDADI dysphagia total scale, percentages changed by ≥ 10%.
TABLE 48 The EORTC’s QLQ-C30 global health status: percentages changed by ≥ 10%, by actual timing of ND
before or after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 42 (84.0) 6 (12.0) 2 (4.0) 50
All others 254 (76.5) 63 (19.0) 15 (4.5) 332
6 months, n (%)
ND before CRT 28 (54.9) 17 (33.3) 6 (11.8) 51
All others 144 (46.5) 131 (42.3) 35 (11.3) 310
12 months, n (%)
ND before CRT 21 (43.8) 17 (35.4) 10 (20.8) 48
All others 107 (35.1) 131 (43.0) 67 (22.0) 305
24 months, n (%)
ND before CRT 14 (29.2) 25 (52.1) 9 (18.8) 48
All others 75 (25.2) 152 (51.0) 71 (23.8) 298
TABLE 49 The EORTC’s H&N35 pain scale: percentages changed by ≥ 10%, by actual timing of ND before or after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 36 (72.0) 6 (12.0) 8 (16.0) 50
All others 262 (78.0) 52 (15.5) 22 (6.6) 336
6 months, n (%)
ND planned before CRT 23 (44.2) 17 (32.7) 12 (23.1) 52
All others 120 (38.7) 114 (36.8) 76 (24.5) 310
12 months, n (%)
ND planned before CRT 16 (33.3) 18 (37.5) 14 (29.2) 48
All others 782 (25.5) 137 (44.8) 91 (29.7) 306
24 months, n (%)
ND planned before CRT 9 (18.8) 23 (47.9) 16 (33.3) 48
All others 62 (20.7) 143 (47.7) 95 (31.7) 300
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TABLE 50 The EORTC’s H&N35 swallowing symptoms scale: comparison by actual timing of ND for those who had
a ND
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 39 (81.3) 8 (16.7) 1 (2.1) 48
All others 283 (87.1) 35 (10.8) 7 (2.2) 325
6 months, n (%)
ND planned before CRT 27 (51.9) 18 (34.6) 7 (13.5) 52
All others 164 (53.8) 121 (39.7) 20 (6.6) 305
12 months, n (%)
ND planned before CRT 20 (41.7) 21 (43.8) 7 (14.6) 48
All others 113 (36.8) 160 (52.1) 34 (11.1) 307
24 months, n (%)
ND planned before CRT 17 (35.4) 25 (52.1) 6 (12.5) 48
All others 100 (33.3) 169 (56.3) 31 (10.3) 300
TABLE 51 The EORTC’s QLQ-C30 problems with teeth scale: percentages changed by ≥ 10%, by actual timing of ND
before or after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 17 (37.8) 26 (57.8) 2 (4.4) 45
All others 91 (28.1) 187 (57.7) 46 (14.2) 324
6 months, n (%)
ND planned before CRT 16 (32.0) 29 (58.0) 5 (10.0) 50
All others 84 (27.6) 176 (57.9) 44 (14.5) 304
12 months, n (%)
ND planned before CRT 15 (33.3) 24 (53.3) 6 (13.3) 45
All others 101 (33.3) 162 (53.5) 40 (13.2) 303
24 months, n (%)
ND planned before CRT 14 (30.4) 29 (63.0) 3 (6.5) 46
All others 81 (27.6) 176 (59.9) 37 (12.6) 294
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TABLE 52 The EORTC’s QLQ-C30 used painkillers scale: percentages changed by ≥ 10%, by actual timing of ND
before or after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 24 (48.0) 25 (50.0) 1 (2.0) 50
All others 92 (27.4) 224 (66.7) 20 (5.6) 336
6 months, n (%)
ND planned before CRT 13 (24.5) 34 (64.2) 6 (11.3) 53
All others 45 (14.6) 189 (61.4) 74 (24.0) 308
12 months, n (%)
ND planned before CRT 12 (25.0) 33 (68.8) 3 (6.3) 48
All others 24 (7.9) 174 (57.2) 106 (34.9) 304
24 months, n (%)
ND planned before CRT 15 (31.3) 25 (52.1) 8 (16.7) 48
All others 21 (7.1) 173 (58.3) 103 (34.7) 297
TABLE 53 The MDADI dysphagia global scale: percentages changed by ≥ 10%, by actual timing of ND before or
after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 35 (74.5) 9 (19.2) 3 (6.4) 47
All others 253 (78.6) 56 (17.4) 13 (4.0) 322
6 months, n (%)
ND planned before CRT 32 (65.3) 15 (30.6) 2 (40.1) 49
All others 186 (62.4) 80 (26.9) 32 (10.7) 298
12 months, n (%)
ND planned before CRT 21 (47.7) 17 (38.6) 6 (13.6) 44
All others 155 (53.5) 99 (34.1) 36 (12.4) 290
24 months, n (%)
ND planned before CRT 20 (45.5) 17 (38.6) 7 (15.9) 44
All others 130 (45.6) 112 (39.3) 43 (15.1) 285
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
A slightly greater percentage of patients who had an early ND had a decreased global health status. This is
not generally the case for the more specific symptom scores in Figures 20–25.
p16 subgroups
The baseline scores are better in the p16-positive group than in the negative group. No difference is seen
between treatment groups, but the plots in Figures 26 and 27 suggest that the p16-positive group is
affected more by CRT than the p16-negative group.
TABLE 54 The MDADI dysphagia total scale: percentages changed by ≥ 10%, by actual timing of ND before or
after CRT
Time point and group Decrease by ≥ 10% Similar Increase by ≥ 10% (improvement) Total
Post CRT, n (%)
ND planned before CRT 43 (89.6) 5 (10.4) 0 (0.0) 48
All others 275 (84.9) 44 (13.6) 5 (1.5) 324
6 months, n (%)
ND planned before CRT 35 (70.0) 14 (28.0) 1 (2.0) 50
All others 229 (76.6) 55 (18.4) 15 (5.0) 299
12 months, n (%)
ND planned before CRT 31 (67.4) 12 (26.1) 3 (6.5) 46
All others 181 (61.4) 85 (28.8) 29 (9.8) 295
24 months, n (%)
ND planned before CRT 31 (68.9) 10 (22.2) 4 (8.9) 45
All others 171 (59.4) 83 (28.8) 34 (11.8) 288
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FIGURE 26 The EORTC’s QLQ-C30 global health status: p16-positive group.
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PET–CT scans and concordance
The PET–CT surveillance arm of the trial contained 282 patients, of whom 276 received CRT. Six patients
did not receive PET–CT imaging: two died early, one progressed, two proceeded directly to ND and one
missed an appointment and died before the rearranged date. PET–CT was performed in 270 patients, and
the resulting assessments are summarised in Table 55.
Concordance rate for nodal disease
The concordance rate, on the basis of the readings reported by the local sites, is 247 out of 270, or 91.5%,
but on review and a correct reading of the local report, the last group in the table (3 + 4 + 6 + 2 + 1)
should be interpreted as concordant, giving a rate of 263 out of 270, or 97.4%. In total, 243 patients
are concordant in primary tumour and neck nodes, 20 are concordant in neck nodes only and seven are
discordant in neck nodes. Therefore, the concordance rate for the sites and the central laboratory is 97.4%,
with a kappa value of 0.78 (95% CI 0.69 to 0.87). The summary assessments are related to NDs performed
in Table 56.
Concordance in primary tumour
Similarly, for primary tumour the concordance rate for the sites and the central laboratory is 243 out of
266 or 91.4%, with a kappa value of 0.63 (95% CI 0.49 to 0.77).
True-negative rate
The number of patients in whom no neck cancer was seen on PET–CT on review and for whom no ND
was carried out was 191. Among this group, 26 experienced recurrence, giving a true-negative rate of
86.4%. Only one recurrence was in the neck alone. Similarly, the true-negative rate for primary tumour
was 29 out of 192 (84.9%).
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FIGURE 27 The EORTC’s QLQ-C30 global health status: p16-negative group.
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TABLE 55 Positron emission tomography–computerised tomography concordance of local and central review assessments
Assessment
Concordance n
Local Central review
Response in
primary tumour
Response in
neck nodes
Response in
primary tumour
Response in
neck nodes
Concordant in primary tumour and nodes
CR CR CR CR Yes 169
CR Not CR CR Not CR Yes 36
Not CR CR Not CR CR Yes 8
Not CR Not CR Not CR Not CR Yes 13
N/A CR N/A CR Yes 2
N/A CR CR CR Yes 2
Concordant in nodes only
CR Not CR Not CR Not CR Yes 4
Not CR Not CR CR Not CR Yes 5
CR CR Not CR CR Yes 3
Not CR CR CR CR Yes 5
Discordant
CR CR Not CR Not CR No 3
CR CR CR Not CR No 3
CR Not CR CR CR No 1
Discordant summary (local radiologist), concordant summary (central reviewer)
CR CR Not CR Not CR No 3a
CR CR CR Not CR No 4b
CR Not CR CR CR No 6c
Not CR CR Not CR Not CR No 2d
Not CR Not CR Not CR CR No 1c
N/A, not applicable.
a Reviewed: text of local report expresses partial in nodes, making these concordant for nodes.
b Reviewed: text of local report expresses partial in nodes, making these concordant for primary tumour and nodes.
c Reviewed: text of local report expresses CR in nodes, making this concordant in primary tumour and nodes.
d Reviewed: text of local report expresses partial in nodes, making these concordant for primary tumour and nodes.
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TABLE 56 Summary of PET–CT scan results and NDs performed
CR in
ND NumberPrimary tumour Neck nodes
Yes Yes No 181
Yes Yes Yes 4
Yes No Yes 36
Yes No No 11a
No Yes Yes –
No Yes No 15
No No Yes 12b
No No No 7
Missing Yes No 4
a Reasons for the 11 having no ND when there was a CR in primary tumour, not in neck nodes: new lung primary
tumour; disease progression or new primary lesion; liver metastases found at assessment; retroperitoneal nodes;
recurrence confirmed 5 weeks after post-CRT assessment; biopsy confirmed no malignancy; biopsy – no malignancy
remains, only debris; neck node judged by MDT to be reactive; faint activity in lymph node on PET–CT scan, but deemed
to be a CR; PET scan reviewed at MDT and considered negative; and judged to have complete metabolic response.
b Reasons for ND when there was not a CR in the primary tumour and not in neck nodes: three were CRs in the primary
tumour on review. There is no further information on the rest.
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Chapter 4 Economic evaluation
Introduction
An economic evaluation was conducted to assess the cost-effectiveness of the PET–CT-guided watch-and-
wait policy compared with planned ND. The evaluation consisted of two components: (1) a WT analysis,
in which cost-effectiveness was assessed over the 24-month trial period using individual patient data
collected in the trial; and (2) a decision-analytic model analysis, in which cost-effectiveness was assessed
over a lifetime horizon, using standard modelling techniques applied to the trial data in order to
extrapolate the trial results. The primary analysis was conducted from a NHS secondary care perspective
(i.e. including NHS hospital costs). In addition, sensitivity analyses were conducted using (1) a NHS and
Personal Social Services (PSS) perspective and (2) a societal perspective.
Methods
Within-trial analysis
Individual patient data collected in the trial were used to determine the costs and quality-adjusted life-years
(QALYs) associated with each treatment arm. QALYs were derived using patient EQ-5D questionnaire
responses, and costs were calculated using information collected in case report forms and patient- and
carer-reported questionnaires. Cost-effectiveness was assessed as the incremental cost-effectiveness ratio
(ICER) and incremental net health benefit (INB). Future costs and health outcomes (beyond 1 year) were
discounted at an annual rate of 3.5%, as per the National Institute for Health and Care Excellence (NICE)’s
Guide to the Methods of Technology Appraisal 2013.63
Quality-adjusted life-years
In the economic evaluation [both WT and lifetime decision model (DM)] patient health benefit was measured
in terms of QALYs. QALYs provide a generic measure of overall patient health and are a composite measure
of patient survival weighted by quality of life (utility) over time; for example, 1 year in full health is equivalent
to 1 QALY, whereas 1 year at half of full health is equivalent to 0.5 QALYs. Expression of health benefit
in terms of QALYs allows decision-makers to make a direct comparison of the cost-effectiveness of
interventions across different disease areas and indications, and NICE currently recommends the use of
QALYs in cost-effectiveness analyses in its reference case.63
Information on patient health-related quality of life during the trial was collected using patient responses
to the EQ-5D-3L (three levels) questionnaire.64 The EQ-5D questionnaire asks patients to identify their
current health status across five health domains: mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. Patients can respond that they currently have no problems, some problems or major
problems within each of the given domains; these responses are coded as 1, 2 or 3, respectively.
According to their responses to the EQ-5D questionnaire, patients may therefore be classified in one of
243 (35) health states.
Patients in the PET-NECK trial were asked to complete the EQ-5D questionnaire at baseline, during
treatment (2 weeks post CRT) and at 3, 6, 12 and 24 months post randomisation. For each time point
patients’ identified health state classifications were converted into quality-of-life values by applying the
standard European Quality of Life UK tariff values;65 these values represent the UK general public’s
preference for each of the possible EQ-5D-defined health states and provide a utility value for each of the
health states. For each time point, patient utilities across the two arms were compared using the Wilcoxon
signed-rank test.66
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79
Quality-adjusted life-years were calculated by combining patient utility values with OS data. The
Kaplan–Meier method was used to account for loss to follow-up and life-years were calculated by taking
the area under the survival curve. The area under the survival curve over each time period was then
weighted by the corresponding utility to calculate patient QALYs.67
Resource use and costs
Data on patient and carer consumption of NHS, PSS and personal resources during the trial were obtained
from a combination of case report forms (completed by nurses/clinicians at the enrolled hospital) and
patient- and carer-reported questionnaires. Case report forms were completed throughout the trial for all
participants to collect information on resource use related to a range of secondary care activities, including
node dissection/salvage surgery, radiotherapy, chemotherapy, SAEs, patient follow-up assessments and
recurrence events. Patient report forms were used for a subset of patients (n = 42) to collect additional
data on secondary care activity outside the patient’s enrolled hospital oncology department, primary and
community care activity (such as GP visits, nurse visits, counselling and therapy services, carers and social
worker visits) and patient societal costs (i.e. patient travel expenses, equipment costs, one-off expenses and
lost earnings resulting from illness). For this subset of patients, carer report forms were also used for those
patients with a friend or family member acting as an informal carer, in order to identify carer societal
costs (i.e. carer travel expenses, equipment costs, one-off expenses and lost earnings resulting from the
associated patient’s illness). In order to ensure quality of reported data and to minimise the burden of
reporting on patients and carers, patient and carer report forms were collected for patients enrolled at the
two highest-recruiting sites only [University Hospital Birmingham (UHB) and UHCW]. Individuals were asked
to recall their use of services over the previous 3-month period (or since completion of the last form when
appropriate), at the same time points as for the EQ-5D questionnaire (i.e. at baseline, treatment and 3, 6,
12 and 24 months post randomisation).
Owing to the small sample numbers of patients and carers providing self-reported cost data (42 patients
and 35 carers) and to the significant uncertainty involved in imputing these data for the whole trial
population, these data were excluded from the base-case analysis of costs. The base-case analysis includes
data on secondary care resource use collected in the case report forms only and, therefore, adopts a
NHS secondary care perspective. Sensitivity analyses were conducted in order to assess the impact of
(1) including the additional patient-reported NHS and PSS data (i.e. using a NHS and PSS perspective) and
(2) including all of the additional patient- and carer-reported data (i.e. using a societal perspective).
Costs were estimated by combining the resource use data with unit costs (Table 57) obtained from
national sources including NHS national reference costs69 and the Personal Social Services Research Unit
(PSSRU)70 costs for NHS and PSS service use costs, and the British National Formulary72 and Drugs and
Pharmaceutical Electronic Market Information (eMit)71 for medication costs. The results of the economic
evaluation are reported in pounds sterling (price year 2015). Unit costs reported in 2013/14 prices were
inflated to 2015 prices in the analysis using the consumer price index inflation value reported by the Office
for National Statistics (note that the prices reported in the original source were non-inflated).76 Costs were
compared between the two arms using the Wilcoxon signed-rank test.66
Missing data
For the calculation of QALYs, multiple imputation using chained equations was conducted using the ‘mice’
package in R (The R Foundation for Statistical Computing, Vienna, Austria). Data on patient baseline
cancer stage, sex and age were used to impute missing EQ-5D data across the data collection time points.
A sensitivity analysis was conducted based on a complete-case analysis in order to explore the impact of
using imputation (see Within-trial analysis, Uncertainty and sensitivity analyses).
For costs, data on societal, primary and community care resource use and secondary care resource use
outside the enrolled hospitals were collected for only a small subset of the overall trial population using
patient- and carer-reported questionnaires. As the sample size of this subpopulation was small (patients,
n = 42; carers, n = 35), the base-case analysis was conducted using costs derived from the case report
forms (collected for the whole trial population and with complete data) only. Sensitivity analyses were
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TABLE 57 Unit costs applied to resource use items in the WT analysis
Resource item Unit cost Source Details/assumptions
Secondary care costs (relating to case report form items)
Inpatient ‘hotel cost’ (per night
cost)
£200 East and North Hertfordshire
NHS Trust’s Performance
Report Month 1168
Oncology assessment £181 Reference Costs 2013–201469 Medical oncology first face-to-face
attendance. CC: WF01B. SC: 370
Cardiology assessment £160 Reference Costs 2013–201469 Cardiology first face-to-face attendance.
CC: WF01B. SC: 320
Respiratory assessment £186 Reference Costs 2013–201469 Respiratory medicine first face-to-face
attendance. CC: WF01B. SC: 340
Other assessment £196 Reference Costs 2013–201469 General medicine first face-to-face
attendance. CC: WF01B. SC: 300
Dental assessment £126 Reference Costs 2013–201469 Dental medicine first face-to-face
attendance. CC: WF01B. SC: 450
Nasopharyngoscopy £114 Reference Costs 2013–201469 Diagnostic nasopharyngoscopy, aged
≥ 19 years. CC: CA71A. SC: 370
Fine-needle aspiration £164 Reference Costs 2013–201469 Minor maxillofacial procedures.
CC: CA95Z. SC: 144
Surgery assessment £150 Reference Costs 2013–201469 General surgery first face-to-face
attendance. CC: WF01B. SC: 100
CT scan £147 Reference Costs 2013–201469 CT scan, more than three areas.
CC: RA14Z. SC: DIAGIMOP
PET–CT scan £649 Reference Costs 2013–201469 Nuclear medicine, category 8 (PET–CT).
CC: RA42Z
MRI scan £145 Reference Costs 2013–201469 MRI scan, one area, post contrast only,
aged ≥ 19 years. CC: RA02A.
SC: DIAGIMOP
Radiography £40 Personal communication with
LTHT (Dr Peter Hall, University
of Leeds, 2015, personal
communication)
Ultrasound £76 Reference Costs 2013–201469 Ultrasound mobile scan or intraoperative
procedures, < 20 minutes. CC: RA25Z.
SC: DIAGIMOP
Other radiography assessment £88 Reference Costs 2013–201469 Clinical oncology (previously
radiotherapy) first attendance.
CC: WF01D. SC: 800
Nurse assessment £100 Unit Costs of Health and
Social Care70
Assume an assessment is equivalent to
1 hour of contact time
Palliative care assessment £97 Unit Costs of Health and
Social Care70
Social other £37 Unit Costs of Health and
Social Care70
Assume equivalent to speech/diet
assessment
Speech assessment £37 Unit Costs of Health and
Social Care70
Assume an assessment is equivalent to
1 hour of contact time
Dietitian assessment £37 Unit Costs of Health and
Social Care70
As above
continued
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TABLE 57 Unit costs applied to resource use items in the WT analysis (continued )
Resource item Unit cost Source Details/assumptions
Rehabilitation assessment £36 Unit Costs of Health and
Social Care70
Assume equivalent to 1 hour of
occupational therapist contact time
Psychology assessment £138 Unit Costs of Health and
Social Care70
Assume hospital assessment cost
equivalent to community visit cost
Counselling assessment £50 Unit Costs of Health and
Social Care70
As above
Peg swab £7 Reference Costs 2013–201469 Directly accessed – pathology services.
Microbiology. CC: DAPS07
Bloods: haematology £3 Reference Costs 2013–201469 Directly accessed – pathology services.
Haematology. CC: DAPS05
Bloods: biochemistry £1 Reference Costs 2013–201469 Directly accessed – pathology services.
Clinical biochemistry. CC: DAPS04
Bloods: microbiology £7 Reference Costs 2013–201469 Directly accessed – pathology services.
Microbiology. CC: DAPS07
Bloods: other £8 Reference Costs 2013–201469 Directly accessed – pathology services.
Other. CC: DAPS09
Secondary care costs (relating to patient-reported items)
Short-stay (≤ 2 days) inpatient
cost
£611 Unit Costs of Health and
Social Care70
Long-stay (> 2 days) inpatient
cost
£2716 Unit Costs of Health and
Social Care70
Hospital day centre £119 Reference Costs 2013–201469 Inpatient specialist palliative care,
same day, aged ≥ 19 years and over.
SC: DCRDN. CC: SD02A
Outpatient visit £109 Unit Costs of Health and
Social Care70
Accident and emergency visit £135 Reference Costs 2013–201469 Total outpatient attendances. SC: 180
Nursing/convalescent home £82 Unit Costs of Health and
Social Care70
Assume cost for 1 day and night equals
the reported private-sector nursing
home cost per week/7
Primary and community care service costs (relating to patient-reported items)
GP surgery visit (telephone call) £46 (28) Unit Costs of Health and
Social Care70
GP home visit £67 Unit Costs of Health and
Social Care70
Assume equal to reported cost for
17-minute surgery visit
District nurse home visit
(telephone call)
£66 (£11) Unit Costs of Health and
Social Care70
Assume each visit equal to 1 hour of
contact time and a call is equivalent to
10 minutes of contact time
Social worker visit (telephone
call)
£79 (£13) Unit Costs of Health and
Social Care70
As above
Physiotherapist visit (telephone
call)
£36 (£6) Unit Costs of Health and
Social Care70
As above
Occupational therapist visit
(telephone call)
£36 (£6) Unit Costs of Health and
Social Care70
As above
Counsellor visit (telephone call) £50 (£8) Unit Costs of Health and
Social Care70
As above
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TABLE 57 Unit costs applied to resource use items in the WT analysis (continued )
Resource item Unit cost Source Details/assumptions
Home help service £24 (£4) Unit Costs of Health and
Social Care70
Assume a visit is equal to 1 hour of
weekday contact and a call is equivalent
to 10 minutes of this time
Psychiatrist £138 Unit Costs of Health and
Social Care70
Assume a visit is equal to 1 hour of
contact time and a call is equivalent to
10 minutes of contact time
Day centre £24 Unit Costs of Health and
Social Care70
Assume equivalent to home help service
visit
Chemotherapy drug costs
5-fluorouracil £3.47 Drugs and pharmaceutical
electronic market information
(eMit), 201571
5 g/100-ml vial, 5%, size 1
Cisplatin £16.69 Drugs and pharmaceutical
electronic market information
(eMit), 201571
100 mg/100-ml vial
Carboplatin £28.89 Drugs and pharmaceutical
electronic market information
(eMit), 201571
600 mg/60-ml vial
Cetuximab £890.50 British National Formulary,
201572
5 mg/ml, 100-ml vial
Docetaxel £29.78 Drugs and pharmaceutical
electronic market information
(eMit), 201571
160 mg/8-ml vial
Delivery cost £328 Reference Costs 2013–201469 Deliver subsequent elements of a
chemotherapy cycle. CC: SB15Z.
SC: DCRDN
Radiotherapy costs
Radiotherapy delivery £149 Reference Costs 2013–201469 Deliver a fraction of complex treatment
on a megavoltage machine. CC: SC23Z.
SC: DCRDN
Radiotherapy planning visit £1587 Reference Costs 2013–201469 Preparation for IMART, with technology
support. CC: SC41Z. SC: DCRDN
Surgery costs
Node dissection £3548 Reference Costs 2013–201469 Elective inpatient. Intermediate
maxillofacial procedures. CC: CA94Z
Salvage surgery £7722 Reference Costs 2013–201469 Elective inpatient. Major maxillofacial
procedures, aged ≥ 19 years, with a
complexity and comorbidity score of ≥ 1.
CC: CA93A
Follow-up visit assessment costs
Anaesthetic examination £85 Reference Costs 2013–201469 Anaesthetics: diagnostic, laryngoscopy
or pharyngoscopy, aged ≥ 19 years.
CC: CA69A
Biopsy £164 Reference Costs 2013–201469 Maxillofacial surgery: minor maxillofacial
procedures. CC: CA95Z
Clinical examination £109 Reference Costs 2013–201469 Maxillofacial surgery: Diagnostic,
laryngoscopy or pharyngoscopy, aged
≥ 19 years. CC: CA69A
continued
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conducted, which included the additional resource use items reported in the patient- and carer-reported
questionnaires. These forms were relatively complete, with most patients returning their forms at each of
the follow-up time points (Table 58). In the case of missing data within each of the forms, values were
based on imputation using the mean of reported values. Ideally, in the case of missing data, multiple
imputation methods should be employed in order to provide reliable estimates for the missing data values;
however, because of the small sample size it is unlikely that complex imputation methods would yield any
more reliable results in this instance.
TABLE 57 Unit costs applied to resource use items in the WT analysis (continued )
Resource item Unit cost Source Details/assumptions
Recurrence treatment costs
Brachytherapy £2393 Reference Costs 2013–201469 1 × preparation for interstitial
brachytherapy (£1196). CC: DCRDN.
SC: SC55Z
1 × deliver a fraction of intraluminal
brachytherapy (£1197). CC: DCRDN.
SC: SC30Z
Chemotherapy course £4753 Reference Costs 2013–201469 Six × procure chemotherapy drugs for
regimens in band 2 (£323). CC: DCRDN.
SC: SB02Z
1 × deliver more complex parenteral
chemotherapy at first attendance (£317).
CC: DCRDN. SC: SB13Z
5 × deliver subsequent elements of a
chemotherapy cycle (£328). CC: DCRDN.
SC: SB15Z
6 ×medical oncology follow-up.
CC: WF01A. SC: 370
Radiotherapy course £1744 Assumes 1 radiotherapy planning visit
and 1 delivery
Annual supportive care cost
post distant recurrence
£1682 Hall et al., 201473
Terminal month palliative care
cost post distant recurrence
£1051 Hall et al., 201473
Resection/free flap
reconstruction
£7722 Reference Costs 2013–201469 Elective inpatient. Major maxillofacial
procedures, aged ≥ 19 years , with a
complexity and comorbidity score of ≥ 1.
CC: CA93A
Societal costs (relating to patient- and carer-reported forms)
Average wage per hour £15.11 Office for National Statistics’
Annual Survey of Hours and
Earnings, 2014 Provisional
Results74
Cost per mile of car travel £0.67 NHS reimbursement data75
CC, currency code; LTHT, Leeds Teaching Hospitals NHS Trust; SC, service code.
Note
The cost of MDT discussions was not included as this information was not collected on the trial case report forms and,
therefore, there are no activity data on which to base this cost. Based on consultation with clinicians, it is unlikely that there
would be a difference in the cost of MDT across the arms, as all patients would require a MDT discussion regardless of
eventual treatment.
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Cost-effectiveness analysis
Cost-effectiveness was measured in terms of the ICER and INB. The ICER is calculated by dividing the
difference in mean cost between the two arms by the difference in mean QALYs between the two arms:
ICER =
Ci − Cc
Ei − Ec
=
ΔC
ΔE
, (1)
where Ci and Ei are the expected cost and effectiveness of the intervention (PET–CT surveillance), Cc and Ec
are the expected cost and effectiveness of the comparator strategy (planned ND), and ΔC and ΔE are the
incremental cost and effect of the intervention compared with the comparator.
When the new intervention dominates the standard care strategy (i.e. is more effective and less costly),
or when the new intervention is dominated by the standard care strategy (i.e. is less effective and more
costly), the decision of whether or not to adopt the new strategy is straightforward (accept and reject,
respectively). In these cases the ICER calculation is meaningless. The ICER becomes important when we
are considering adopting an intervention that requires a trade-off between additional effect for additional
cost and less effect for less cost. Assuming that a new intervention is more costly and more effective than
the current standard care strategy, the ICER represents the additional cost associated with the intervention
per additional unit of benefit (QALY) that it provides compared with current treatment; alternatively, if the
intervention is less costly and less effective than the standard care intervention, the ICER represents the
cost saved per QALY lost compared with current treatment. The cost-effectiveness of an intervention is
then determined by whether or not the ICER value falls above or below the decision-maker’s willingness to
pay per QALY. In the UK, NICE adopts a willingness-to-pay threshold value of £20,000 per QALY: if a new
intervention has an ICER value below £20,000 per additional QALY (or > £20,000 saved per QALY lost),
then it is likely to be considered a cost-effective use of NHS resources, whereas an ICER value above
£20,000 per additional QALY (or < £20,000 saved per QALY lost) indicates that the intervention is not
expected to be a cost-effective use of resources. For the case of positive incremental cost and QALYs (i.e.
the intervention is more effective and more costly), this decision rule is expressed in the following formula:
ΔC
ΔE
< λ, (2)
where λ is the adopted willingness-to-pay threshold (£ per QALY).
TABLE 58 Proportion of patient-reported questionnaires returned
Follow-up time point
Strategy
ND PET–CT surveillance
Received (n) Expected (n) Missing (%) Received (n) Expected (n) Missing (%)
Within 2 weeks of CRT 39 42 7 38 40 5
3 months post-CRT
assessment
37 42 12 38 40 5
6 months post
randomisation
36 40 10 36 37 3
12 months post
randomisation
36 36 0 37 37 0
24 months post
randomisation
34 34 0 35 35 0
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When the threshold is known, cost-effectiveness can be expressed in terms of net health benefit (NB).
The NB for the given intervention (NBi) and comparator strategy (NBc) and the INB of the intervention are
calculated as follows:77
NBi = Ei −
ΔCi
λ
NBc = Ec −
ΔCc
λ
INB = NBi − NBc = ΔE −
ΔC
λ
.
(3)
The NB equation expresses the overall benefit of a strategy in terms of QALYs by converting the expected
cost of the intervention on to the QALY scale using the given threshold value. Unlike the ICER, for which
interpretation depends on whether or not the incremental cost and QALYs are positive or negative, the
interpretation of NB is straightforward: for any given set of strategies, the strategy with the highest net
benefit is the most cost-effective; equivalently, a strategy is cost-effective if its INB is positive. All results of
the economic evaluation are reported in terms of both ICER and NB values.
Uncertainty and sensitivity analyses
Non-parametric bootstrapping was used to determine the level of sampling uncertainty around the WT
cost-effectiveness result by generating 10,000 estimates of incremental costs and benefits from the trial
results. The bootstrap approach considers the original sample as if it is the population and draws multiple
random samples with replacements from the original sample in order to simulate possible alternative sample
sets. Results are presented using scatterplots on the cost-effectiveness plane (which plots incremental
QALYs against incremental costs) to illustrate the uncertainty surrounding the cost-effectiveness estimates.
On the cost-effectiveness plane a result is considered cost-effective if it falls on or below the given
cost-effectiveness willingness to pay per QALY threshold. The cost-effectiveness acceptability curve is
derived by calculating the proportion of bootstrapped estimates that are cost-effective across a range of
willingness-to-pay thresholds, to show the probability that PET–CT-guided treatment is cost-effective across
different threshold values.
For the WT analysis, three additional sensitivity analyses were conducted to explore additional uncertainties
in the analysis.
Within-trial sensitivity analysis 1: imputation of additional patient-reported cost data
(NHS and Personal Social Services perspective)
In the base-case analysis, costs were calculated using data from the trial case report forms that provided
information on a range of secondary care resource usage for the total trial population (n = 564). Additional
data on primary and community care resource use, as well as additional secondary care resource usage
(outside the enrolled oncology department), were collected for a subgroup of the trial population (n = 42)
enrolled at the two main recruiting centres (UHB and UHCW). Patients were asked to recall their use of NHS
and PSS services over the past 3 months (or since completion of the last form when appropriate) at baseline,
during treatment (2 weeks post CRT), and at 3, 6, 12 and 24 months post randomisation. In the base-case
analysis this information was excluded because of the small sample size available for these data and the
significant uncertainty incorporated in any attempt to impute these data to the whole trial population. A
sensitivity analysis was conducted to assess the potential impact of including these additional cost data by
imputing the mean reported values for the additional resource use items collected in the patient-reported
forms to the total trial population. Mean values were calculated using a complete-case analysis of the
patient- and carer-reported data. Owing to the small sample size and significant number of missing data,
it was deemed inappropriate to attempt to conduct multiple imputation for missing data.
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On the patient-reported questionnaires, patients were asked to report any additional visits to hospital
(inpatient, day centre, outpatient, accident and emergency department or nursing home visits), not
including visits to their enrolled oncology department; the aim was to capture additional secondary care
resource use not already captured in the case report forms routinely completed at the patient’s enrolled
oncology department. However, when additional hospital visits were reported, patients were asked to give
the name of the hospital they visited, and a significant number of patients identified the hospital as UHB
or UHCW. The majority of patients did not specify the department visited, so it is unclear if these hospital
visits constituted unique events that have not already been captured in the case report forms. Two
analyses were therefore conducted:
1. WT sensitivity analysis 1.1: in this analysis it was assumed that patients correctly reported their use of
secondary care resources, that is, if the hospital site was reported as UHB or UHCW, patients reported
only those hospital events that occurred outside the oncology department and, therefore, each
reported event represented a unique resource use item not already contained within the case
report forms
2. WT sensitivity analysis 1.2: in this analysis it was assumed that for any instance in which patients
identified the hospital visited as either UHB or UHCW these data would already have been captured in
the case report forms and these events are therefore excluded from the analysis.
Within-trial sensitivity analysis 2: imputation of additional patient- and carer-reported
societal costs (societal perspective analysis)
For the subgroup of patients enrolled at UHB and UHCW, patients and carers were asked to report on the
impact of the patient’s illness on travel expenses, one-off expenses, equipment costs and lost productivity
(i.e. lost earnings), at the same time points as for the patient questionnaires discussed in WT sensitivity
analysis 1 (baseline, treatment and 3, 6, 12 and 24 months post randomisation). A sensitivity analysis was
conducted to assess the potential impact of including these additional cost data, in addition to the costs
included in WT sensitivity analysis 1, by imputing the mean reported values for the additional resource use
items collected in the patient- and carer-reported forms to the total trial population. Owing to the fact that
the additional costs included in WT sensitivity analysis 1 have been split into two analyses (WT sensitivity
analysis 1.1 and sensitivity analysis 1.2), two corresponding analyses have been conducted from a
societal perspective:
1. WT sensitivity analysis 2.1, based on inclusion of societal costs plus additional patient-reported costs as
given in WT sensitivity analysis 1.1 (i.e. using patient-reported costs as reported)
2. WT sensitivity analysis 2.2, based on inclusion of societal costs plus additional patient-reported costs as
given in WT sensitivity analysis 1.2 (i.e. excluding patient-reported secondary care visits where the
attended hospital was identified as one of the enrolled hospitals).
Within-trial sensitivity analysis 3: complete-case analysis for calculation of
quality-adjusted life-years
In the base-case analysis, multiple imputation methods were used in order to account for missing EQ-5D
data within the trial. A sensitivity analysis was conducted using complete-case analysis for the calculation
of QALYs in each arm (i.e. ignoring missing data).
Lifetime decision model analysis
In order to estimate the lifetime cost-effectiveness of PET–CT-guided management, a de novo decision-
analytical model was constructed. In line with the WT analysis, the base-case model adopts a UK
secondary care perspective and future costs and QALYs were discounted at an annual rate of 3.5% in line
with NICE guidance.63 A sensitivity analysis was conducted in which a broader NHS and PSS perspective
was adopted. The model was built and analysed using R software.
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Model structure
The model structure (Figure 28) is split into two phases: an initial 6-month treatment phase, in which
patients receive CRT and (potential) ND; and a follow-up phase, in which patients may go on to recover,
develop local recurrence (LR) or distant recurrence (DR), or die. Within the treatment period, cost and
QALYs for each of the treatment arms are taken directly from the results of the first 6 months of the WT
analysis. For the follow-up period, longer-term cost and QALYs for each of the treatment arms are
estimated using a modified Markov model. The model begins at this point in order to enable the analysis
to capture the full cost and utility decrements associated with LRs and DRs, as these data were not fully
captured in the trial.
Markov models describe patient progression over time through a pathway of health states, with movement
between the health states being triggered by events such as disease progression or death. Resource use
and costs are associated with each health state, and patients accumulate costs and health benefits in each
state over monthly cycles. The analysis adopts a lifetime horizon, truncated at 100 years.
During the treatment phase of the model, patients in the standard care arm (arm A) receive planned ND
either before or after CRT. Patients in the intervention arm (arm B) receive CRT followed by PET–CT at
9–13 weeks post CRT, which dictates whether or not patients go on to receive ND. In the subsequent
follow-up phase of the model, patients enter one of four health states: disease free (DF), LR, DR or death.
During any cycle in the follow-up period patients in the DF state may remain DF, develop a LR or DR,
or die. Similarly, patients in the LR state may recover, develop a DR or die, and patients in the DR state
may remain in DR or die. Entry into the LR state is associated with a one-off treatment cost and utility
decrement, after which patients either recover (with costs and utility equal to those in the DF state) or
advance to the DR state. Patients who enter the DR state similarly incur a one-off treatment cost and
further utility decrement and, subsequently, either remain in the DR state (with an ongoing supportive care
cost and utility decrement) or die. Once in the DR state, it is assumed that patients cannot recover and
either remain in the DR state or die.
Start
CRT
Arm A
Treatment period (6 months)
ND
ND
Arm A
CRT
CRT
Disease-free
follow-up
Arm B
PET–CT ND
Death
Locoregional
recurrence
(or non-complete
response)
treated with ND 
or salvage surgery
Distant or 
unresectable
recurrence
treated with 
palliative care
FIGURE 28 Lifetime DM structure.
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Model parameters
The model input parameters were derived using information from a range of sources. When possible,
data from the trial were used directly and, when necessary, published literature was used to inform
remaining parameters.
For the 6-month initial treatment phase of the model, costs and QALYs for each of the arms were taken
directly from the trial-reported data. Resource use items relevant to the treatment phase (i.e. surgery,
radiotherapy, chemotherapy, treatment response assessment and adverse events and recurrence) were
assigned costs and evaluated, as discussed earlier (see Methods, Within-trial analysis). Bootstrap methods
were used to account for sampling uncertainty around the results.
For the follow-up modified Markov phase of the model, the proportion of patients beginning in each of
the health states of the model was derived directly from the trial data using data on OS, recurrence-free
survival and types of recurrences experienced.
The cost for the DF state was derived from the trial data, based on calculating the average monthly cost
in each arm for DF patients over the follow-up period (6–24 months). The cost of LR and DR treatment
(applied to patients’ first cycle in each of the recurrence states) was derived from the trial data on
recurrence treatments administered on patients’ first recurrence event. No data were available from the
trial regarding the ongoing treatment of patients who experienced a recurrence event; the subsequent cost
of LR and DR beyond initial treatment is therefore uncertain. For patients who experienced a LR and,
subsequently, recovered after treatment, ongoing costs were assumed to be equal to those for patients in
the DF state. For patients remaining in the DR state it was assumed that patients would incur an ongoing
supportive care cost, which was derived from the literature.73
For the health state utilities, DF utility was derived directly from the trial data by calculating the average
utility for patients in the trial who were DF over the second year trial follow-up period (12–24 months).
There were no data available from the trial from which the utility of patients experiencing a LR or DR could
be derived. Several studies were identified in the literature that have explored health-related quality-of-life
for patients with H&N cancers. Most of these studies were deemed inappropriate for the derivation of the
current model recurrence health states because the majority either reported only utilities derived from the
EORTC QLC-C30 questionnaire (a cancer-specific health-related quality-of-life questionnaire), which cannot
be easily converted in to EQ-5D utilities,78–81 or did not report health state utilities that could be reliably
mapped to the health states used in the current model.82 One UK study83 was identified. However, this
study calculated EQ-5D utilities from a sample of 50 oncology nurses; because health-care professionals
are known to be poor proxies for patients, this study was similarly excluded from consideration for the
base-case analysis. de Almeida et al.84 conducted an elicitation of utilities from a sample of 50 healthy
Canadian subjects using both standard gamble and visual analogue scale (VAS) methods. The authors
report utility values for a range of health states, including several remission, LR and DR states. As this study
was deemed to be the best-quality study identified in the literature, it was used to derive the recurrence
health state values for the current DM. Probabilistic utility decrement values for the local and DR health
states were derived by sampling from the remission, LR and DR distributions in the de Almeida et al.84
study and taking the resulting mean differences and standard error values. The base-case analysis uses the
reported utilities in de Almeida et al.84 based on the standard gamble elicitation. A sensitivity analysis was
conducted using the VAS-reported values.
The mortality risk within the DF, LR and DF after LR states was assumed to be equal to the mortality risk
within the general population (taken from Office for National Statistics 2013 statistics85) multiplied by an
excess mortality factor of 20% derived from the literature.86 The mortality risk within the DR state was
derived by calibrating the model survival curve with the Kaplan–Meier survival data from the trial. The rate
of disease progression from the DF state to LR and DR within the first 5 years was derived directly from the
trial data, using the trial recurrence-free survival Kaplan–Meier data to derive monthly primary recurrence
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transition probabilities, accounting for loss to follow-up. Stochastic primary recurrence probabilities were
derived by simulating 10,000 bootstrap data samples from the original Kaplan–Meier data (i.e. sample with
replacement), which were used to derive separate recurrence probabilities for each of the 10,000 model
simulations in the probabilistic analysis (see Lifetime decision model analysis, Uncertainty and sensitivity
analyses). In the base-case analysis recurrence events were assumed to occur only within the first 5 years
post randomisation, based on observations within the literature, which indicate that the majority of
recurrences occur within the first 5 years from initial diagnosis.87 This assumption was also supported by
the trial follow-up data, which indicated that the number of recurrence events had fallen close to zero at
5 years post treatment. A sensitivity analysis was conducted to assess the potential impact of recurrences
beyond 5 years (see Lifetime decision model analysis, Uncertainty and sensitivity analyses). The proportion
of patients experiencing a LR or DR in each arm was derived from the trial data by calculating the relative
proportion of LR versus DR events within the trial. This proportion was assumed to be constant over time
in the model.
There were no data available from the trial regarding the rate of progression from LR and DF after LR to
subsequent LR or DR (i.e. only primary recurrences were captured in the trial follow-up). The rate of
subsequent recurrences were therefore derived from a recent study88 that reported observed LRs and DRs
in 176 patients with local recurrent disease after primary curative treatment of HNSCC.
A full list of model parameters and distributions applied in the base-case model is given in Table 59.
Cost-effectiveness analysis
As for the WT analysis, cost-effectiveness was measured in terms of the ICER and INB (see Lifetime decision
model analysis, Uncertainty and sensitivity analyses for more details on the calculation of ICERs and INB).
Uncertainty and sensitivity analyses
Probabilistic sensitivity analyses were conducted to assess the impact of joint parameter uncertainty on the
results. Probabilistic analysis accounts for joint parameter uncertainty in non-linear models by assigning
probability distributions to each of the input parameters and randomly drawing from these probabilities over
10,000 Monte Carlo model simulations to produce different cost and QALY estimates in each simulation of
the model. As for the bootstrap WT analysis, the results are presented on the cost-effectiveness plane as a
scatterplot, using cost-effectiveness acceptability curves to show the probability that the two strategies are
cost-effective across different willingness-to-pay per QALY thresholds.
TABLE 59 Decision model base-case parameters
Parameter Mean Distribution SD Source
Global parameters
Discount rate 0.035 Fixed – NICE guidance63
Start age (years) 57 Fixed – PET-NECK baseline trial data
Percentage male 82% Fixed –
Health state starting distribution (i.e. end of 6-month treatment period)
ND
Recurrence 0.06 Beta 0.015 PET-NECK trial data
Proportion of recurrences local
(vs. distant)
0.35 Beta 0.069
Dead 0.03 Beta 0.010
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TABLE 59 Decision model base-case parameters (continued )
Parameter Mean Distribution SD Source
PET–CT
Recurrence 0.05 Beta 0.013 PET-NECK trial data
Proportion of recurrences local
(vs. distant)
0.41 Beta 0.066
Dead 0.02 Beta 0.008
Monthly health state costs
DF £70 Gamma £95 PET-NECK trial data on DF patients (n = 439)
LR initial treatment £3964 Gamma £4343 PET-NECK trial data on LR patients (n= 39)
DF after LR £70 Gamma £95 Assumed equivalent to DF cost
DR initial treatment £3635 Gamma £3197 PET-NECK trial data on DR patients (n= 63)
DR follow-up (ongoing care) £140 Gamma £32 Hall et al., 201473
Terminal-month cost £1051 Gamma £115 Hall et al., 201473
Health state utilities
DF 0.71 Beta 0.04 PET-NECK trial data on DF patients during
second year of follow-up
LR decrement –0.11 Beta 0.12 de Almeida et al., 201484
DF after LR 0.71 Beta 0.03 Assumed equivalent to DF utility
DR decrement –0.47 Beta 0.20 de Almeida et al., 201484
Dead 0 Fixed –
Transition probabilities/effects
Primary recurrence over first
5 years
Derived from the trial Kaplan–Meier
curves for recurrence-free survival in
each arm
PET-NECK trial data
Proportion of recurrences local
(vs. distant) in planned ND arm
0.35 Beta 0.069 PET-NECK trial
Proportion of recurrences local
(vs. distant) in PET–CT
surveillance arm
0.41 Beta 0.066
Probability of LR from DF after
LR state
0.02 Beta 0.002 Matoscevic et al., 201488
Probability of DR from LR/DF
after LR states
0.02 Beta 0.003 Matoscevic et al., 201488
Baseline mortality in DF and LR
states
Life table Fixed – Office for National Statistics,85 2013
age- and sex-standardised rates
Excess mortality factor for DF
and LR states
1.20 Fixed – van der Schroeff et al., 201086
Mortality in DR state 0.30 Beta 0.30 Calibration of model survival curve against
the trial survival data
SD, standard deviation.
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One-way sensitivity analyses were conducted to test the impact of changes in individual parameter
estimates on the results. Individual parameters were altered by ± 25% from their baseline value, with the
impact on the expected INB reported in a tornado diagram.
For the lifetime DM analysis, three additional sensitivity analyses were conducted to assess the impact of
key assumptions used in the model.
Decision model sensitivity analysis 1: imputation of additional patient-reported cost data
(NHS and personal social services perspective)
As for the WT cost-effectiveness analysis, the base-case DM analysis was based on utilisation of data from
the trial relating to patients’ consumption of NHS secondary care resources, using the trial case report
forms, which were collected for the total trial population. In line with the sensitivity analyses conducted
in the WT sensitivity analysis 1.1 and sensitivity analysis 1.2 (see Within-trial analysis, Uncertainty and
sensitivity analyses), two corresponding sensitivity analyses were conducted in the model analysis to assess
the impact of including additional patient-reported cost data:
1. DM sensitivity analysis 1.1: in this analysis the treatment-phase costs for the model were taken from
the treatment-phase costs generated from the WT sensitivity analysis that included the additional
patient-reported cost data, assuming that patients correctly reported their use of additional secondary
care resources (i.e. corresponding to analysis WT sensitivity analysis 1.1). Similarly, the monthly cost of
the DF state was recalculated using the results of WT sensitivity analysis 1.1. In addition, the average
monthly patient-reported cost associated with the use of primary, community and additional secondary
care (i.e. outside the enrolled oncology department) was applied to the local and DR health states.
As this is likely to underestimate the primary and community care costs for these states (because the
added cost data are derived from primarily DF patients), no other data were available to determine
the exact cost of primary and community care for recurrent patients.
2. DM sensitivity analysis 1.2: this analysis involved the same steps as outlined in DM sensitivity analysis 1.1
above, but instead used data from the WT sensitivity analysis, including additional patient-reported data
and excluding secondary care resource use where patients identified the visited hospital as one of the trial
centres (i.e. WT sensitivity analysis 1.2; seeWithin-trial analysis, Uncertainty and sensitivity analyses for
further details).
Decision model sensitivity analysis 2: visual analogue scale utility values for the local
recurrence and distant recurrence states
In the base-case analysis, utility in the recurrence health states was derived using data reported in
de Almeida et al.,84 based on an elicitation of utility values using the standard gamble method. The
authors also reported utilities based on using the VAS tool. A sensitivity analysis was conducted using
these alternative values in order to assess the impact of the method of utility derivation on the results.
Decision model sensitivity analysis 3: recurrences beyond 5 years post diagnosis estimated
using a parametric survival curve
In the base-case analysis, no recurrence events were assumed to occur beyond 5 years in the model.
A sensitivity analysis was conducted assuming that recurrences could occur beyond 5 years: long-term
recurrence probabilities for the planned ND arm were estimated using a Gompertz parametric survival
curve fitted to the trial baseline Kaplan–Meier data on recurrence-free survival; a HR was then applied to
this curve in order to derive DF survival within the PET–CT surveillance arm (using the HR observed across
the trial follow-up period), as outlined in Briggs et al.89 The Gompertz distribution was identified as the
best-fitting curve to estimate long-term recurrence events (compared with the exponential, Weibull,
gamma and log-normal distributions), based on an analysis of the Akaike information criterion (AIC) and
Bayesian information criterion (BIC) (Table 60; better-fitting curves are indicated by lower AIC and BIC values)
and a visual inspection of the curve fits (Figure 29).
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Results
Within-trial analysis
Within-trial costs and utilities
Costs: base case (NHS secondary care perspective)
A summary of the 2-year WT costs included in the base-case analysis (i.e. NHS secondary care costs) is
provided in Table 61.
The total per-patient costs over the 2-year trial follow-up period were significantly higher in the standard
care (planned ND) arm than in the PET–CT surveillance arm (mean £13,989 vs. £12,476; p = 0.000). This is
primarily because of the higher up-front cost of surgery (£2542 vs. £303) as well as higher adverse event
costs (£1167 vs. £655), which result in higher treatment-phase costs for planned ND than for PET–CT
surveillance (£12,289 vs. £10,578). In contrast, subsequent costs in the follow-up period (6–24 months
post randomisation) were non-significantly higher in the PET–CT arm (mean £1898 vs. £1700, p = 0.24).
This is mainly because of higher costs associated with surgery (£467 vs. £266) and recurrence (£671 vs.
£496) in the PET–CT arm during the follow-up phase.
Costs: sensitivity analysis 1 (NHS and Personal Social Services perspective)
A summary of the patient-reported costs used in sensitivity analysis 1 is presented in Table 62. These costs
include patient-reported primary, (additional) secondary and community care costs collected for a subset
(n = 42) of patients enrolled at the two main recruiting centres (UHB and UHCW). WT sensitivity analysis 1.1
includes patient-reported costs as they were reported; WT sensitivity analysis 1.2 excludes hospital visits for
patients who identified the visited hospital as either UHB or UHCW (because of the likelihood that these
events will be duplicated in the trial case report forms).
For both analyses the total mean patient-reported costs were higher in the planned ND arm; however,
the cost difference was greater in WT sensitivity analysis 1.1 (£18,245 vs. £13,869) than in WT sensitivity
TABLE 60 Akaike information criterion and BIC to estimate the goodness of fit of alternative parametric survival
curve model specifications for the estimation of long-term recurrences
Trial arm
Model specification
AIC BIC
Planned ND
Exponential 679.50 683.14
Gamma 674.96 682.96
Weibull 673.83 681.11
Log-normal 665.86 673.14
Gompertz 659.03 666.31
PET–CT surveillance
Exponential 734.08 737.72
Gamma 735.58 742.86
Weibull 735.16 742.44
Gompertz 727.89 735.17
Log-normal 726.19 733.48
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FIGURE 29 Plot of parametric survival curves (using Gompertz and log-normal model specifications) against trial
data on patient recurrence-free survival. (a) Planned ND arm; and (b) PET–CT surveillance arm. Log-normal and
Gompertz specifications are shown here, as these were the two models identified as having the best fit via an
analysis of AIC and BIC. The Gompertz curve was used in the sensitivity analysis, as this had the best overall fit
when taking into account AIC, BIC and a visual inspection of the goodness of fit.
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TABLE 61 Within-trial base-case costs: summary of the average per patient secondary care costs by treatment phase
Cost category
Strategy (£)
Mean
difference (£)
p-value
(Wilcoxon
signed-rank
test)
Planned ND (n= 282) PET–CT (n= 282)
Mean Median SD Mean Median SD
Treatment period (0–6 months)
Surgery 2542 3566 1616 303 0 997 –2238 0.000
Radiotherapy 5768 6087 1677 5963 6087 1334 194 0.451
Chemotherapy: concomitant 1444 724 1811 1527 764 1837 82 0.361
Chemotherapy: neoadjuvant 774 0 1252 922 0 1313 148 0.224
Treatment assessment 437 508 183 354 360 123 –83 0.000
PET–CT 69 0 230 833 652 358 763 0.000
SAE 1167 0 2081 655 0 1185 –512 0.010
Recurrence 88 0 633 21 0 151 –67 0.166
Total treatment period cost 12,289 12,052 3969 10,578 10,081 3155 –1711 0.000
Follow-up period (6–24 months)
Surgery 266 0 938 467 0 1203 201 0.029
Radiotherapy 24 0 407 0 0 0 –24 0.319
Follow-up assessments 416 484 223 449 484 192 33 0.271
PET–CT 70 0 237 103 0 274 34 0.065
SAE 429 0 1316 208 0 706 –221 0.146
Recurrence 496 0 1846 671 0 2181 175 0.248
Total follow-up costs 1700 542 5041 1898 589 2970 198 0.243
Total costs (0–24 months)
Surgery 2807 3566 1462 770 0 1468 –2037 0.000
Radiotherapy 5793 6087 1643 5963 6087 1334 170 0.533
Chemotherapy: concomitant 1444 724 1811 1527 764 1837 82 0.361
Chemotherapy: neoadjuvant 774 0 1252 922 0 1313 148 0.224
Treatment assessment 437 508 183 354 360 123 –83 0.000
Follow-up assessments 416 484 223 629 652 121 214 0.271
PET–CT 139 338 0 936 652 464 797 0.000
SAE 1596 0 3057 863 0 1690 –733 0.609
Recurrence 584 0 1932 693 0 2181 109 0.609
Total overall cost 13,989 13,278 5041 12,476 11,940 4613 –1513 0.000
SD, standard deviation.
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analysis 1.2 (£11,291 vs. £10,193). Note that because of the small numbers of completed questionnaires
at each time point, particularly within the planned ND arm, these results are subject to significant sampling
uncertainty (as is reflected in the large standard deviation values) and should therefore be interpreted
with caution.
Costs: sensitivity analysis 2 (societal perspective)
A summary of the patient- and carer-reported societal costs used in sensitivity analysis 2 is presented in
Table 63. These costs include reported equipment costs, one-off expenses, transport costs and lost
earnings. As for the patient-reported costs reported in Table 62, the reported societal costs were higher
in the planned ND arm than in the PET–CT surveillance arm, and this difference was most substantial for
the patient-reported costs (total patient costs £17,136 vs. £11,567; total carer costs £6762 vs. £5388).
However, as for the previous sensitivity analysis, these costs should be interpreted with caution given the
substantial uncertainty because of the small sample sizes contributing to each of the cost estimates.
TABLE 62 Within-trial patient-reported costs included in sensitivity analysis WT sensitivity analysis 1.1 and WT
sensitivity analysis 1.2
Questionnaire
time point
Strategy (£)
Mean
difference (£)
p-value
(Wilcoxon
signed-rank
test)
Planned ND PET–CT surveillance
n Mean Median SD n Mean Median SD
Sensitivity analysis 1.1: analysis using patient data as reported
Treatment period 17 3170 3261 2059 25 2244 1191 1994 –926 0.118
3 months post
randomisation
15 3225 3183 1898 20 1098 1007 501 –2127 0.000
6 months post
randomisation
4 2009 2166 1281 10 1076 928 814 –933 0.240
12 months post
randomisation
16 1224 825 1406 21 1125 872 1137 –99 0.963
24 months post
randomisation
15 1183 797 1406 14 1087 843 1099 –96 0.963
Totala – 18,245 18,245 1469 – 13,869 13,869 1494 –4377 0.000
Sensitivity analysis 1.2: analysis excluding patient-reported secondary care resource usage in which the visited
hospital was indicated as UHB or UHCW
Treatment
period
17 962 753 667 25 1032 846 720 70 0.547
3 months post
randomisation
15 1216 787 914 20 883 787 304 –333 0.802
6 months post
randomisation
4 855 843 502 10 748 751 358 –107 0.733
12 months post
randomisation
16 1121 721 1430 21 935 707 684 –186 0.914
24 months post
randomisation
15 1083 696 667 14 904 683 661 –179 0.929
Totala – 11,291 11,219 1355 – 10,193 10,193 810 –1098 0.000
SD, standard deviation.
a Total cost after imputation of mean costs to the total trial population. Calculation of total cost required extrapolation
between time points as questionnaires were limited to 3-month recall periods. The total assumes that the 9-month cost
is equal to the mean of the 6- and 12-month costs; the 15-month cost is equal to the 12-month cost; the 18-month
cost is equal to the mean of the 12-month and 24-month costs; and the 21-month cost is equal to the 24-month cost.
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Utilities
A summary of the mean utilities in each arm over time based on both the base-case analysis (multiple
imputation for missing data) and sensitivity analysis 3 (complete-case analysis) is given in Table 64.
Patient-reported utilities were largely similar between the two arms, with the largest difference occurring
at 3 months post randomisation.
Base-case cost-effectiveness results
The results of the WT cost-effectiveness analysis are presented in Table 65 (deterministic results) and Table 66
(probabilistic results). Over the 2-year trial period, PET–CT-guided management was associated with an expected
incremental cost saving of £1492 and an expected incremental effect of +0.08 QALYs compared with planned
ND. PET–CT surveillance was therefore found to be cost-effective and dominates the standard care strategy,
being less costly and more effective with an INB of +0.16 QALYs (95% CI 0.03 to 0.28 QALYs).
TABLE 63 Within-trial patient- and carer-reported societal costs included in WT sensitivity analysis 2
Questionnaire
time point
Strategy (£)
Mean
difference
p-value
(Wilcoxon
signed-rank
test)
Planned ND PET–CT surveillance
n Mean Median SD n Mean Median SD
Sensitivity analysis 2: patient costs
Treatment period 17 1951 1211 3026 25 1547 34 2530 –404 0.421
3 months post
randomisation
15 3462 58 6756 20 2804 20 5193 –657 0.891
6 months post
randomisation
3 3475 1200 5468 10 940 103 1394 –2535 0.942
12 months post
randomisation
16 1932 482 2979 21 1831 1 3170 –101 0.747
24 months post
randomisation
15 286 0 871 14 125 0 458 –161 0.649
Totala – 17,136 17,136 4018 – 11,567 11,567 4013 –5569 0.000
Sensitivity analysis 2: carer costs
Treatment period 13 1644 1688 859 22 1732 1365 1159 88 0.733
3 months post
randomisation
10 445 414 135 16 849 528 760 405 0.861
6 months post
randomisation
3 1538 1723 395 8 416 209 527 –1122 0.085
12 months post
randomisation
10 381 302 469 14 451 253 516 70 0.861
24 months post
randomisation
6 294 212 284 11 276 119 347 –18 0.733
Totala – 6762 6762 429 – 5388 5388 660 –1374 0.000
SD, standard deviation.
a Total costs calculated after imputation of sensitivity analysis mean costs to total trial population. Calculation of total cost
required extrapolation between time points as questionnaires were limited to 3-month recall periods. The total assumes
that the 9-month cost is equal to the mean of the 6- and 12-month costs; the 15-month cost is equal to the 12-month
cost; the 18-month cost is equal to the mean of the 12-month and 24-month costs; and the 21-month cost is equal to
the 24-month cost.
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Figure 30 shows the results of the WT probabilistic cost-effectiveness analysis on the incremental
cost-effectiveness plane. Each of the points represents one of the 10,000 simulated bootstrap results,
and provides an indication of the expected uncertainty around the mean cost-effectiveness result. From
this graph we can see that in almost every simulation PET–CT surveillance is expected to be cost-saving
compared with planned ND (i.e. the majority of points lie below the zero line for the incremental cost
results). The expected incremental benefit of PET–CT-guided treatment is more uncertain, with points lying
across both the positive and negative incremental benefit domains. At a £20,000 per QALY threshold,
PET–CT surveillance is cost saving 99% of the time, and more effective than planned ND 91% of the time.
TABLE 64 Patient-reported utilities over time (non-discounted) for imputed utilities (used in the WT base-case
analysis) and complete case utilities (used in sensitivity analysis 3)
Time point Statistic
Strategy (sensitivity analysis 3)
p-value (base case;
Wilcoxon signed-rank test)Planned ND PET–CT
Baseline Mean 0.76 (0.76) 0.76 (0.77) 0.884
SD 0.24 (0.23) 0.24 (0.23)
Median 0.80 (0.80) 0.80 (0.80)
Treatment Mean 0.55 (0.50) 0.49 (0.52) 0.764
SD 0.27 (0.30) 0.31 (0.30)
Median 0.62 (0.62) 0.62 (0.62)
3 months post randomisation Mean 0.35 (0.41) 0.67 (0.64) 0.000
SD 0.39 (0.38) 0.31 (0.32)
Median 0.19 (0.62) 0.73 (0.73)
6 months post randomisation Mean 0.65 (0.66) 0.68 (0.64) 0.015
SD 0.28 (0.28) 0.30 (0.32)
Median 0.73 (0.73) 0.76 (0.73)
12 months post randomisation Mean 0.72 (0.70) 0.70 (0.73) 0.556
SD 0.30 (0.31) 0.34 (0.31)
Median 0.76 (0.75) 0.80 (0.80)
24 months post randomisation Mean 0.71 (0.78) 0.74 (0.77) 0.007
SD 0.29 (0.25) 0.34 (0.31)
Median 0.76 (0.80) 0.85 (0.85)
SD, standard deviation.
TABLE 65 Within-trial analysis base-case deterministic cost-effectiveness results (NHS secondary care perspective
and imputed QALYs)
Strategy
Total
cost (£) Total QALY
Incremental
cost (£)
Incremental
QALY ICER NB (QALYs)
Incremental NB
(QALYs)
Planned ND 13,989 1.20 – – – 0.50 –
PET–CT 12,476 1.27 –1513 0.07 Dominant 0.66 0.15
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Figure 31 shows the cost-effectiveness acceptability curve for the WT base-case analysis. This graph shows
the probability that each strategy is the most cost-effective alternative (i.e. has the highest expected net
benefit) across a range of willingness to pay per QALY thresholds. At a £20,000 per QALY threshold,
PET–CT surveillance is associated with a 99% probability of being cost-effective compared with planned
ND. This probability remains above 93% up to a £150,000 per QALY threshold.
Sensitivity analysis
Sensitivity analysis 1: imputation of additional patient-reported cost data (NHS and
personal social services perspective)
The results of the sensitivity analysis, including the additional patient-reported cost data collected for a
subgroup of patients in the trial [including data on resource usage of primary, (additional) secondary and
community care services], are presented in Table 67. Inclusion of the patient-reported additional costs
leads to substantial increases in the expected per patient lifetime cost in both arms, with an increase from
£13,944 in the base case to £32,469 in the planned ND arm, and from £12,457 to £26,350 per patient in
the PET–CT surveillance arm. As the increase in costs is greater in the planned ND arm than in the PET–CT
surveillance arm, the relative cost-effectiveness of PET–CT surveillance is increased, with a rise in the
expected INB from 0.16 QALYs to 0.39 QALYs. The probability that PET–CT is cost-effective compared with
planned ND is 100% at a £20,000 per QALY thresholds, and remains above 99% up to a threshold value
of £150,000/QALY (results not shown).
Table 68 shows the results of the same analysis but with the additional cost data amended to account for
potential error in patient-reported values. Again, the expected lifetime cost associated with both arms is
increased from the base-case analysis; however, the increase is smaller in this instance and the relative
difference in cost increase between arms is reduced. The result is that the INB associated with PET–CT
surveillance is slightly reduced to 0.21 QALYs, compared with 0.39 QALYs in the previous analysis.
Within-trial sensitivity analysis 2: inclusion of societal costs (societal perspective)
The results of the WT sensitivity analysis including both the additional costs included in WT sensitivity
analysis 1 and patient and carer-reported societal costs (such as travel, equipment and lost earning
expenses) are shown in Tables 69 and 70.
As in WT sensitivity analysis 1, including societal costs in the analysis leads to substantial increases in the
expected cost of each strategy. Again, this cost increase appears to be more pronounced in the planned
ND arm, leading to PET–CT surveillance being more cost-effective with increased INB values (to +0.70
QALYs in WT sensitivity analysis 2.1 and to +0.53 QALYs in WT sensitivity analysis 2.2).
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FIGURE 31 Cost-effectiveness acceptability curve for the base-case WT cost-effectiveness analysis.
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Within-trial sensitivity analysis 3: complete-case analysis for quality-adjusted
life-years calculation
The results of the sensitivity analysis using complete-case analysis for the WT QALY calculation are reported
in Table 71. The PET–CT-guided watch-and-wait policy remains the dominant strategy, being more
effective and less costly than planned ND. The expected incremental cost and QALY outcomes are very
similar to the base case and result in the same expected INB (0.16 QALYs).
The results of this analysis indicate that the use of multiple imputation versus complete-case analysis for
the calculation of QALYs in the WT analysis has minimal impact on the overall results. As a result of this
finding, no corresponding sensitivity analysis using complete-case QALYs in the DM was conducted.
Lifetime decision model analysis
Base-case results
Results of the lifetime DM base-case analysis are presented in Table 72. Compared with planned ND,
PET–CT surveillance is expected to lead to a lifetime cost saving of –£1485 and a health gain of +0.13
QALYs per patient. The intervention therefore dominates standard care, being more effective and less
costly than planned ND and resulting in an expected INB of 0.21 QALYs. There is, however, uncertainty
around this result, with a wide CI around the mean value (INB 95% CI –0.41 to +0.85 QALYs).
Figure 32 shows the results of the model base-case analysis on the incremental cost-effectiveness plane.
Each of the points represents one of the 10,000 simulated model results and provides an indication
of the expected uncertainty around the mean cost-effectiveness result. The diagonal line represents
NICE’s willingness to pay per QALY threshold of £20,000 per QALY: points lying under the line indicate
simulations where the intervention is expected to be cost-effective, whereas points lying above the line are
not cost-effective. This graph illustrates the increased uncertainty around the lifetime expected incremental
cost and QALY results compared with the WT analysis, with points being widely distributed across both
cost-effective and non-cost-effective areas of the graph. The majority of the uncertainty lies around the
expected effectiveness of the PET–CT surveillance strategy: at a willingness to pay per QALY threshold of
£20,000 per QALY, the probability that PET–CT is cost saving compared with planned ND is 96%
(compared with 99% in the WT analysis), whereas the probability that PET–CT is more effective than
planned ND is 66% (compared with 91% in the WT analysis).
The uncertainty around the lifetime modelled results is reflected in the cost-effectiveness acceptability
curve shown in Figure 33.
This graph shows the probability that each strategy is the most cost-effective alternative (i.e. has the
highest expected net benefit) across a range of willingness to pay per QALY thresholds. At a £20,000 per
QALY threshold, PET–CT surveillance is associated with a 75% probability of being cost-effective compared
with planned ND (compared with 99% in the WT analysis), dropping to 68% at a £100,000/QALY
threshold, and remaining above 67% at a £150,000/QALY threshold.
Sensitivity analysis
One-way sensitivity analysis: tornado plot
The results of the one-way sensitivity analysis, altering individual model parameters by 25%, are presented
in Figure 34. The results are most sensitive to changes in the treatment period costs and QALYs, and
parameters concerned with the rate of recurrences in each arm. In particular, increasing the rate of primary
recurrences in the PET–CT surveillance arm (or decreasing the rate of primary recurrences in the planned
ND arm) results in the PET–CT watch-and-wait strategy no longer being cost-effective, with the INB falling
below zero. Changes to other cost and utility parameters had little impact on the results.
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Decision model sensitivity analysis 1: inclusion of additional patient-reported cost data
(NHS and personal social services perspective)
The results of DM sensitivity analysis 1 are presented in Table 73 (DM sensitivity analysis 1.1) and Table 74
(DM sensitivity analysis 1.2). As for the base-case analysis, PET–CT surveillance dominates standard care
(i.e. is cost saving and more effective); however, the expected costs of each strategy are substantially
higher than in the base-case analysis. In DM sensitivity analysis 1.1, the per patient lifetime expected costs
of planned ND and PET–CT surveillance increase from £24,074 and £22,589 to £125,147 and £120,872,
respectively, and in DM sensitivity analysis 1.2 the costs increase to £99,898 and £99,198, respectively. At
a £20,000 per QALY threshold the probability that PET–CT surveillance is the most cost-effective strategy is
98% in DM sensitivity analysis 1.1 and 81% in DM sensitivity analysis 1.2 (compared with 75% in the base
case). In DM sensitivity analysis 1.1, this value remains above 70% up to a threshold of £150,000/QALY,
whereas in DM sensitivity analysis 1.2, this value remains above 67%.
Although these results suggest that PET–CT surveillance remains cost-effective over a broader NHS and PSS
perspective, the results should be considered as exploratory only because of the substantial uncertainty
around the additional costs used to inform this analysis (which were based on data from a small
subpopulation of the trial cohort).
Decision model sensitivity analysis 2: visual analogue scale utility values for the local
recurrence and distant recurrence states
The results of the DM sensitivity analysis using health state utilities derived from reported VAS utilities from
de Almeida et al.84 are reported in Table 75. Using the alternative utility values (for the recurrence states)
has little impact on the results. The expected QALY values in both arms are slightly reduced compared with
the base case, but the incremental effect is unchanged and PET–CT surveillance remains cost-effective.
Decision model sensitivity analysis 3: additional recurrences allowed beyond 5 years post
diagnosis in local and distant recurrence health states
The results of DM sensitivity analysis 3 are presented in Table 76. Allowing primary and subsequent
recurrences to occur beyond 5 years has little impact on the results. The QALY increment associated with
PET–CT surveillance is slightly reduced (from 0.13 QALYs in the base case to 0.10 QALYs), which results in
a small decrease in the expected INB (from 0.21 QALYs in the base case to 0.18 QALYs); however, PET–CT
surveillance remains cost-effective. As in the base-case analysis, there is uncertainty around this result, with
wide CIs around the expected health gain (0.18 QALYs, 95% CI –0.43 to 0.87 QALYs).
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 20 40 60 80 100 120 140
Pr
o
b
ab
ili
ty
 o
f 
co
st
-e
ff
ec
ti
ve
n
es
s
Willingness to pay per QALY threshold (£000/QALY)
Planned ND
PET–CT surveillance
FIGURE 33 Lifetime DM: cost-effectiveness acceptability curve.
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
Pa
ra
m
et
er
D
is
co
u
n
t 
ra
te
C
o
h
o
rt
 s
ta
rt
in
g
 a
g
e
Pl
an
n
ed
 N
D
 a
rm
: t
re
at
m
en
t 
p
er
io
d
 c
o
st
s 
(f
ir
st
 6
 m
o
n
th
s)
PE
T–
C
T 
ar
m
: t
re
at
m
en
t 
p
er
io
d
 c
o
st
s
Pl
an
n
ed
 N
D
 a
rm
: t
re
at
m
en
t 
p
er
io
d
 Q
A
LY
s
PE
T–
C
T 
ar
m
: t
re
at
m
en
t 
p
er
io
d
 Q
A
LY
s
Pl
an
n
ed
 N
D
 a
rm
: r
ec
u
rr
en
ce
 a
t 
6 
m
o
n
th
s
PE
T–
C
T 
ar
m
: r
ec
u
rr
en
ce
 a
t 
6 
m
o
n
th
s
Pl
an
n
ed
 N
D
 a
rm
: p
ri
m
ar
y 
re
cu
rr
en
ce
 r
at
e
PE
T–
C
T 
ar
m
: p
ri
m
ar
y 
re
cu
rr
en
ce
 r
at
e
Se
co
n
d
ar
y(
+
) 
LR
 r
at
e
Se
co
n
d
ar
y(
+
) 
D
R
 r
at
e
Pl
an
n
ed
 N
D
 a
rm
: p
er
ce
n
ta
g
e 
o
f 
LR
 v
s.
 D
R
PE
T–
C
T 
ar
m
: p
er
ce
n
ta
g
e 
o
f 
LR
 v
s.
 D
R
Ex
ce
ss
 m
o
rt
al
it
y 
fo
r 
N
H
SC
C
 p
at
ie
n
ts
M
o
rt
al
it
y 
in
 D
R
 s
ta
te
U
ti
lit
y:
 d
is
ea
se
-f
re
e 
an
d
 D
Fa
LR
U
ti
lit
y:
 L
R
 d
ec
re
m
en
t
U
ti
lit
y:
 D
R
 d
ec
re
m
en
t
C
o
st
: d
is
ea
se
-f
re
e 
an
d
 D
Fa
LR
C
o
st
: L
R
C
o
st
: D
R
C
o
st
: t
er
m
in
al
 t
re
at
m
en
t –
0.
1
0.
0
0.
1
0.
2
In
cr
em
en
ta
l n
et
 h
ea
lt
h
 b
en
ef
it
 (
Q
A
LY
s;
 b
as
e-
ca
se
 v
al
u
e 
=
 0
.2
1)
0.
3
0.
4
05
C
o
st
 o
f 
PE
T–
C
T 
sc
an
C
o
st
 o
f 
n
o
d
e 
d
is
se
ct
io
n
 s
u
rg
er
y
H
ig
h
 v
al
u
e
(+
25
%
 f
ro
m
 b
as
el
in
e)
Lo
w
 v
al
u
e
(–
25
%
 f
ro
m
 b
as
el
in
e)
FI
G
U
R
E
34
Th
e
re
su
lt
s
o
f
D
M
o
n
e-
w
ay
se
n
si
ti
vi
ty
an
al
ys
is
(t
o
rn
ad
o
p
lo
t)
.
D
Fa
LR
,
d
is
ea
se
fr
ee
af
te
r
lo
ca
lr
ec
u
rr
en
ce
.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
TA
B
LE
73
D
ec
is
io
n
m
o
d
el
se
n
si
ti
vi
ty
an
al
ys
is
1.
1:
D
M
co
st
-e
ff
ec
ti
ve
n
es
s
se
n
si
ti
vi
ty
an
al
ys
is
u
si
n
g
ad
d
it
io
n
al
co
st
d
at
a
(N
H
S
an
d
PS
S
p
er
sp
ec
ti
ve
,a
d
d
it
io
n
al
d
at
a
u
se
d
as
re
p
o
rt
ed
)
St
ra
te
g
y
To
ta
lc
o
st
(£
)
(9
5%
C
I)
To
ta
lQ
A
LY
(9
5%
C
I)
In
cr
em
en
ta
lc
o
st
(£
)
(9
5%
C
I)
In
cr
em
en
ta
l
Q
A
LY
(9
5%
C
I)
IC
ER
N
B
(Q
A
LY
s)
(9
5%
C
I)
In
cr
em
en
ta
l
N
B
(Q
A
LY
s)
(9
5%
C
I)
Pl
an
ne
d
N
D
12
5,
14
7
(9
1,
26
7
to
16
6,
17
7)
9.
01
(7
.8
8
to
10
.4
7)
–
–
–
2.
74
(0
.5
0
to
4.
65
)
–
PE
T–
C
T
12
0,
87
2
(8
6,
90
5
to
16
1,
95
5)
9.
13
(8
.0
5
to
10
.5
4)
–
42
76
(–
11
,2
77
to
31
54
)
0.
13
(–
0.
49
to
0.
78
)
D
om
in
an
t
3.
09
(0
.8
8
to
5.
04
)
0.
34
(0
.0
2
to
0.
70
)
TA
B
LE
74
D
ec
is
io
n
m
o
d
el
se
n
si
ti
vi
ty
an
al
ys
is
1.
2:
D
M
co
st
-e
ff
ec
ti
ve
n
es
s
se
n
si
ti
vi
ty
an
al
ys
is
u
si
n
g
ad
d
it
io
n
al
co
st
d
at
a
(N
H
S
an
d
PS
S
p
er
sp
ec
ti
ve
,e
xc
lu
d
in
g
se
co
n
d
ar
y
ca
re
re
so
u
rc
e
u
se
it
em
s
id
en
ti
fy
in
g
U
H
B
o
r
U
H
C
W
as
th
e
vi
si
te
d
h
o
sp
it
al
)
St
ra
te
g
y
To
ta
lc
o
st
(£
)
(9
5%
C
I)
To
ta
l
Q
A
LY
(9
5%
C
I)
In
cr
em
en
ta
lc
o
st
(£
)
(9
5%
C
I)
In
cr
em
en
ta
l
Q
A
LY
(9
5%
C
I)
IC
ER
N
B
(Q
A
LY
s)
(9
5%
C
I)
In
cr
em
en
ta
l
N
B
(Q
A
LY
s)
(9
5%
C
I)
Pl
an
ne
d
N
D
99
,8
98
(6
8,
36
0
to
13
9,
65
4)
9.
01
(7
.8
7
to
10
.4
6)
–
–
–
4.
01
(1
.9
0
to
5.
87
)
–
PE
T–
C
T
99
,1
98
(6
7,
30
4
to
13
9,
04
9)
9.
13
(8
.0
5
to
10
.5
4)
–
70
0
(–
61
90
to
53
62
)
0.
13
(–
0.
49
to
0.
79
)
D
om
in
an
t
4.
18
(2
.0
4
to
6.
04
)
0.
17
(–
0.
22
to
0.
57
)
TA
B
LE
75
D
ec
is
io
n
m
o
d
el
se
n
si
ti
vi
ty
an
al
ys
is
2:
D
M
co
st
-e
ff
ec
ti
ve
n
es
s
se
n
si
ti
vi
ty
an
al
ys
is
–
Q
A
LY
s
b
as
ed
o
n
V
A
S
u
ti
lit
ie
s
St
ra
te
g
y
To
ta
lc
o
st
(£
)
(9
5%
C
I)
To
ta
l
Q
A
LY
(9
5%
C
I)
In
cr
em
en
ta
lc
o
st
(£
)
(9
5%
C
I)
In
cr
em
en
ta
l
Q
A
LY
(9
5%
C
I)
IC
ER
N
B
(Q
A
LY
s)
(9
5%
C
I)
In
cr
em
en
ta
l
N
B
(Q
A
LY
s)
(9
5%
C
I)
Pl
an
ne
d
N
D
24
,1
36
(1
2,
97
7
to
63
,9
56
)
8.
94
(7
.8
5
to
10
.0
9)
–
–
–
7.
73
(5
.6
0
to
9.
10
)
–
PE
T–
C
T
22
,6
51
(1
1,
32
3
to
62
,9
58
)
9.
07
(8
.0
2
to
10
.0
9)
–
14
85
(–
28
05
to
22
3)
0.
13
(–
0.
50
to
0.
79
)
D
om
in
an
t
7.
94
(5
.7
8
to
9.
28
)
0.
21
(–
0.
41
to
0.
86
)
TA
B
LE
76
D
ec
is
io
n
m
o
d
el
se
n
si
ti
vi
ty
an
al
ys
is
3:
D
M
co
st
-e
ff
ec
ti
ve
n
es
s
se
n
si
ti
vi
ty
an
al
ys
is
–
re
cu
rr
en
ce
s
al
lo
w
ed
b
ey
o
n
d
5
ye
ar
s
St
ra
te
g
y
To
ta
lc
o
st
(£
)
(9
5%
C
I)
To
ta
lQ
A
LY
(9
5%
C
I)
In
cr
em
en
ta
lc
o
st
(£
)
(9
5%
C
I)
In
cr
em
en
ta
l
Q
A
LY
(9
5%
C
I)
IC
ER
N
B
(Q
A
LY
s)
(9
5%
C
I)
In
cr
em
en
ta
l
N
B
(Q
A
LY
s)
(9
5%
C
I)
Pl
an
ne
d
N
D
24
,3
13
(1
3,
14
9
to
63
,6
42
)
8.
76
(7
.6
0
–
10
.3
2)
–
–
–
7.
55
(5
.4
1
to
9.
12
)
–
PE
T–
C
T
22
,8
41
(1
1,
49
2
to
62
,3
59
)
8.
86
(7
.7
3
–
10
.4
0)
–
14
72
(–
29
34
to
38
1)
0.
10
(–
0.
56
to
0.
80
)
D
om
in
an
t
7.
72
(5
.5
5
to
9.
29
)
0.
18
(–
0.
43
to
0.
87
)
DOI: 10.3310/hta21170 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 17
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mehanna et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
Summary
An economic evaluation was conducted to assess the cost-effectiveness of PET–CT-guided watch-and-wait
policy compared with planned ND. The evaluation consisted of two components: (1) a WT analysis, in
which cost-effectiveness is assessed over the 24-month trial period using individual patient data collected
in the trial; and (2) a decision-analytic model analysis, in which cost-effectiveness is assessed over a lifetime
horizon, using standard modelling techniques applied to the trial data in order to extrapolate the trial
results. Owing to the availability of data within the trial, the base-case analysis was conducted from a NHS
secondary care perspective. Additional sensitivity analyses were conducted using a NHS and PSS perspective
and a societal perspective (including patient and carer one-off expenses, travel costs and lost earnings).
Results of the WT base-case analysis indicate that the PET–CT watch-and-wait strategy is cost-effective
over a 2-year time horizon. Using a NHS secondary care perspective, PET–CT surveillance yielded an
average per-patient cost saving of £1492 (95% CI –£698 to –£2239) and an expected health gain of 0.08
QALYs (95% CI –0.03 to 0.19 QALYs) compared with planned ND. The PET–CT watch-and-wait policy
therefore dominates standard care, being more effective and less costly, producing a 2-year incremental
net health gain of 0.16 QALYs (95% CI 0.03 to 0.28 QALYs) per patient, with a 99% probability of being
cost-effective at a £20,000 per QALY threshold.
The results of the base-case lifetime DM analysis indicate that PET–CT surveillance is expected to remain
cost-effective over a lifetime horizon; however, there is increased uncertainty around this result compared
with the WT analysis. In the base-case analysis the PET–CT watch-and-wait policy is associated with an
expected lifetime cost saving of –£1485 (95% CI –£2815 to £159) compared with planned ND, and an
expected health gain of 0.13 QALYs (95% CI –0.41 to 0.85 QALYs), resulting in an incremental net health
gain of 0.21 QALYs (95% CI –0.41 to 0.85 QALYs). At a £20,000 per QALY threshold there is a 75%
probability that PET–CT surveillance is the most cost-effective strategy, dropping to 68% at a £100,000
per QALY threshold. These results were sensitive to parameters relating to the rate of recurrence in each
arm, although the incremental health benefit associated with PET–CT surveillance dropped below zero
(i.e. indicating non-cost-effectiveness) in only two scenarios: (1) increasing the expected rate of primary
recurrence in the PET–CT arm by 25% or (2) decreasing the rate of primary recurrence in the planned ND
arm by 25%.
The results of both the WT and DM sensitivity analyses indicate that the inclusion of additional primary,
secondary, community and societal care costs is likely to result in substantial increases in the expected cost
of both treatment strategies, and may lead to an increase in the expected cost-effectiveness of PET–CT
surveillance. However, these results should be considered with caution given the significant uncertainty
involved in including the additional costs that were derived from small sample sizes from the trial.
Discussion
In the WT base-case analysis PET–CT surveillance was found to be cost-effective, producing an incremental
cost saving of –£1415 and an incremental health benefit of 0.07 QALYs compared with planned ND over a
2-year time horizon. This result is relatively certain, with an expected INB of 0.15 QALYs (95% CI 0.02 to
0.27 QALYs) and a probability of cost-effectiveness of 99% at a £20,000 per QALY threshold, and with
results being robust to sensitivity analyses. In the lifetime DM base-case analysis PET–CT surveillance
remained cost-effective, producing a lifetime cost saving of –£1485 and an incremental health benefit of
0.13 QALYs. However, this result was more uncertain, with a wide CI around the expected incremental net
benefit (0.21 QALYs, 95% CI –0.41 to 0.85 QALYs), and a probability of cost-effectiveness of 75% at a
£20,000 per QALY threshold, dropping to 68% at a £100,000 per QALY threshold. This uncertainty is
largely attributable to uncertainty around the QALY benefit associated with PET–CT surveillance (mean
0.13 QALYs, 95% CI –0.49 to 0.79 QALYs), which is likely to be a result of uncertainty around the relative
rate of recurrences between the two arms. Although there is uncertainty around the lifetime results,
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PET–CT surveillance remained cost-effective across a range of sensitivity analyses, and was found to be
non-cost-effective only when assuming a significant increase in the rate of primary recurrences in the
PET–CT arm compared with the planned ND arm, which is expected to represent a highly unlikely scenario.
Thus, although uncertainty exists, the mean result was relatively robust to sensitivity analyses.
The results of this analysis are in line with previous economic evaluations of PET–CT surveillance strategies
to guide the use of surgery in H&N cancer patients.90–94 In a recent study, Pryor et al.94 found that a similar
PET–CT-guided strategy was a safe and significantly less costly alternative strategy than planned surgery
from an Australian health service perspective.94 Similarly, Rabalais et al.,92 Sher et al.90 and Hollenbeak
et al.93 all found PET–CT surveillance to be cost-effective from an American health-care perspective. As far
as these authors are aware, no full economic evaluation of PET–CT surveillance for H&N cancer has
previously been conducted from a UK NHS perspective; therefore, these results represent the first indication
that PET–CT is likely to provide a cost-effective alternative to planned ND within the UK health-care system,
and adds support to the current body of studies in favour of adopting PET–CT into routine clinical practice.
Ideally, cost-effectiveness analyses should be conducted from a NHS and PSS or societal perspective,
in order to fully account for resources that will be consumed as a result of implementing the new
intervention.63 In this evaluation, however, we have adopted a NHS secondary care perspective in the base
case, which accounts only for the use of secondary care (i.e. hospital) resources. This is a clear limitation of
the analysis, and is a result of a lack of reliable and sufficient data within the trial on which to derive full
NHS and PSS or societal costs; such data were available for only a small subsample of 42 patients and
35 carers. Sensitivity analyses were conducted to assess the potential impact of including these additional
costs, the results of which indicate that inclusion of broader costs within the analysis is likely to result in
substantial increases in the expected cost of both treatment strategies, and may in fact lead to PET–CT
surveillance becoming more cost-effective than in the base case. This suggests that the use of PET–CT may
lead to resource savings across primary and societal care, in addition to the savings evident in the hospital
secondary care setting. As previously stated, these results should be interpreted with caution because of
the uncertainty around the additional cost data used in these analyses; nevertheless, it is encouraging that
these exploratory results indicate that PET–CT surveillance remains cost-effective when adopting a broader
perspective. Future work should focus on obtaining more accurate estimates of NHS, PSS and societal care
costs, in order to enable future UK economic evaluations to adopt a broader perspective.
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Chapter 5 Discussion
Interpretation
The results of this study show that PET–CT-guided surveillance followed by ND appears to be equivalent to
a planned ND regimen for the management of advanced (N2/N3) nodal disease in patients with H&N
cancer being treated with CRT, and demonstrated non-inferiority for differences of > 4% in OS. This
strongly supports the efficacy of the PET–CT-guided surveillance policy. The policy is also cost-effective in
the short term, and potentially in the long term.
Surveillance policy resulted in far fewer patients requiring ND and, as a result, considerably fewer
complications of surgery. The effect of ND on quality of life, however, was not high in that both groups
appear to have similar quality of life in the longer term. It is notable, however, that patients randomised to
the planned ND experienced more SAEs. One would expect these to be related to surgery, but these were
mainly related to CRT, especially in the arm of patients who were randomised to ND after CRT. It is not
clear why this should be, or whether or not this is a significant finding. The locoregional control rate and
death from other causes were the same in both arms. Importantly, we demonstrated the feasibility and
success of a PET–CT-guided policy in a multicentre randomised prospective setting, something that had not
been demonstrated before.
The fact that concordance between the central laboratory and the local radiology readings was very high
demonstrates the applicability of the surveillance regimen across PET–CT sites in the UK. It is also a
testament to the quality of the training of PET–CT radiologists in the UK.
It is important to note that most of the patients had OPC and a large proportion of these were caused by
the human papillomavirus (HPV-positive OPC). The subgroup analysis suggests that the surveillance policy
is particularly effective in the HPV-positive subgroup. This may be because HPV-positive OPC responds well
to CRT and, therefore, there is a smaller risk of persistent disease in HPV-negative patients. However, the
subgroup analysis also shows the surveillance policy to be non-inferior for HPV-negative patients.
Generalisability
It is important to note that most of the patients had N2a or N2b disease and that very few patients had
N3 disease. This may be partly because N3 disease is not common. However, there may also be a degree
of selection bias by investigators, who may have been less keen to submit patients with N3 disease to
randomisation. On the one hand, this may have been because they were concerned that the surveillance
policy may result in residual disease in the N3 population, which would be difficult to salvage. On the
other hand, clinicians may have been concerned that subjecting a patient to a planned ND, especially
before CRT, may not be in the patient’s best interest if there was a high chance that the primary site
would not respond to CRT.
Overall evidence
The study supports claims that ND does not confer any survival benefits or an increase in nodal recurrence
in patients who show a CR compared with patients who undergo a surveillance policy.17,18
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The rate of complications following ND is only slightly higher following PET–CT than planned NDs done
before or immediately after CRT. The differences in the rate of complications were not significant.
As was expected, outcomes were significantly better among patients with HPV-positive OPC than among
those with HPV-negative disease. However, there is no difference between the planned ND and
surveillance arms by HPV status. Indeed, HPV-positive patients may benefit from undergoing surveillance.
Of interest is the fact that there were no quality-of-life differences between the ND and surveillance arms.
This suggests that the main determinant of quality of life in these patients is the CRT.
Also of interest is the fact that HPV-positive patients had significantly worse quality of life during
treatment, but that they recovered from that and had an overall better quality of life than HPV-negative
patients in the longer term. The reasons for this may be that the HPV-positive patients are a younger
group who are usually employed and have young families; therefore, the effect of treatment may have
more of an impact on their daily lives during that period. However, because they are younger and fitter, in
the longer term they recover more quickly and have a higher baseline quality of life when considering the
effect of age on quality of life.
Overall conclusions
In the authors’ opinion, this study strongly supports the efficacy of the PET–CT-guided surveillance policy.
The policy is also cost-effective in the short term, and potentially in the long term. Importantly, surveillance
resulted in 80% of patients avoiding ND and, therefore, fewer complications of surgery. Patients in the
surveillance arm had similar quality-of-life scores as patients in the ND arm and, when accounting for the
cost-savings associated with PET–CT surveillance, the intervention was found to be more cost-effective in
the short term and, potentially, in the long term also.
This is the largest report in the literature on the accuracy of PET–CT scanning in assessing residual disease
at the primary site that provides sufficient evidence to allow the replacement of EUA (the current gold
standard) by PET–CT scanning, which is a less invasive non-operative technique.
Most of the patients in this study had N2a or N2b disease and few patients had N3 disease; therefore, we
cannot confirm the efficacy of the surveillance policy for very large N3 nodal disease.
Further research
The aim of the economic evaluation was to identify the WT and long-term incremental cost-effectiveness
of a PET–CT-guided watch-and-wait policy compared with planned ND in HNSCC patients. As yet,
comparisons of CT-driven response systems and PET–CT-driven systems in multicentre randomised settings
have not been published. Unfortunately, because of cost constraints, we did not undertake contrast CT at
the same time as PET–CT, so we cannot compare the efficacies of the two modalities. Therefore, the
relative efficacy and cost-effectiveness of PET–CT compared with CT-based approaches is still unclear.
The majority of patients recruited into the study had N2 disease. This means that the study results and
the PET–CT surveillance policy may not be applicable to very large N3 nodal disease. This requires
further assessment.
Further research is also required for the equivocal cases. This is especially the case with PET-negative
disease with persistent nodes on anatomical CT scanning. Research to assess prolonged surveillance with
CT or assessment of the persistent node using ultrasound-guided fine-needle aspiration is warranted.
DISCUSSION
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